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ABSTRACT
Haematopoiesis is the result of tightly regulated signal transduction pathways 
mediated by cytokines and their receptors. Aberrations in these pathways are an 
underlying cause for diseases such as leukaemia and other myeloproliferative and 
lymphoproliferative disorders.
The PI3-Kinase/Akt pathway is central to regulation of cell survival and 
proliferation. This study found that the PI3-Kinase pathway is activated in AML 
cells. This activation was reduced or abolished when the cells were incubated with 
the PI3-Kinase inhibitor, LY294002. Leukaemic cell survival appeared to be 
dependent on PI3-Kinase activation as incubation with LY294002 resulted in a 
reduction in cell number and an increase in apoptosis. This was also true for the 
CD34+/38- leukaemic stem cell population. Further work indicated that activation of 
Akt alone was sufficient to protect factor dependent cells from cytokine withdrawal 
induced apoptosis and also from the cytotoxic effects of Ara-C and Etoposide.
The JAK/ STAT Pathway is important for many biological responses including 
differentiation and proliferation and its dysregulation has also been reported in many 
malignancies.
It was shown that G66976, a selective PKC inhibitor, is a potent inhibitor of JAK 2 
in in vitro kinase assays and in whole cell systems and inhibits signaling
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downstream of multiple JAK2 coupled cytokines including IL-3, GM-CSF and EPO. 
G66976 was also found to inhibit signalling downstream of disease-associated forms 
of JAK2 such as the TEL-JAK2 fusion and mutant JAK2 V617F.
The majority of primary AML cells investigated had constitutive STAT activation 
which was reduced by incubation with G66976 in the majority of cases. This 
reduction was accompanied by a decrease in cell survival and proliferation. This 
work indicates that both the PI3-Kinase/Akt and the JAK/STAT pathways would be 
appropriate targets for the development of small molecule inhibitors for use in the 
treatment of AML.
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CHAPTER 1-INTRODUCTION
1.1 Haematopoiesis
Haematopoiesis is the continuous process by which blood cells are generated. It is an 
orderly progression which requires complex regulation by cytokines and their 
associated receptors. Aberrations in this process lead to the development of diseases 
such as leukaemia and myeloproliferative disorders. Blood cells originate from a self 
renewing population of haematopoietic stem cells (HSC) that become committed to 
differentiate down the erythroid, megakaryocytic, granulocytic, monocytic and 
lymphocytic lineages. HSCs are found in the Sca-1+ C-Kit + Lin- population in 
mice and this is likely to be the case in humans. 1 Evidence suggests that these most 
primitive of cells are largely quiescent with the majority being out of cycle at any 
one time. 1 Haematopoiesis is predominantly confined to the bone marrow, after 
birth, except in some pathological conditions where extramedullary haematopoiesis 
occurs in the liver and spleen. The decision as to whether a HSC undergoes self 
renewal or lineage commitment is governed by the expression of a number of 
transcription factors. SCL, GAT A 2 and AML-1 are required for definitive 
haematopoiesis 1 whereas the expression of PU-1 and GATA-1, amongst others, 
influences lineage commitment.
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There are two models as to how cytokines may influence cell fate: 1) The Instructive 
model which states that haematopoietic cytokines and factors extrinsic to the cell 
control commitment and differentiation and 2) The permissive model which states 
that intracellular pre determined factors govern unilineage differentiation and that 
cytokines provide a supportive role.2
Low levels of multiple cytokines modulate HSC transcription factor expression to 
maintain basal haematopoiesis and short lived amplifications of specific cytokines 
are produced in response to haematopoietic stresses. The cytokine environment 
supporting basal haematopoiesis appears to be produced locally by mesenchymal 
cells within the bone marrow, through the secretion and cell surface presentation of 
cytokines.
These ‘stromal cells’ include specialised fibroblasts, endothelial cells, osteoblasts 
and perhaps adipocytes and produce SCF, TPO, Flt3L and GMCSF. These cytokines 
are locally concentrated and support HSC survival and proliferation.1
1.2 Cytokines and their receptors
Cytokines are soluble polypeptides which form an integrated network of cell to cell 
communication and humoral interactions regulating growth, differentiation and 
survival. A particular cytokine may exhibit a wide variety of biological functions 
plus several cytokines may exert similar and overlapping effects.
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Cytokine receptors can be classified broadly according to their structure into 
receptor tyrosine kinases, class I and II cytokine receptors, protein serine/ threonine 
kinase receptors, TNF receptors and G protein coupled receptors. Class 1 cytokine 
receptors and receptor tyrosine kinases will be concentrated on here.
1.2.1 Class I  cytokine receptors
Most cytokine receptors consist of a multi-subunit protein complex with a specific 
ligand binding subunit and a signal transducing subunit which may be shared with 
other members of the cytokine receptor superfamily and is responsible for 
transmission of the signals to downstream target proteins.
Cytokine receptors typically have a 210 amino acid extracellular domain consisting 
of two fibronectin type III modules connected by a hinge region. These proteins 
have conserved motifs in their N-terminal segment containing cysteine (C) and 
tryptophan (W) and a tryptophan-serine-X tryptophan serine (W-S-X-W-S) 
sequence, where X is any non conserved amino acid, in the carboxy-terminus. The 
W-S-X-W-S motif is in the hinge region and is thought to act as a ligand binding 
site. The cytokine receptor super family has been further classified based on 
structural motifs in their extracellular domain into i) The gpl30 family which 
consists of receptors for IL-6, IL-11, ciliary neurotrophic factor, cardiotrophin, 
leukaemia inhibitory factor and oncostatin M. They all signal through a common (3 
chain called gp-130 and each have a unique ligand binding a  subunit, ii) The IL-2
18
receptor family-the IL-2 receptor consists of 3 subunits a , |3 and y. The y chain is 
shared by the receptors for IL-4, IL-7, IL-9 and IL-15. The a  subunit acts as a ligand 
binding domain and the p and y as signal transducing units, iii) The growth hormone 
family-this family includes receptors for growth hormone, erythropoietin, prolactin, 
GCSF and thrombopoietin. These receptors exist as homodimers. Binding of the 
ligand leads to a change in the orientation of the two receptor subunits and this 
conformational change is transmitted through the juxtamembrane and 
transmembrane domains, leading to activation. 3There is no cross reaction between 
ligands and each receptor transduces signals specific for a cytokine, iv) The 
interferon (IFN) family-this family is comprised of the IFN-a and IFN-y receptors 
together with the IL10 receptor, v) The gp-140 family-this family consists of 
receptors for IL3, IL5 and GMCSF. They share a common p unit (gp-140) for signal 
transduction and have unique a  ligand binding units. 4
The cytokine receptor superfamily is characterised by a lack of intrinsic tyrosine 
kinase activity. They couple ligand binding with tyrosine phosphorylation utilising 
janus kinases (JAK), cytosolic kinases which are associated with the proximal 
domains of the cytokine receptor at Box 1 and 2 motifs.4 The conserved motifs 
consist of a PxP or PxxP sequence and a sequence LxxL. This region has been 
shown to be essential for receptor function and critical for the association of JAKs 
with the receptor complex. 4,5It is also responsible for the specificity of JAK kinase 
activation. Jiang et al used mutational analysis and created chimeric receptors by 
swapping the Box 1 motif of the Epo receptor which transmits signals utilising
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JAK2, with that of the (3 chain of IL-2. This chimeric receptor was able to activate 
JAK2 on IL2 stimulation, thus confirming the role of the Box 1 motif in influencing 
JAK specificity. 4,6
When a ligand binds to its cognate receptor, the receptor dimerises and brings into 
apposition two JAK molecules, these then auto/transphosphorylate and become 
activated. The activated JAK molecules phosphorylate the receptor creating 
phosphotyrosine docking sites for downstream signalling molecules including signal 
transducers and activators of transcription, STATs.
A cytokine may activate one or more JAKs. Those cytokines which activate more 
than one JAK may do so independently as in the case of IL-6 which can activate 
JAK1, 2 and Tyk2 and the absence of one JAK does not preclude activation of the 
others or as in the case of interferons may show co-dependence i.e. the absence of 
one JAK prevents activation of the other. Table 1 illustrates the pattern of JAK 
utilisation amongst the different cytokines.
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Table 1 JAKs in cytokine signalling5
Ligand Kinase
Epo JAK 2
Thrombopoietin JAK2
Growth Hormone JAK2
Prolactin JAK2
G-CSF JAK2, JAK1
IL2,IL4, IL7,IL9,IL12 JAK3, JAK1
IL3, IL5, GM-CSF JAK2, JAK1
IFN a, IFN {3 JAK1, Tyk2
IFNy JAK1, JAK2
IL10 JAK1, Tyk2
IL12 JAK2, Tyk2
IL6, CNTF, LIF, IL11 JAK1, JAK2, Tyk2
1.2.2 Receptor tyrosine kinases
The receptor tyrosine kinases are a family of more than 50 different transmembrane 
receptors. They differ from the cytokine receptor superfamily in that they possess a 
tyrosine kinase domain in their intracellular portion. They all share common 
structural and functional features and apart from the insulin receptor all consist of a 
single polypeptide chain. This can be divided into an extra cellular and intracellular 
portion and a short transmembrane domain. Many of the growth factors that bind to 
these receptors are dimeric molecules and are therefore able to bind two receptors at 
the same time creating a stable receptor dimer. Dimerisation promotes
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auto/transphosphorylation of the receptor and may induce a conformational change 
leading to receptor activation and the creation of docking sites for the interaction of 
downstream signalling molecules. This group of receptors includes the receptor for 
stem cell factor, C-Kit which is expressed on many haematopoietic progenitors and 
germ cells and the FLT3 receptor.
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There are four known members of the JAK family, JAK1, JAK2, JAK3 and Tyk2. 
They range from 1 lOkDa to 140kDa. The genes localise to 3 chromosomal clusters; 
JAK1 is encoded by a gene located on human chromosome lp31.3, JAK2 by a gene 
on 9p24 and JAK3 and Tyk2 genes are located on chromosome 19 at 19pl3.1 and 
19p 13.2 respectively.7 JAK1, 2 and Tyk2 are ubiquitously expressed. In contrast 
JAK3 is predominantly expressed in cells of myeloid and lymphoid lineage.5,7
1.3.1 JAK Structure.
Amino acid sequencing of the JAKs reveals that they possess seven highly 
conserved regions, JH1-JH7, that follow a non-conserved amino terminus of about 
30-50 amino acids. They are unusual when compared to other members of the 
cytosolic protein tyrosine kinase family in that they lack any SH2 or SH3 domains. 
The other distinctive feature is that the regions JH1 and JH2 both have extensive
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homology to tyrosine kinase domains and together they comprise approximately 
50% of the JAK molecule. Only the JH1 region appears to be functional. The 
activation loop of all JH1 domains contains a KE/DYY motif which appears to be a 
site of autophosphorylation; phosphorylation of the first of these tandem motifs, 
Y1007 in JAK2, appears to be essential for full kinase activity. 8 The JH2 domain 
lacks certain critical amino acids and does not appear to be associated with kinase 
activity. It is now clear that this domain plays a regulatory role. Deletion analysis of 
JAK2 showed that the pseudokinase domain, but not JH3-JH7, negatively regulated 
JAK2 catalytic activity as well as STAT 5 activation by JAK2. Furthermore JAK2 
kinase inhibition was mediated by an interaction between JAK2 kinase and the 
pseudokinase domain. 9 Auto/transphosphorylation of conserved tyrosine residues in 
the JAK activation loop determines levels of catalytic activity. If Tyrosine 980 of 
JAK3 is mutated to phenylalanine the resultant mutant displays reduced kinase 
activity, however mutation of tyrosine 981 leads to significantly increased kinase 
activity. Substrate phosphorylation is dependent on phosphorylation of Y980. 10 
Tyrosines not within the activation loop are also autophosphorylated on JAK2. 
Argetsinger et al found that tyrosines 221 and 570 were autophosphorylated and that 
mutation of these tyrosines to phenylalanine led to an altered catalytic activity, 
suggesting that they may have a regulatory role. Phosphorylation of Y221 led to an 
increased catalytic activity and phosphorylation of Y570 appeared to have an 
inhibitory effect. These tyrosines fall within a YXXL motif which appears to be a 
favoured motif for JAK phosphorylation, together with the closely related YXXI/V 
motifs. 11
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The amino terminal region of JAK molecules spans 550 amino acids and is 
relatively non conserved between JAK family members. It is thought to be involved 
in receptor association and specificity of binding. 12 The JH3-JH4 region shows 
some similarities to SH2 domains and the JH4-JH7 region constitutes a FERM (Four 
point one, Ezrin, Radixin, Moesin) domain. These domains consist of 3 lobes, the FI 
(aa 37-115) in JAK2 has homology to Ubiquitin, the F2 (aal46-258) in JAK2 has 
homology to acyl coenzyme A binding protein and F3 (aa269-397) has homology to 
phosphotyrosine binding/ pleckstrin homology domain. 11 The linker between 
domains FI and F2 which is at the centre of a hydrophobic core plays an essential 
role in stabilising the structure of the FERM domain. Zhou et al found that some 
naturally occurring mutations in the JAK3 FERM domain led to impaired kinase- 
receptor interaction but also abrogated catalytic activity and ATP binding. 13 They 
also found that a tyrosine kinase inhibitor which altered the conformation of the 
kinase domain also significantly affected the binding of JAK3 to the receptor 
suggesting that the FERM domain and the kinase domain reciprocally affect each 
others structure and function. This is thought to be because the FERM domain has a 
permissive role in stabilising the conformation of the activated kinase domain.
1,3.2 JAKs in development
Studies with JAK knockout mice have furthered our understanding of JAK function 
in mammalian development and growth.
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JAK1 is ubiquitously expressed and is widely utilised by interferon receptors and 
receptors using gpl30 and the common yc. JAK1-/- mice have grossly normal 
nonlymphoid organogenesis, however the JAK1-/- mice die in the perinatal period 
from an inability to nurse. This neurologic defect is thought to be due to a failure of 
signalling via cytokines utilising gpl30 e.g. LIF, CT-1 and CNTF and thus a failure 
to promote neuronal survival. 7,14 JAK1 deficiency also leads to reduced numbers of 
T and B lymphocytes which has been attributed to failure in IL-7 signalling.
JAK2 is also widely expressed, like JAK1. Targeting the JAK2 gene results in 
embryonic lethality at day 12.5 due to failure of erythropoiesis analogous to that 
observed in the EPO knockout mouse.7,12,14 Cells from the JAK2 knockout mouse 
also show that JAK2 is essential for IL-3, GMCSF, IL-5, TPO and IFNy but not IL-6 
and IFNaf3 signalling.
JAK3 selectively associates with the common y chain and not with other cytokine 
receptors. Mutation of either the yc or JAK3 in humans results in severe combined 
immunodeficiency, characterised by lack of T cells and NK cells but not B cells. 
JAK3 -/- mice are defective in their response to IL-2, IL-4 and IL-7. Consistent with 
a role in IL-2 signalling JAK3 deficient mice have a defect in peripheral tolerance 
and lymphoid homeostasis. Failure of IL-7 signalling is thought to be responsible for 
the reduced numbers of lymphoid cells and the lack of thymic progenitors and the 
absence of NK cells has been attributed to impairment in IL-15 signalling.7,12,14
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Tyk 2 contributes to IFN a /(3 as well as IL-6, IL-10 and IL-12 signalling. Tyk2 -/- 
knockout mice display relatively subtle defects in IFN a/p signalling. They maintain 
antiviral responses within the normal range despite having a defect in response to 
low dose IFNa. IL-10 signalling is relatively normal but IL-12 responses are 
reduced but not absent. Thus unlike other JAKs many of the in vivo functions of Tyk 
2 are redundant. 12,14
1.3.3 STAT structure and function
STATs are latent transcription factors that play a critical role in signal transduction 
pathways associated with several cytokines. There are seven members of the STAT 
family ranging in size from 750-850 amino acids: STATS 1-6 including 5a and 5b 
which are encoded by two distinct genes on chromosome 17. There are 6 conserved 
domains; amino terminal, coiled coil, SH2, linker, DNA binding and transcriptional 
activation domain. The amino terminal consists of 130 amino acids and is conserved 
amongst STATs. It appears to be critical for STAT function as small deletions were 
found to eliminate the STATs ability to be phosphorylated. 4 The crystal structure 
for the first 123 residues of STAT 4 has been resolved and suggests that this domain 
consists of 8 helices that are assembled in a hook like structure. It has been 
implicated in various protein-protein interactions affecting transcription and it 
enables dimerised STAT molecules to polymerise and bind to DNA cooperatively. 15 
This region is followed by the DNA binding domain that is located between amino 
acids 400 and 500. It is highly conserved amongst the STATs and enables the
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STATs, with the exception of STAT 2, to differentially bind more than 10 GAS (y 
activated sequences) sequences. These sequences are characterised by the consensus 
motif TTNCNNNAA. 4 Adjacent to the DNA binding domain lays the linker region 
which is a putative SH3 domain. It is not well conserved and it is therefore uncertain 
as to whether it functions as an SH3 domain, especially as critical amino acids 
involved in binding to the PXXP motifs do not appear conserved. 4 The SH2 domain 
is highly conserved, however, and is situated adjacent to the putative SH3 domain. It 
plays a critical role in STAT signalling through its capacity to bind with 
phosphotyrosine residues and is essential for the recruitment of STATs to the 
receptor complex, for the interaction with JAK kinases and is also required for 
STAT homo and heterodimerisation. The domain consists of an anti parallel [3-sheet 
flanked by two a  helices. This forms a pocket with an absolutely conserved arginine 
at the base which mediates the interaction with phosphate. 12 Immediately 
downstream of the SH2 domain at around amino acid 700 is a tyrosine residue 
present in all STATs which plays a critical role in STAT activation. Phosphorylation 
of this residue has been found to be essential for activation and dimerisation of 
STATs and this can be achieved by growth factor receptors, JAK and Src kinases 
depending on the cell type and the nature of the ligand- receptor interaction. 4 Most 
vertebrate STATs contain a second phosphorylation site within their C termini on a 
serine residue. Comparing the C-termini of STATs 1, 3 and 4 it was noted that 
unlike most amino acids, a PMSP motif between positions 720 and 730 is perfectly 
conserved. In addition STAT 5a and 5b contain a conserved PSP motif in the same 
position. Mutation of this serine to alanine leads to a reduced transcriptional activity
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in STATs 1, 3 and 4 but in STAT 5 mutation did not affect transcriptional activity. 
The mechanisms by which this serine phosphorylation occurs and it’s biological 
impact are unclear in most situations.16
The transactivation domain is at the carboxy terminus of the STAT molecule. It is 
poorly conserved among the STATs. Isoforms of STAT 3, 4 and 5 have been 
identified in which the C-terminal has been truncated; they appear to function as 
dominant negative regulators. The crystal structure of STAT 1 complexed with DNA 
has been elucidated by Chen et a l.17 STAT 1 utilises a DNA binding domain with an 
immunoglobulin fold. The STAT 1 dimer forms a C shaped clamp around the DNA. 
This is stabilised by mutual highly specific interactions between the SH2 domain of 
one monomer and the C-terminal phosphorylated tyrosine on the other. The 
phosphotyrosine binding site of one monomer is joined with the DNA binding 
domain which suggests a potential role for the SH2-phosphotyrosine interaction in 
stabilisation of DNA promoter sites.
1.3.4 JAKZSTATSignalling
When a cytokine binds to its cognate receptor, the receptor oligomerises and brings 
two JAK molecules, associated with the Boxl motif of the receptor, into apposition. 
They auto/transphosphorylate and become activated. The activated JAK then 
phosphorylates the receptor and creates docking sites for several down stream 
signalling molecules including STATs, via their SH2 domains. The STATs are then
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phosphorylated on the conserved tyrosine residue in the carboxy terminus which 
allows them to form stable homo or heterodimers by interactions between the 
phosphotyrosine residue on one molecule and the SH2 domain of the other. These 
dimers then translocate rapidly to the nucleus and induce gene expression. A wide 
range of cytokines activate JAK1, 2 and Tyk2 but only those utilising the common y 
chain activate JAK3.The specificity of STAT phosphorylation appears to be 
determined by the docking sites for STATs on the receptor rather than the JAK 
kinases. 4 IFNa, J3 and GCSF all activate JAK1 -however IFNa and (3 stimulation 
lead to the phosphorylation of STAT 1 and 2 which form a complex with a third 
protein p48. In contrast GCSF stimulation leads to the formation of STAT 3 and 5 
homodimers, some STAT 1 homodimers and STAT 1/3 and 3/5 heterodimers. This
diversity among which STAT complexes are activated may contribute to the cellular
1 8responses to a given cytokine or growth factor. The specificity of STAT activation 
is partially mediated through their recruitment to specific tyrosines on a particular 
receptor. For instance tyrosine 440 on the IFN y receptor a  chain is responsible for 
recruitment and activation of STAT 1. Similarly several studies have identified the 
YXXQ motif as a consensus STAT 3 docking site. It is possible that STAT 
molecules can be activated by JAK kinases in the absence of receptor docking. It has 
been proposed that JAK1 and JAK2 can specifically activate and recruit STAT 1 and 
STAT 5 respectively. This would explain why full activation of STAT 1 by GCSF or 
GH, or STAT 5 by GCSF and GMCSF can occur in the absence of receptor 
tyrosines. 18 There is also evidence that STATs can utilise other receptor 
components as docking sites for instance STAT 1 can bind to STAT 2 already
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docked to an activated IFNa/(3 receptor. It is also likely that the particular JAKs and
1 8STATs activated may also depend on the cell type and its state of differentiation. 
1.3.5 Regulation o f the JAK/STAT Pathway
The JAK/ STAT Pathway is important for many biological responses including 
differentiation, proliferation and oncogenesis. Various mechanisms therefore exist to 
modulate this signalling pathway both positively and negatively. These regulatory 
processes determine the rate at which STAT signals are transduced and these signals 
can be modulated at various stages of the pathway.
A signalling pathway can be down regulated at the level of the receptor which can 
occur via the production of soluble receptors which compete for ligand binding or by 
receptor endocytosis. This is supported by the discovery of a 10 amino acid motif 
within the intracellular domain of gpl30 that regulates endocytosis. 12
Ubiquitin proteasome dependent degradation may also play a role in downregulation 
of cytokine signalling. The significance of this remains controversial but there is 
some evidence to suggest that phosphorylated STATs 4, 5 and 6, but not STATs 1,2 
and 3 can be stabilised by proteasome inhibitors. Proteasome inhibitors have also 
been shown to prolong JAK activity. 12
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JAK activation is dependent on phosphorylation on defined tyrosine residues. Two 
SH2 containing phosphatases, SHP1 and SHP2 have been found to regulate JAK 
activity. These enzymes are mainly cytoplasmic; their SH2 domains allow 
association with phosphotyrosines present on activated receptors or on signalling 
molecules as well as on activated JAKs. This association triggers activation of the 
phosphatase domain and subsequent dephosphorylation of the substrate. SHP1 
expression is largely restricted to haematopoietic tissues whereas SHP2 is more 
widely expressed. Evidence suggests that loss of a receptor’s ability to recruit 
SHP1/SHP2 leads to prolongation of JAK activity. In the EPO receptor when 
receptor tyrosine motifs responsible for the recruitment of SHP are lost, there is 
prolongation of JAK activation. A naturally occurring mutation on the EPO receptor 
resulting in its truncation leads to familial erythrocytosis. 19 Hypermethylation of 
normally unmethylated CpG islands of tumour suppressor genes is associated with 
transcriptional silencing. Silencing of the SHP1 gene by promoter methylation has 
been detected in various kinds of leukaemia, lymphomas and Myeloma. Mutations 
in SHP2 (PTPN11) occur in approximately 50% of individuals with Noonan’s 
Syndrome. Some of these patients develop a myeloproliferative disease which 
usually resolves but can develop into leukaemia. 20 It is not known whether each 
JAK is dephosphorylated by a different tyrosine phosphatase or whether one enzyme 
carries out this task for the whole family.
CD45 is a transmembrane phosphatase that negatively regulates JAK/STAT 
signalling stimulated by IL-3, IL-4 and EPO. 12 CD45 is restricted to haematopoietic
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cells and appears to regulate all four JAKs. Mice deficient in CD45 show 
hyperactivation of JAK1 and JAK3, associated with a loss of antigen responses in T 
and B lymphocytes. However CD45 has no major effect on cytokine signalling. 
Neither SHPs nor CD45 associate with the JAK kinase domain suggesting that other 
tyrosine phosphatases may deactivate JAKs.20
The PTP1B and T cell protein tyrosine phosphatase (TC-PTP) have a high level of 
homology in their catalytic domain. PTP1B is expressed in many tissues and is 
located on the cytosolic face of the endoplasmic reticulum due to a hydrophobic 
sequence in its C-terminal end. 20 JAK2 and Tyk 2 have been shown to be 
physiological substrates of PTP1B and fibroblasts deficient in this phosphatase show 
changes in phosphorylation including hyperphosphorylation of JAK2 suggesting a 
role in regulation of cytokine signalling. 4TC-PTP is widely expressed but has a 
particularly high expression in haematopoietic cells. 21 Both TC-PTP and PTP1B 
selectively recognise a motif centred on two tyrosine residues present in the JAK 
activation loop, but each one exhibits a different specificity for surrounding residues. 
PTP1B interacts with the D/E-pYpY-K/R sequence present in JAK2 and Tyk2 while 
TC-PTP interacts with the D/E-pYpY-T/V sequence present in JAK1 and JAK3.This 
allows for selective JAK dephosphorylation and subsequent deactivation.20
The mammalian SOCS family contains eight members which include CIS and 
SOCS1-7. They all share a central SH2 domain, a conserved C-terminal motif called 
the SOCS Box and an amino terminal region which is highly variable in length and
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nucleotide sequence. The SH2 domain allows for protein-protein interactions with 
the cytokine receptor and with other signalling components. SOCS 2, 3 and CIS bind 
phosphotyrosines on the receptor whereas SOCS1 binds to phosphotyrosine residues 
on JAK. 20 Both the SH2 domain and the N terminal domain are required for 
inhibition of cytokine signalling. 22 The first SOCS family member to be isolated 
was CIS which was cloned as an immediate early gene induced by IL-2, IL-3 and 
erythropoietin. CIS is able to associate with phosphorylated tyrosines on the 
receptor. It binds to phosphorylated Y 401 of the EPO receptor, the binding site for 
STAT 5, thereby suppressing STAT 5 mediated signalling. 4,18,20 The SOCS family 
can suppress cytokine signalling either by inhibiting the activity of JAKs, by 
competition with STATs for phosphorylated docking sites on the receptors or by 
targeting bound signalling proteins to the ubiquitin proteasome pathway through the 
SOCS box which is part of an E3 ubiquitin ligase. 20 Thus protein turnover is 
regulated by targeting of proteins for polyubiquitination and proteasome mediated 
degradation. This is brought about by the SOCS box acting as a link between SH2 
interacting proteins and an E3 ubiquitin ligase. In unstimulated cells most SOCS 
genes are expressed at very low levels. Many cytokines that signal via the 
JAK/STAT pathway induce the expression of SOCS genes to a variable extent in 
different cell types and tissues.
Overexpression of SOCS1 can inhibit virtually any JAK signal. SOCS1 interacts 
with the JAK kinase domain and and suppresses IL6 signal transduction pathways.23 
There is evidence that SOCS1 binds directly to the activation loop of JAK2
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specifically binding Tyrosine 1007 which as previously stated is required for JAK 
kinase activity. SOCS may function as a tumour suppressor gene and its down 
regulation may contribute to tumour progression. The growth of cells transformed by 
an oncogenic form of KIT or by the TEL-JAK2 fusion protein can be suppressed by 
over expression of SOCS1. It requires the presence of the SH2 domain for inhibition 
of TEL-JAK2 but not for KIT implicating different functions of the SOCS1 proteins. 
20 The SOCS gene can be down regulated by transcriptional repression by proto­
oncoproteins or by silencing via hypermethylation. Methylation of CpG islands in 
the region of the tumour suppressor induces a block in transcriptional initiation. 
Hypermethylation of the SOCS1 gene has been reported in different solid tumours 
and haematopoietic malignancies and is associated with activation of the JAK/STAT 
pathway and of expression of downstream target genes.20 Recently amplification of 
the JAK2 gene with resultant constitutive phosphorylation of JAK2 has been 
described in primary mediastinal large B cell lymphoma (MedBl cell line). 24 The 
constitutive activation was found to be due to delayed protein degradation caused by 
a biallelic mutation of SOCS1 abrogating the SOCS box function of the protein.25
The STAT proteins can be modulated directly. Carboxy terminus truncated isoforms 
can act as dominant negative inhibitors and the STATs can be directly 
dephosphorylated. The PIAS (protein inhibitor of activated STATs) family appear to 
bind to activated STAT dimers blocking their ability to bind DNA. The PIAS family 
consists of PIAS 1, PIAS 3, PIAS x and PIAS y. PIAS 1 and 3 have been proposed to 
block the DNA binding activity of STAT 1 and STAT 3 respectively. In contrast
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PIASx and PIASy repress the transcriptional activity of STAT 1 and 4 by recruiting 
co-repressor molecules such as histone deacetylases. 20 Cells derived from patients 
with anaplastic lymphoma expressing NPM-ALK have constitutive activation of 
STAT3 which is thought to be due to loss of PIAS3. There is also some evidence to 
suggest that PIASy may contribute to the growth of MDS blasts and disease 
progression.20
In summary several different steps of the signal transduction pathway appear to be 
targeted by negative regulators, including the receptor/ligand complex, JAK kinases, 
and STAT transcription factors. This negative regulation can be achieved by 
dephosphorylation of signalling intermediates by protein tyrosine phosphatases such 
as SHP-1, interruption of the pathways and negative feedback loops (CIS family) 
and by proteolytic degradation.
1.4 PI 3-Kinase Pathway
The class 1 phosphoinositide 3 kinases are a ubiquitously expressed family of 
proteins which are central to cell survival and proliferation. They are subdivided into 
2 groups-the class la and class lb PI3-Kinases.The class la PI3-Kinases signal 
downstream of tyrosine kinases and Ras. They are heterodimeric proteins consisting 
of a 110 kda catalytic unit (pi 10a, pi 100 or pi 105) and a regulatory unit (p85a, 
p850 or p55y) and are responsible for phosphorylating inositol lipids on the 
3’hydroxyl position, in response to growth factor signalling. Each of the catalytic
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units can associate with all of the regulatory units.26 The class lb PI3-Kinase, pi lOy 
is activated by G-protein coupled receptors. There is only one catalytic unit and one 
regulatory unit known as pi 10y and pi 01 respectively. The expression of pi 108 and 
pllOy subunits is mainly restricted to leukocytes whereas pi 10a and pi 10(3 are 
more widely expressed.26
Akt, a serine/threonine kinase is a key mediator of PI3-Kinase signalling. 27 
Stimulation by cytokines leads to the binding of the p85 regulatory unit, via its SH2 
domains, to phosphotyrosine residues on the receptor or associated signalling 
proteins. This activates PI3-Kinase and stabilises the active complex at the cell 
membrane where it’s major physiological substrate (phosphatidylinositol (4,5) P2) 
resides. PI3-Kinases can also be directly activated by GTP bound Ras. PI3-kinase 
phosphorylates PI(4,5)P2 creating PI (3,4,5) P3 (PIP3)- this recruits Akt via its 
Pleckstrin Homology (PH) domain to the plasma membrane where it is 
phosphorylated by another PH domain containing serine/threonine kinase, 
3’phosphoinositide dependent kinase 1 (PDK1). PDK1 phosphorylates Akt on 
threonine 308 leading to its activation. Maximal activation requires further 
phosphorylation on serine 473 carried out by PDK2 an enzyme which is 
uncharacterised. 28 So far approximately 10 kinases have been proposed to function 
as PDK2 including mTOR, integrin linked kinase and DNA dependent protein 
kinase. 29 Activated Akt is then responsible for the phosphorylation of numerous
downstream targets, regulating apoptosis and survival, cell growth and the cell cycle.
28
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The PI3-Kinase/Akt pathway is tightly controlled by the phosphatases, phosphatase 
and tensin homolog deleted on chromosome 10 (PTEN) and SH2 containing 
phosphatase 1 and 2 (SHIP 1/2), which are responsible for dephosphorylating PIP3 
on its 3’ and 5’ phosphates respectively.
There is now increasing evidence for PI3-Kinase/Akt dysregulation in human 
malignancy. 28 The pi 10a subunit is encoded for by the PIK3CA gene. 
Heterozygous point mutations in PIK3CA have been reported to occur in 30% of all 
breast and colon cancers but are less frequent in cancers of the brain, stomach, liver 
and ovary. The mutations are non randomly distributed over the primary structure of 
pi 10a and cluster to regions in the p85 binding domain, the C2 domain, the helical 
domain and the C terminus of the catalytic domain. The cancer specific point 
mutations of pi 10a confer a gain of function resulting in increased lipid kinase 
activity.30 In AML, we have screened 92 samples and found no PIK3CA mutations 
(unpublished data). Lee et al found 1 mutation in 88 acute leukaemias screened. 31 
The molecular mechanisms by which the mutants gain enzymatic function and hence 
oncogenic potential are not known.
PTEN is considered a tumour suppressor gene and loss of PTEN or SHIP activity 
can lead to over activity of PI3-Kinase. PTEN mutations have been described in a 
variety of solid tumours at high frequency and in addition in acute leukaemia and 
non Hodgkin’s lymphoma (NHL). Sakai et al looked at a series of lymphoid cell 
lines and primary lymphoid tumours and found PTEN mutations in 22% of the cell
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lines but only 4.6% of the primary lymphoid tumours.32 Gronbaek et al found 5% of 
their diffuse large B cell lymphoma samples had PTEN mutations (2/39) 33 and 
Dahia et al found mutations in 10% of NHL samples but only 1.35% of acute 
leukaemias.34 Therefore it can be seen that although PTEN inactivation is a possible 
mechanism for PI3-Kinase overactivity, so far mutations in PTEN have only been 
found in a small proportion of primary haematopoietic malignancies.
Dysregulation of upstream protein tyrosine kinases (PTK) may also lead to 
activation of the PI3-Kinase pathway. This loss of control of PTK activity may be 
due to chromosomal translocations such as t(9:22)(Bcr-Abl), gain of function 
mutations e.g. FLT3 internal tandem duplication (ITD) in AML and PTK gene 
overexpression e.g. neu/ ErbB2 and EGF receptor in breast and lung cancer.35 The 
final common pathway in these genetic changes is of constitutive kinase activation 
and of quantitative and qualitative changes in downstream signalling.
Activating Ras mutations (20-30% across all malignancies) may also lead to PI3- 
Kinase overactivity. 28 Akt2 mutations have been described in some solid tumours, 
as a rare occurrence. 28 Staal et al described Aktl gene amplification in an 
adenocarcinoma of the stomach out of 225 samples of a diverse range of 
malignancies screened.36 Cheng et al found Akt2 gene amplification in 2/15 ovarian 
primary tumours and 1/10 pancreatic carcinoma samples. 37,38 Akt overexpression 
has also been linked to tumour progression.39
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The role of dysregulation of PI3-Kinase in AML is less clear and is investigated 
further in Chapter 5.
1.5 MAP-Kinase Pathway
The MAP-Kinases are widely expressed serine/threonine kinases which have 
important roles in cell proliferation and survival. Aberrant activation of this pathway 
is common in malignantly transformed cells. Three different groups of MAP- 
Kinases exist, P38 MAPKinase family, the extracellular signal regulate kinase 
(ERK) family and the JNK family. I will be concentrating here on the 
Ras/Raf/MEK/ERK signaling pathway.
Ras is a small GTP binding protein which is a common upstream molecule in several 
signaling pathways including Ras/Raf/MEK/ERK and the PI3-Kinase pathway. 
Three different Ras proteins exist, H-Ras, N-Ras and K-Ras. Ras proteins are small 
membrane associated proteins with intrinsic GTPase activity allowing them to 
switch between active and inactive states. This switch depends upon the binding of 
GTP and GDP respectively. In order for Ras to function in the active state it is 
recruited to the membrane which is highly dependent on lipid modification of the 
Ras protein called prenylation. Prenylation is accomplished by two enzymes, 
famesyl and geranylgeranyl transferases which add 15 and 20mer isoprenoids to the 
Ras protein. 40 Binding of ligand to the receptor leads to dimerisation of the receptor 
tyrosine kinase and activation of the tyrosine kinase domains. The signal is
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transmitted to the GRB2/SOS complex which then promotes Ras activation. 
Although Ras has some intrinsic GTPase activity proteins such as pl20GAP and 
NF-1 promote inactivation of Ras changing Ras-GTP to Ras-GDP.40
Raf is a serine/threonine kinase which can be activated by a number of different 
mechanisms. It can be activated by recruitment to the plasma membrane by 
interaction with Ras, by dimerisation of two Raf molecules and by phosphorylation 
on different domains. 39 Raf activity can be modulated by adapter proteins such as 
Bag-1, Hsp70 and 14-3-3. There are three members of the mammalian Raf family, 
Rafl, A-Raf and B-Raf. All three family members are able to phosphorylate and 
activate MEK although B-Raf is more potent than Raf-1 which itself is more potent 
than A-Raf.
MAPKs are activated by dual phosphorylation of conserved threonine and tyrosine 
residues within the activation loop (denoted T-X-Y) and phosphorylate targets on 
serine and threonine residues within a consensus PXT/SP motif (X can depend on 
the MAPK).
MEK a dual specificity kinase phosphorylates ERK on threonine and tyrosine 
residues which are required for full activation. ERK is then able to directly 
phosphorylate a set of transcription factors; Etsl, cJun and cMyc. ERK may also 
phosphorylate RSK which translocates to the nucleus and phosphorylates other 
transcription factors including CREB. CREB activation results in transcription of
40
Bcl-2 an antiapoptotic factor. Thus the overall effect of activation of the 
Ras/Raf/MEK/ERK pathway is of increased DNA synthesis, promotion of 
proliferation and increased survival.
Deregulation of the RAS pathway in cancer can occur via several methods; either 
directly through activating point mutations or indirectly through mutations of other 
oncogenes e.g receptor tyrosine kinases such as FLT3 and c-KIT or tumour 
suppressor genes e.g Neurofibromin (NF-1). Ras mutations are frequently observed 
in AML (20-30%), juvenile myelomonocytic leukaemia (30%), CMML (50%) and 
MDS (15-20%). N-RAS is mutated in the majority of cases and RAS proteins are 
typically activated by point mutations at critical RAS regulatory sites such as codons 
12, 13, and 61. These mutations increase the half life of RAS-GTP through 
interruption of the normal intrinsic or GAP-stimulated GTPase activity. Inactivation 
of the RAS-GAP AF9Q34 through the t(9;ll)(q34;q23) or inactivation of NF-1 can 
also cause deregulation of RAS activity by increasing the half life of activated GTP 
bound RAS. 41
Juvenile myelomonocytic leukemia (JMML) is a rare, clonal, mixed 
myeloproliferative and myelodysplastic disorder afflicting young children. The 
pathogenesis of JMML arises from dysregulation of signal transduction through the 
Ras pathway. Potential causative mutations or other genetic abnormalities in three 
genes (RAS, NF1, and PTPN11), all of which are positioned in the GM-CSF/Ras 
signal transduction pathway, account for up to 75% of cases of JMML.
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Alterations in the RAS signaling cascade are very common in melanoma. RAS itself 
is not frequently mutated although signaling molecules downstream of RAS such as 
B-Raf are often altered. B-Raf, has been found to be mutated in approximately 60% 
to 70% of superficial spreading melanomas. 42
Activation of these signaling cascades results in changes in proliferation, 
differentiation and apoptosis.
1.6 Protein Kinase inhibitors
Small molecule inhibitors are useful agents in the investigation of cell signaling. 
They are rapid and simple to use and can be used both in transformed cell lines and 
normal cells and tissues. They inhibit endogenous kinases and there is no need for 
exogenous overexpression of dominant-inhibitory molecules leaving the cells little 
time to adapt and develop resistance to the agent. Early workers felt that as the 
majority of small molecule inhibitors are targeted to the ATP binding site which is 
highly conserved across protein kinases it would be difficult to achieve specificity. 
The kinase domains of all tyrosine kinases have a bilobar structure, with an N 
terminal lobe that binds ATP and magnesium, a C terminal lobe containing the 
activation loop and a cleft between the lobes to which polypeptide substrates bind. 
However it is possible to gain some selectivity as the development of agents such as 
the Abl inhibitor STI571 (Imatinib mesylate) illustrate. This is likely to be due to 
some key diversity around the proximal region of the ATP binding domain together 
with conformational changes between active and inactive kinases. The activation
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loop controls catalytic activity by switching between states in a phosphorylation 
dependent manner, in fully active kinases the loop is held in an open conformation 
by phosphorylation on serine, threonine or tyrosine residues within the loop and in 
this conformation a p strand loop provides a base for substrate binding. This active 
conformation is very similar in all known structures of protein kinases. 43 In the 
inactive state, however, there is much greater diversity and the activation loop often 
occludes substrate binding.
The potency of these inhibitors is compared using the IC50 i.e. the drug 
concentration required for 50% inhibition. Of course, for ATP competitive inhibitors 
this will be dependent on the ATP concentration within the assay and this is also 
important to remember when comparing in vitro (ATP concentrations in micromolar 
range) and in vivo (ATP intracellular concentration in millimolar range) results.
As well as being important for the investigation of the physiological role of kinases 
within the cell these agents are now being developed for therapeutic use in many 
malignancies. This is because several protein kinases have been found to be 
dysregulated in a number of cancers. Protein tyrosine kinases can be activated by 
several mechanisms including chromosomal translocation as in BCR-Abl in chronic 
myeloid leukaemia; point mutations, in-frame deletions or insertions as in FLT3 in 
AML and over expression for example epidermal growth factor receptor and HER2 
in various carcinomas. Increased activity can also occur as a result of reduced 
negative regulation e.g. reduced tyrosine phosphatase activity or decreased 
expression of inhibitor proteins. Aberrant PTK activation can lead to increased
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survival and proliferation in tumour cells, resistance to cytotoxic therapy and in 
some tumours an increase in angiogenesis, invasiveness and metastatic potential.
The issue of selectivity is of course paramount when considering transferring these 
drugs to clinical practice. These protein kinases are widely expressed and one could 
expect many unwanted consequences associated with inhibition of tyrosine kinases 
in normal tissues. Selectivity can be achieved depending on the mode of binding of 
the tyrosine kinase inhibitor - for instance does it bind to the wild type or mutated 
kinase, to the activation loop in the active or inactive conformation? This can be 
illustrated by the findings of Schnittger et al. They investigated the activity of 3 
inhibitors; Imatinib, SU5614 and PKC412 on BAF3 cells expressing the KIT D816V 
mutation. This mutation leads to constitutive activation of the kinase. They found 
that both Imatinib (known to inhibit wild-type KIT) and SU5614 were inactive in 
these cells but they were fully sensitive to the effects of PKC412. The profound 
differences in the sensitivity of the KIT D816V mutant to different PTK inhibitors 
probably relates to the binding mode of these agents. Structural studies have shown 
that Imatinib binds the kinase domain of KIT as well as ABL in the inactive state. A 
point mutation within the activation loop like Asp 816 valine in KIT confers 
constitutive activation and thus resistance to Imatinib. In contrast PKC412 is thought 
to bind within the ATP binding pocket of the active conformation of PDGFRA, 
which is probably also the case for its binding to the KIT receptor.44 One of the new 
Abl kinase inhibitors Dasatinib (BMS-354825) is also a Src inhibitor. In vitro this 
drug is more potent than imatinib.45Whereas Imatinib binds to the inactive
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conformation of the kinase loop which is distinct between Abl and Src, Dasatinib 
binds to the loop whether open or closed therefore inhibiting both kinases. In 
addition it is a smaller molecule than Imatinib and thus the P-loop must undergo 
major conformational changes to inhibit its binding and it is therefore able to inhibit 
many of the tyrosine kinase mutations that lead to imatinib resistance. Nilotinib 
(AMN107) is an ABL kinase inhibitor which was specifically developed to be more 
selective for BCR ABL and yet maintain clinical efficacy against some of the 
commoner mutations asssociated with imatinib resistance. Like imatinib Nilotinib 
also binds to the inactive conformation of ABL but gains in potency due to an 
improved topological fit 46. Selectivity can also be achieved by targeting cancer 
specific proteins especially if the protein is restricted to cancer tissue, if it has 
specific enzymatic activity that shows a gain of function compared with wild type 
enzyme and if the mutant protein plays a causative role in the disease process. This 
is the situation for BCR-Abl in CML. In addition CML cells display ‘oncogene 
addiction’ and the cells cannot survive with out BCR-Abl. This can be explained by 
the fact that BCR-Abl blocks downstream apoptotic pathways and so pro-apoptotic 
proteins accumulate upstream. When the apoptotic block is removed by inhibition of 
BCR-Abl, apoptosis occurs. Non small cell lung cancer cells expressing upregulated 
EGFR also demonstrate ‘oncogene addiction’ and are susceptible to EGFR 
inhibition with Gefitinib. It has been suggested that cells with multiple genetic 
aberrations, and thus alteration of a number of signalling pathways are less likely to 
become addicted to a single abnormal kinase. 47
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Experience with Imatinib has demonstrated that resistance to tyrosine kinase 
inhibitors can occur through a number of mechanisms likely to be applicable to other 
tyrosine kinase inhibitors. Decreased intracellular drug levels may occur because of 
excess binding by a - 1-acid glycoprotein or by increased drug efflux from P- 
glycoprotein over expression. Influx proteins are less well characterised in the area 
of multi drug resistance than efflux proteins. The organic cation transporter proteins 
(OCT) are involved in the absorption, distribution and elimination of drugs in vivo49. 
White et al demonstrated that the interpatient variability in IC50 of imatinib, defined 
as 50% reduction in phosphorylated CrKL, was mainly due to differences in 
intracellular uptake and retention of imatinib. Prazosin, an OCT-1 transporter 
blocker, eliminated this interpatient variability suggesting that differential 
expression or function of OCT-1 is a significant determinant of imatinib 
response.49Gene amplification of the BCR-Abl kinase has been associated with the 
development of resistance to Imatinib as has clonal evolution. This evolution has 
been observed in paired cytogenetic analyses from the beginning of Imatinib therapy 
and at the development of resistance. These chromosomal abnormalities include 
second Philadelphia chromosome, the development of trisomy 8, loss of a p53 allele 
via alteration of the short arm of chromosome 17 or the development of new 
reciprocal translocations. The best documented mechanism of resistance to Imatinib 
in CML is the occurrence of gene mutations in the Abl tyrosine kinase domain. 
These single nucleotide substitutions result in replacement of individual amino acids 
that have varying effects on the conformation of the Abl portion of the BCR-Abl and 
it’s binding to drugs or substrates. These mutations are distributed at multiple sites
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throughout the BCR-Abl kinase, including within the nucleotide binding or P-loop, 
within the active site where Imatinib binds and within the activation loop and 
carboxy terminal. 48 It is clear that CML stem cells are relatively more resistant to 
imatinib than more differentiated cells50 leading to disease persistence even in 
optimally responding patients.5Copland et al investigated possible underlying 
mechanisms for this resitance and were able to exclude gene amplification as a 
possible cause. They found that these more primitive cells expressed higher BCR 
ABL transcript levels and in addition found increased protein expression of BCR 
ABL, Phosphotyrosine and phospho-CrKL confirming increased BCR ABL activity 
in this fraction.52 Methods of overcoming resistance include increasing the dose of 
Imatinib, the development of new inhibitors and the use of combination therapy. 
Dasatinib is very much more potent than imatinib and inhibits BCR ABL + cells 
further back in the stem cell compartment; however the quiescent fraction of stem 
cells appears to be inherently resistant to imatinib and dasatinib.52There is some in 
vitro evidence that suggests that using imatinib in combination with the famesyl 
transferase inhibitor, Lonafamib, may reduce resistance of this primitive quiescent 
cell fraction.53
The success of Imatinib in CML has provided encouragement that kinase inhibitors 
may be valid therapeutic modalities; however in chronic phase CML, the BCR-Abl 
translocation is thought to be the sole abnormality driving the disease; in diseases 
where several genetic abnormalities exist, such as in AML, a combined therapeutic 
approach is likely to be necessary. The phenomenon of ‘oncogene addiction’ 
discussed earlier may allow for a greater therapeutic window.
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1.7 JAK 2 Inhibitors
JAK2, a member of the Janus kinase (JAK) family of protein tyrosine kinases 
(PTKs), is an important intracellular mediator of cytokine signaling. Mutations of 
the JAK2 gene are associated with haematologic cancers (discussed in detail in 
chapter 4), and aberrant JAK activity is also associated with a number of immune 
diseases, including rheumatoid arthritis. Therefore, the development of JAK2- 
specific inhibitors could have many clinical applications. However as a corollary of 
its widespread involvement in haematopoietic cytokine signaling, predictable side 
effects of JAK2 inhibition would include anaemia, thrombocytopenia and 
neutropenia.
1.7.1 AG490
AG490 is a tyrphostin inhibitor containing a cyano group which gives it its yellow 
colour. It inhibits JAK2 and JAK3 at micromolar concentrations and is also known 
to inhibit the EGFR tyrosine kinase. It has negligible effects on JAK1 and Lck. 
AG490 was found to induce death in Pre B ALL cells which constitutively express 
phosphorylated JAK2 and was also found to eradicate the recurrent form of Pre B 
ALL in SCID mice into which the disease had been engrafted.54 De Vos et al found 
that AG490 suppressed cell proliferation and induced apoptosis in IL-6-dependent 
MM cell lines. They found JAK2 kinase activity, ERK2 and STAT3 
phosphorylation were all inhibited.55 Another group combined therapy with AG-490
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and IL-12 and found that this combination induced greater antitumour effects than 
either agent alone in a murine myeloma tumor model. 56 AG490 was also found to 
inhibit JAK3 mediated IL-2 induced T cell proliferation in T cell lines. 57 Levitzki 
also reported that AG490 triggers apoptosis in prostate cancer cells by inhibition of 
autocrine/paracrine IL-6. 58 On the face of it AG490 would appear to be a useful 
JAK2/3 inhibitor; however Kleinberger-Doron et al report that AG490 inhibits the 
activation of the enzyme CDK2 without affecting its levels or its intrinsic kinase 
activity, leading to cell cycle arrest at Gl/S. 59 Therefore it is possible that some of 
the effects of AG490 on cell survival and proliferation may have been mediated by 
CDK2 inhibition and cell cycle arrest rather than being directly attributable to JAK 
inhibition. Without the use of other JAK inhibitors with a different structure, a 
dominant negative JAK protein or even RNA interference these results may be 
regarded as being flawed.
1.7.2 JAK Inhibitor 1
JAK inhibitor 1 (JI1) is a Pyridone containing tetracycle that inhibits JAK family 
members. It is a reversible inhibitor competitive with respect to ATP and non 
competitive with respect to substrate. It shows selectivity for JAK family members 
and within the family inhibits Tyk2 and JAK2 (IC50 InM) more potently than JAK1 
and JAK3 (IC50 5and 15nM respectively). 60 Lucet et al use JI1 to examine the 
crystal structure of the active catalytic domain of JAK2. They found that JI1 was 
buried deep within a constricted ATP-binding site, in which extensive interactions,
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including residues that are unique to JAK2 and the JAK family, are made with the 
inhibitor. 61 JI1 is able to inhibit IL-2 and IL-4 driven proliferation of a murine T cell 
lymphoma line, mediated through JAK1 and JAK3 inhibition (IC50 lOOnM). 
Simultaneously inhibition of ST AT 5ab phosphorylation occurs. Non specific effects 
of JI1 are evident with its ability to inhibit PMA induced proliferation which does 
not require signaling through JAK family members.60
1.7.3 JAK3 Inhibitors
Unlike other JAKs, JAK3 expression is restricted to haematopoietic tissues and its 
use is limited to cytokines signalling through the common y chain including IL-2, 4, 
7 and 15 and 21. These cytokines modulate lymphoid development and function and 
JAK3 inhibitors are being developed as immunosuppressant and anticancer agents. 
A highly specific JAK3 inhibitor should have limited and precise effects but because 
of the homology between JAKs this selectivity is particularly challenging. JAK2 is 
essential for many haematopoietic cytokines including EPO and GMCSF and TPO. 
By inference pharmacological inhibition of JAK2 could lead to anaemia, 
thrombocytopenia and neutropenia. JAK1 inhibition could lead to an interruption in 
IFN signaling and may lead to an increased susceptibility to viral infections. 
Therefore concurrent inhibition of these kinases could lead to an intolerable side 
effect profile. However despite this some selective agents have been discovered and 
are discussed below.
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CP690550 is an orally active drug which is a potent inhibitor of JAK3 in the 
nanomolar range in vitro and is ~ 30 fold and ~ 100 fold less potent for JAK 2 and 
JAK1 respectively. This drug is effective at preventing transplant rejection in 2 
models: a murine heterotopic heart transplant and a non human primate renal 
transplant model. In both cases the drug prolonged graft survival. It was found to 
block IL-2 signalling and IL-2 dependent gene expression without having an effect 
on T cell receptor signaling. This would allow it to be used synergistically with 
calcineurin inhibitors. The side effect profile of this drug is acceptable with no 
reported granulocytopenia or thrombocytopenia suggesting that in vivo JAK2 
inhibition is not a great problem. 62
The dimethyl quinazolines inhibitors, WHI-P154 and WHI-P131 are reported to 
inhibit JAK3 with an IC50 for WHI-P154 of 28pM but it did not inhibit JAK1 and 
JAK2. The reported IC50 for WHI-P131 was 9pM. WHI-P131, did not inhibit 
JAK1, JAK2, SYK, BTK, LYN, or IRK at concentrations as high as 350 microM. 
WHI-P131 and WHI-P154 inhibited JAK3 and induced apoptosis in leukaemia cell 
lines, NALM6 and LC1;19 but not in JAK3 negative melanoma or squamous 
carcinoma cells.63
PNU 156804, an undecylprodigiosin antibiotic has been shown to inhibit IL-2 
induced cell proliferation, IL-2 induced JAK3 autophosphorylation and lead to a 
reduction of STAT 5a^ and ERK phosphorylation. Stepkowski et al report that PNU 
156804 was able to prolong the survival of murine heart allografts in a dose
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dependent manner. It also acted synergistically with cyclosporine and additively 
with rapamycin to block allograft rejection. 64
Because of JAK3’s limited expression and the fact that its only consequential 
biological function is restricted to immune cells, a selective JAK3 antagonist is not 
associated with widespread effects on other organs and as such a selective JAK3 
antagonist would differentiate itself from other currently available 
immunosuppressants. These drugs are heading towards clinical trials and may also 
find uses in the treatment of cancer, autoimmunity and allergy.
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Figure 1.1. A diagram illustrating the 3 main signalling pathways downstream of 
a class 1 cytokine receptor and the level of blockade of relevant kinase 
inhibitors.
1.8 Acute Myeloid Leukaemia
Acute myeloid leukaemia is a clonal haematopoietic stem cell disorder 
encompassing a group of heterogeneous diseases which are characterized by 
uncontrolled proliferation of the malignant clone and impaired normal 
haematopoiesis leading to neutropenia, thrombocytopenia and anaemia. Untreated 
patients die o f infection or bleeding in a matter of weeks. The diagnosis is made
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morphologically with immunophenotyping, cytogenetics and molecular techniques 
all adding to the biological picture. Despite improvements in cytotoxic therapy and 
supportive care, the majority of patients are destined to die from their disease with 
only about one third of patients aged between 18-60 being cured. One of the most 
important prognostic factors is karyotype. Patients can be divided into favourable, 
intermediate and poor prognostic groups on the basis of their cytogenetic profiles. 
Good risk is defined by the presence of t(15; 17), t(8;21) and inv (16), intermediate 
by the presence of a normal karyotype or abnormalities not encompassed by the 
good or poor risk groups and poor risk is defined by the presence of a complex 
karyotype or abnormalities of chromosome 3, 5 or 7. The relapse risk at 5 years is 
quoted as being 35%, 51% and 76% respectively. 65 The presence of an activating 
mutation in the FLT3 gene is an important predictor of relapse risk in patients with 
AML. 66 An internal tandem duplication of the FLT3 gene can be detected in 20- 
30% of adults with AML and appears to be associated with an increased relapse risk 
rather than a failure to enter remission. The presence of the FLT3 mutation has aided 
prognostication in the intermediate cytogenetic risk group. Other predictors of 
relapse are increasing patient age, high white cell count and a history of preceding 
myelodysplasia. The increasing relapse risk with age is likely to reflect the increase 
in adverse cytogenetic abnormalities and/or an increased incidence of drug resistant 
phenotypes e.g. P-gp positivity. There is an increased frequency of FLT3 gene 
mutations in patients with a high white count and this may account for the higher 
relapse rate in this group.
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AML has been proposed to arise from the collaboration of two broad classes of 
mutation, a class I or proliferative mutation and a class II or blocking mutation. Thus 
dysregulated proliferation and impaired differentiation bestows a survival advantage 
on the leukaemic cell. A very large number of mutations associated with AML have 
been discovered with over 300 chromosomal translocations having been reported to 
occur.
Deregulated proliferation may arise as a result of mutations affecting proliferative 
signaling pathways for instance in class III tyrosine kinase receptors. The FLT3 
receptor is present on early haematopoietic progenitors and AML blasts. Mutations 
in the FLT3 receptor juxtamembrane region result in a gain of function of the 
receptor. The exact stretch of DNA duplicated can vary from approximately 16 to 
108 nucleotides but is always in frame. Mutation can also occur in the activation 
loop of the kinase again leading to presumed constitutive activation, the prognostic 
impact of these mutations is less clear.
C-KIT is a class III receptor tyrosine kinase for stem cell factor, stem cell factor 
binding promotes dimerisation and transphosphorylation and downstream signaling 
events leading to cell growth. Constitutively activated forms of the c-KIT have been 
associated with systemic mast cell disease, acute myeloid leukemia, and 
gastrointestinal stromal tumors. The most common mutations in systemic mast cell 
disease and AML are the D816V and D816Y mutations in the activation loop.67
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JAK2 is activated by the V617F point mutation in the overwhelming majority of 
polycythaemia vera and a significant proportion of essential thrombocythaemia and 
myelofibrosis, all these disorders can evolve into AML. It has also been reported in 
5% of patients with myelodysplastic syndrome 68 and so would be thought likely to 
be found in those patients who transform to AML, although most reports so far have 
not found this to be the case.
Activated tyrosine kinases can transmit proliferative signals by the engagement of 
the Ras family of G proteins and mutations of genes encoding these proteins may 
mimic the effects of receptor tyrosine kinase mutations. There are 3 functional Ras 
genes, N-(neuroblastoma line), K-(Kirsten) and H-(Harvey) Ras. Bowen et al 
screened a large number of AML patients less than 60 years and found N-Ras 
mutations in 11% and K-ras mutations in 5% of patients, no H-Ras mutations were 
found. They found these mutations rarely coexisted with FLT3 mutations and unlike 
FLT3 ITD, they did not appear to influence clinical outcome.69
Usually the RTK pathways in AML are activated by gain of function mutations one 
exception to this would be a mutation in NF-1 leading to loss of function. NF-1 
inactivates RAS by enhancing its GTPase activity and thus this mutation leads to 
activation of RAS. An activating mutation in the PTPNllgene encoding SHP-2, 
leads to removal of phosphates from key substrates which paradoxically leads to 
increased signalling through receptor tyrosine kinase pathways.
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Transcription factors are commonly disrupted in AML usually as a result of 
chromosomal translocations but also as a result of point mutations. Transcription 
factors commonly involved in chromosomal rearrangements include the core 
binding factor complex, the retinoic acid receptor, the MLL protein and Hox 
proteins. Point mutations in myeloid transcription factors including C/EBPa and 
PU1, may also lead to loss of normal myeloid differentiation in AML.
The core binding factor complex is a heterodimer of CBFp and one of 3 alpha units; 
CBFotl, AML1 (CBFa2) and CBFa3. CBFP enhances DNA binding by 
stabilization of the protein’s conformation. CBFp markedly augments the metabolic 
stability of AML1, which by itself is highly susceptible to proteasome-mediated 
degradation. CBFp does not bind DNA directly but increases the affinity of the 
alpha subunits for consensus DNA binding motifs. The core binding factor regulates 
a number of haematopoietic genes critical for myeloid development. CBFp and 
AML1 are reported to be disrupted by chromosomal translocations in 30% of cases 
of AML leading to chimeric fusion proteins such as AML-ETO, AML1-EVI1 and 
CBFp-MYHll. These chimeric fusion proteins disrupt normal AML1 function by 
acting as dominant negative transcription factors. The characteristic differentiation 
block occurring in CBF leukaemias may also occur as a result of point mutations in 
CCAAT/enhancer binding protein, a myeloid transcription factor required for 
granulocytic differentiation. Interestingly C/EBPa point mutations are known to act 
as a class II mutation in 7-11% of cases of AML.
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Acute promyelocytic leukaemia is always associated with rearrangement of the 
retinoic acid receptor alpha (RARa). In over 98% of cases of APL this is secondary 
to the t( 15; 17) which generates the PML-RARa fusion protein. Other fusion 
partners include PLZF, STAT 5b and nucleophosmin. RARa acts as a regulator of 
myeloid development. In normal cells RARa would heterodimerise with a member 
of the retinoid-X receptor (RXR) family to allow high affinity DNA binding.70 The 
configuration of the heterodimer binding together with the presence of corepressor 
or coactivator binding determines the pattern of response. In the absence of ligand, 
retinoic acid, corepressors bind to the ligand binding domain of RAR and silence 
gene expression by the recruitment of histone deacetylases and SIN 3. PML-RARa 
or the other chimeric proteins bind corepressors and recruit HDAC and SIN3 and 
thus lead to gene silencing. PML-RARa also disrupts the normal PML nuclear 
bodies.70 FLT3 mutations are a common cooperating mutation in APL occurring in 
approximately 35% of cases.66
The mainstays of treatment in APL are ATRA and Arsenic which overcome the 
differentiation block by reactivation of the RAR target genes and degradation of the 
PML-RARa, leading to terminal differentiation of the promyelocytes.
Mutations in AML may also affect self renewal an example of this is the MLL 
rearrangement. The mixed lineage leukaemia gene is located on chromosome 1 lq23 
and rearrangements of this gene are common in therapy related leukaemias 
particularly where topisomerase II inhibitors have been previously used. The MLL 
gene may be rearranged with a number of fusion partners. The MLL-fusion protein
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is able to dimerise with itself and wild type MLL and these complexes are recruited 
to Hox genes to activate their expression. Hox gene expression is associated with 
increased self renewal in haematopoietic cells.71
In many cases of AML the clinical outcome may be correlated with expression of 
pro apoptotic and pro survival molecules. These molecules may be activated by 
protein tyrosine kinase activation via pathways such as PI3-Kinase. Akt 
phosphorylates BAD leading to the release of the anti-apoptotic molecule Bcl-2.
P53 is a focal point in the regulation of apoptosis and cell cycle. Mutations within 
P53 are associated with adverse response to chemotherapy in AML. The function of 
this protein may be affected in many ways including repression of pl4 ARF by 
AML1-ETO or by mutations in the nucleophosmin (NPM) gene.72 71 Mutations in 
nucleophosmin occur in approximately one third of de novo AML cases, the 
expression of this cytoplasmic variant is associated with the expression of genes 
thought to maintain a stem cell phenotype. 71 Disruption of the normal PML body 
function and failure of NPM to sequester MDM2 can also lead to decreased P53 and 
loss of G1 checkpoint control.71,73,74
It can be seen that the molecular biology of AML is complex with many defects and 
biological processes intertwining. It is envisaged that through a more clear 
understanding of these processes more precise and specific therapies for AML will 
be developed.
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1.9 Molecularlv targeted treatment in AML
NPM1, FLT3 and Ras mutations are the most frequently mutated genes in 
haematological malignancies.75Intensive research has been focused on the 
development of specific inhibitors that target these enzymes.
The FLT3 receptor is a membrane bound receptor crucial for the maintenance, 
proliferation and differentiation of haematopoiesis.76 It is expressed by normal 
myeloid and lymphoid progenitors as well as by leukaemic cells in 70-90% of AML 
patients.77 Mutations are commonly found in AML (25-40%) 41 and less commonly 
in myelodysplasia (2.5-8.8%). There are two main types of FLT3 mutations-intemal 
tandem duplications (ITD) of the juxtamembrane domain and point mutations in the 
highly conserved tyrosine kinase domain (TKD)-both of which cause constitutive 
activation of FLT3 and concomitant activation of downstream signalling pathways 
(e.g Ras and PI3-kinase/Akt).78 Interestingly these two types of activating mutations 
show differences in their signaling properties. FLT3 ITDs activate STAT 5 and 
repress c/EBPa and Pu-1 whereas FLT3 TKDs do not. 79Several small molecule 
tyrosine kinase inhibitors with varying specificity for FLT3 have been developed 
including CEP701, SU5416, SU5614 and PKC412. Some of these compounds have 
demonstrated promising clinical results. CEP701 is an orally available 
indolocarbazole derivative that preferentially inhibits autophosphorylation of wild 
type and mutant FLT3 with only limited inhibition of c-KIT, c-FMS and PDGFRp. 
In a phase I/II trial in relapsed and refractory AML, CEP701 was well tolerated and
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demonstrated some clinical activity in 5 out of 14 patients. 41 However responses 
were short lived (2 weeks to 3months).
SU5416 is a potent inhibitor of several tyrosine kinase receptors, including both wild 
type and mutant FLT3 (IC50 0.1 -0.25pM), vascular endothelial growth factor 
receptor (VEGFR)-1 and VEGFR-2 and c-KIT. Several phase II trials of this agent 
in refractory AML have been carried out. Objective responses have been few. A 
phase II trial of SU5416 in c-KIT positive refractory AML was carried out in 42 
patients. One patient had a complete remission lasting 2 months and 7 patients had 
partial responses lasting 1-5 months. None of the patients with FLT3 ITD responded 
to SU5416. 41
PKC 412 is an inhibitor of protein kinase C, kinase insert domain containing 
receptor, c-KIT, fibroblast growth factor receptor, PDGFRa and p. In a phase II 
study in 20 relapse/refractory AML or high grade MDS patients with FLT3 
mutations, 14 patients achieved more than a 50% reduction in peripheral blast counts 
and 7 of these 14 had a more than 2 log reduction in peripheral blast count that 
lasted more than 4 weeks. FLT3 autophosphorylation was inhibited in most patients 
demonstrating in vivo target inhibition. 41 Trials are underway to investigate FLT3 
inhibitors in combination with chemotherapy.
As discussed in section 1.5 dysregulation of Ras in AML can occur directly through 
point mutations or indirectly through mutations of other oncogenes. Proper
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intracellular localization of Ras proteins is critical for the successful transduction of 
mitogenic stimuli. To properly bind to the plasma membrane and gain full biological 
activity Ras proteins must undergo several post translational modifications including 
prenylation, proteolysis, carboxymethylation and palmitoylation. These steps are 
catalysed by specific enzymes including famesyltransferase, human Ras converting 
enzyme-1, isoprenylcysteine carboxyl methyltransferase and palmitoyl acyl 
transferase. Inhibitors of each of these steps are being developed but the 
development of famesyltransferase inhibitors is the most advanced. FTI’s elicit a 
number of cellular effects including alteration of cell cycle progression, induction of 
apoptosis, effects on actin stress fibres, changes in cell morphology and inhibition of 
anchorage dependent growth. 41 R115777 (tipifamib/Zamestra) has been the most 
extensively studied. Several clinical trials have been reported in AML/MDS and 
overall response rates of 20-30% have been observed. Responses have included 
complete remissions. R115777 is currently under investigation in combination with 
classical chemotherapeutic agents such as etoposide, idarubicin and cytarabine.
Mammalian target of rapamycin (mTOR) is an essential mediator of growth signals 
that originate from PI3-kinase. As discussed earlier dysregulation of the PI3-kinase 
pathway has been reported in a number of malignancies including AML. mTOR was 
originally identified as the target of the macrolide antibiotic rapamycin. mTOR is a 
serine/threonine kinase involved in the regulation of cell growth and proliferation by 
translational control of key proteins such as the cyclin-dependent kinase (CDK) 
inhibitor p27kipl, retinoblastoma protein, cyclin Dl, c-myc, or STAT 3. mTOR is
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activated by different stimuli including nutrients or growth factors. Once activated, 
mTOR can phosphorylate its downstream targets, the ribosomal p70S6 kinase 
(p70S6K) and the 4E-binding protein 1 (4E-BP1)80. mTOR inhibitors (rapamycin, 
or analogues such as CCI-779, RAD001, AP23573), have been shown to have a 
potent anti-neoplastic effect in many solid tumor models. Recher et al found that 4 
out of 9 patients with relapsed/refractory AML had a significant clinical response 
after treatment with Rapamycin81. These agents are currently being further 
evaluated.
An example of molecularly targeted therapy which is now in common use is that of 
ATRA in acute promyelocytic leukaemia. In 100% of APL cases the RARa gene is 
involved in reciprocal translocations which generate RAR fusion proteins. The most 
common translocation is the t( 15; 17)(q22 ;q21) which results in the PML-RARa and 
is found in 95% of all APL cases. This translocation results in the abnormal 
recruitment of NCoR/SMRT through oligomerisation of RARa by the coiled coil 
domain of PML. PML-RARa oligomers are able to associate with more than one 
NCoR/SMRT complex simultaneously while wild type binds to only one. This 
results in a local increase in concentration of HDAC complexes on the DNA of 
target genes and enhanced transcriptional repression in the presence of physiological 
concentrations of retinoic acid. Higher than physiological doses of retinoic acid are 
required for the dissociation of the NCoR/SMRT/HDAC complex and thus to allow 
recruitment of the coactivators and for transcriptional activation. Treatment with
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ATRA has revolutionized the management of APL leading to a good prognosis and 
overall survival rates of 60-70%.
AML is a heterogeneous disease with aberrations in multiple signaling pathways 
often within the same clone. As has been discussed above, the cooperation of at least 
two mutations is thought to be necessary for the onset of AML one leading to a 
proliferative advantage such as FLT3-ITD and another leading to a block in 
differentiation such as CBFp. It seems unlikely that inhibition of a single pathway 
would be sufficient in AML to bring about long term responses and this seems to be 
the case with clinical trials with FLT3 inhibitors so far. However a combinatorial 
approach either using two or more kinase inhibitors or with a kinase inhibitor 
together with classical chemotherapeutic agents may be more successful.
1.10 Aims
The aim of the following research was to investigate the activity of the protein 
kinase inhibitor G66976 on JAK family members and to take this information and 
further our knowledge of the role of the JAK/STAT pathway in AML. In particular 
the effect of JAK kinase inhibition on survival and proliferation in haematopoietic 
cell lines and primary AML cells was investigated. As PI3-Kinase/Akt and 
Ras/MAPK are involved in signaling downstream of a number of tyrosine kinases 
including JAKs and as they may be affected directly by mutation, the activity of PI3- 
kinase and MAPK inhibitors in AML was also examined.
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CHAPTER 2-MATERIALS AND METHODS
2.1 General Cell Culture
2.1.1 Reagents 
Cell culture media
Gibco,Invitrogen LifeTechnologies Paisley,UK 
RPMI 1640 medium (21875-034)
DMEM medium (31885-023)
Foetal Calf Serum (FCS) (10106-169) heat inactivated at 56°C for
30mins
Dulbecco’s phosphate buffered saline (PBS) (14190-094)
Dulbecco’s phosphate buffered saline containing Ca++ and Mg ++ (14040-091) 
Foetal Bovine serum Hyclone, USA (SH30071)
Tissue culture plastics were from Costar NY 14831 USA and BD Biosciences, San 
Jose, CA, USA
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2.1,2 Growth factors
Murine IL-3
Human stem cell factor
Recombinant human GMCSF
Human Erythropoietin
Human IL-3
Human IL-6
Interferon a
Interferon y
Peprotech EC Ltd, London, UK 
Peprotech EC Ltd, London, UK 
Behringwerke-Hoechst, Marburg, Germany 
POM ‘Eprex’
Sandoz, Frimley Park, UK 
Peprotech EC Ltd London UK 
Peprotech EC Ltd London UK 
Peprotech EC Ltd London UK
The following products were purchased from SIGMA-Aldrich, UK.
Phorbol 12 Myristate 13 Acetate (PMA) (P-1680)
Penicillin and Streptomycin (P-4458)
Trypsin-EDTA (T-4174)
2.1.3 Cell lines
Name Description Mutations/Fusion protein
3 2D murine myeloid line
TF-1 human erythroleukaemia line
Mo 7E human megakaryoblastic leukaemia
HL60 human acute myeloid leukaemia M2 N Ras
KG-1 a human acute myeloid leukaemia
K562 human chronic myeloid leukaemia in blast crisis BCR-ABL
Jurkat human T cell Leukaemia PTEN deletion
U937 human histiocytic lymphoma/monocytic markers
U266 } B-RAF
MM1S } Cell lines derived from human myeloma patients
KMS-BM }
KMS-PE }
KARPAS 299 human anaplastic lymphoma NPM-ALK
SUDHL1 human anaplastic lymphoma NPM-ALK
KMH2 human Hodgkin’s lymphoma
293T human embryonal kidney
HELA human cervical carcinoma line
293T and HELA cells were cultured in DMEM with 10% FCS. The human myeloma 
lines were grown in RPMI 1640 with 10% foetal bovine serum; all other lines were 
cultured in RPMI 1640 with 10% FCS. TF-1 and Mo7E cells were supplemented
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with 20ng/ml of rhGMCSF whilst 3 2D cells were either supplemented with 10% 
WEHI 3B conditioned medium or with lOng/ml murine IL-3.
2.1.4 Primary cells
Patient samples were obtained from patients presenting to University College 
Hospital, London, at presentation or relapse of AML. Informed consent was 
obtained from all patients prior to obtaining the sample. All patients had circulating 
leukaemic blasts in the peripheral blood and these were isolated by ficoll gradient 
centrifugation. All samples tested had more than 90% blasts by morphology and/or 
immunophenotyping. Mononuclear cells were frozen in RPMI 1640 with L 
Glutamine (30%), foetal calf serum (50%) and dimethyl sulfoxide (DMSO) (20%) 
and stored in liquid nitrogen.
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2.1.5 Inhibitors
Inhibitor Stock Cat N° Supplied by
concentration
G66976 lOmM G-6203 LClabs, Woburn,MAO 1801
G66983 5mM 365251 Calbiochem,California,USA
AG490 lOOmM 658401 Calbiochem Califomia,USA
LY294002 50mM L-7962 LClabs, Woburn,MAO 1801
U0126 lOmM U-6770 LClabs, Woburn,MAO 1801
Staurosporine ImM S4400 Sigma Aldrich, UK
All inhibitors were dissolved in DMSO and stored at-20°C or -80°C for prolonged 
periods.
2.1.6 Chemotherapeutic agents
Cytosine Arabinoside (Ara C) David Bull Laboratories, Victoria, Australia.. 
Etoposide (VP 16) Medac, Stirling University, UK.
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2.1.7 Ficoll gradient Centrifugation
Peripheral blood or bone marrow was diluted 1:2 with PBS with no additives and 
layered on to an equal volume of Ficoll-Paque ™ Plus (Amersham, Bucks, UK (17- 
1440-03)). The cells were then spun at 1800rpm for 20mins. Cells from the interface 
were then removed, placed in a clean tube, and washed once in PBS. The resulting 
pellet was then resuspended in RPMI 1640 and incubated at 37° 5% CO2 .
2.2 SDS-PAGE and immunoblotting
2.2.1 Reagents
Pefabloc Boehringer-Mannheim, Germany 
Aprotinin (A4529) SIGMA, Poole UK 
Leupeptin SIGMA 
PepstatinA SIGMA 
Microcystin LR SIGMA (M2193)
Protease inhibitor cocktail SIGMA (P8340) 
dl-Dithiothreitol (DTT) SIGMA (D9163)
Acrylamide/N’N’-bis-methylene 30%:0.8% National Diagnostics, Hull,UK 
Ammonium persulphate (APS) BDH, UK 
N’N’N’N-tetra-methylethylenediamine (TEMED) Biorad, CA,USA 
Prestained molecular weight markers, Gibco (10748-010)
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Hybond-C-Extra nitrocellulose membrane, Amersham Life Sciences, Bucks, UK 
Non-fat dried milk (MARVEL)
Peroxidase-conjugated anti-sera DAKO Ltd, High Wycombe, Bucks,UK 
Enhance chemoluminescence kits (ECL and ECL-plus) Amersham Life sciences 
Hyperfilm™ ,high performance autoradiography film, Amersham Life Sciences
2.2.2 SDS-PAGE buffers, stains and gels
Lysis Buffer (made in ddH20)-50mM HEPES pH7.5, lOOmM NaCl, 1% Triton 
X100, ImM EDTA, ImM EGTA, 20mM NaF, ImM Na orthovanadate, Aprotinin 
10 pg/ml, Pepstatin 10 pg/ml, Leupeptin 10 pg/ml, Microcystin 5pM and Pefabloc 
ImM added to lysis buffer immediately prior to use.
1 litre of lOx Gel running buffer-Tris base 30.3g, Glycine 144.2g, SDS lOg
1 litre of lOx transfer buffer-Tris base 30.3g, Glycine 144.2g, Methanol lOOmls
Gel sample buffer-50mls 4x made in ddH20, 1M Tris pH 6.8 17.5ml, SDS 4g, DTT 
2.315g, Glycerol 20mls, Bromophenol blue 50mg
Coomassie blue stain-Methanol 500mls, Water 400mls, Acetic acid lOOmls, 
Coomassie R-250 2.5g
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Destain-Methanol 250mls, Water 680mls, Acetic acid 70mls
Acrylamide Gels
7.5% separating gel 10% separating gel Stacking gel
H20 3.66mls 2.86mls 3.49mls
lM Tris 3.74mls (pH 8.8) 3.74mls (pH 8.8) 625pi (pH6.8)
Acrylamide 2.54mls 3.34mls 835pl
10% SDS lOOpl lOOpl 50pl
10% APS (v/v) 7 5 pi 75 j l a 1 38pl
TEMED 9pl 9pl 7.5pl
2.2.3 Antibodies
Phospho-p42/44 (Thr 202/Tyr204)(9211) 
Phospho-FKHRL 1 ( Thr 32)(06-952) 
Phospho-Akt (Ser 473) (9271) 
Phospho-Akt (Thr 308)
Phospho-STAT 5(Y694) (9351) 
Phospho-STAT 3 (Tyr 705) (9131) 
Phospho-STAT 1 (Tyr 701) (9171) 
Phospho-p70S6Kinase (Thr 389) (9205)
New England Biolabs 
Upstate Biotechnology 
Cell Signalling Technology 
Cell Signalling Technology 
Cell Signalling Technology 
Cell Signalling Technology 
Cell Signalling Technology 
Cell Signalling Technology
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Phospho-GSK 3(3(Ser 9)(9331) 
p27 (C-19) (sc-528)
PTEN (N-19) (sc-6818)
Stat 5b (C-17)
Bcl-X (610211)
Bax (N-20) (sc-493)
Bcl-2 (610538)
JAK 2 PYPY(44-426)
JAK 2(C-20) (sc-294)
JAK 1 PYPY(44-422) 
Anti-phosphotyrosine 4G 10(05-321) 
USA
Anti-HA probe (F-7) (sc-7392)
Cell Signalling Technology 
Santa Cruz Biotechnology Inc 
Santa Cruz Biotechnology Inc 
Santa Cruz Biotechnology Inc 
BD Transduction Labs 
Santa Cruz Biotechnology Inc 
BD Transduction labs 
Biosource Int,CA93012.USA 
Santa Cruz Biotechnology 
Biosource Int,CA93012.USA 
Upstate Biotechnology Inc, NY
Santa-Cruz Biotechnology
2.2.4 Preparation of denaturing polyacrylamide gel
Gels were prepared on the day of use. The separating gel was prepared and poured 
into a Mighty-Small Hoefer gel caster (Hoefer scientific instruments, San Francisco, 
USA), isobutanol was layered on top and the gel allowed to polymerise at room 
temperature.
The isobutanol layer was removed and the gel washed with ddH20. The stacking gel 
was then prepared and layered on top and a 10 well comb inserted making sure that
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there were no air bubbles. The gel was allowed to polymerise and once set, the comb 
removed. The wells were then washed 3 times with running buffer to remove 
unpolymerised acrylamide. The gels were then transferred to the running apparatus.
2.2.5 Cell lysate preparation
The factor dependent cell lines were washed free of growth factors starved for a 
minimum of 4 hours. They were then incubated with the indicated concentrations of 
inhibitor for 30mins before stimulation with either IL-3 lOng/ml (32D) or rhGMCSF 
20ng/ml (M07E and TF-1). Lysates were made after lOminutes stimulation.
Primary cells were cultured in RPMI 1640 and 10% FCS. The inhibitor under 
investigation was added at the indicated concentration and the cells incubated at 37° 
5% CO2 . Lysates were made after a minimum of 4 hours incubation. Factor 
independent cell lines were treated as primary cells but were incubated with inhibitor 
for a minimum of 6 hours.
Samples were pelleted by centrifugation at 2000 rpm for 3mins at 4°C, the 
supernatant was aspirated and the cells washed with 1 ml of PBS. The pellet was 
aspirated to dryness and resuspended in lysis buffer. The cells were lysed on ice for 
lOmins. Samples were then clarified by centrifugation at 14000rpm for 10 mins at 
4°C, and the supernatant removed to a clean tube. 4x sample buffer was then added,
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the samples boiled for 5mins and then either loaded immediately on to the gel or 
stored at -20°C.
For the suspension cell lines, both factor dependent and independent, lxlO6 cells 
were lysed in 45 pi of lysis buffer and 15 pi of sample buffer added and 4xl05 cell 
equivalents were loaded per well. 1 million primary cells were lysed in 15pl of lysis 
buffer and 5 pi of sample buffer added, lx l06 cell equivalents were loaded per well.
2.2.6 Preparation o f lysates from adherent cells
The media was aspirated from plate and placed in a labelled 15ml tube. The plate 
was washed twice in cold PBS and the wash added to the tube. The cells were then 
trypsinised from the plate using lx trypsin-EDTA and added to the same tube. The 
cells were centrifuged at 1500rpm for 4mins and the supernatant removed. 1ml of 
PBS was then added and the cells resuspended and transferred to a 1.5ml 
centrifugation tube. The cells were again centrifuged at 1500rpm for 4 minutes and 
the supernatant aspirated. 1ml of lysis buffer was then added to the cells and the 
cells lysed on ice for 30mins. The nuclear debris was then removed by centrifugation 
at 14000rpm for lOmins and the supernatant removed to a clean tube. If samples 
were to be used for western blotting 45pl of this was removed and 15pl of 4x sample 
buffer added, for immunoprecipitation method 2.7.2 was followed.
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2.2.7 Polyacrylamide gel electrophoresis and immunoblotting
Acrylamide gels were prepared as described in section 2.2.4. Prestained molecular 
size markers and equal volumes of samples were loaded on to 10% or 7.5% SDS- 
PAGE gels. They were run using Hoefer gel apparatus at 150V until adequate 
separation had occurred. Protein samples were transferred on to Hybond-C-Extra 
nitrocellulose membrane using the Owl Panther Semidry Electroblotter (HEP 1) 
(Owl separation systems) at a constant current of 0.75 AMPs for 1 hour. The 
membrane was then blocked for 1 hour in 5% dried non-fat milk (w/v) in PBS/0.1% 
Tween-20 to prevent non-specific protein binding. The membrane was then washed 
3 times for 5mins each wash in 0.1% PBS/Tween-20. Membranes were then 
incubated in the indicated primary antibody, at the manufacturer’s recommended 
concentration, made up in 3% BSA (w/v) 0.1% PBS/0.1% Tween-20. All phospho- 
specific antibodies were incubated overnight at 4°C, most other antibodies were 
incubated at room temperature for 1 hour. Primary antibody was then removed and 
the membrane washed 3 times, 5mins per wash, in 0.1% PBS/Tween-20. The 
membrane was then incubated with the appropriate horseradish peroxidase linked 
secondary antibody 1:10 000 in 2% (w/v) milk /PBS 0.1%/Tween-20, for lhour. The 
membrane was then washed 3 times in PBS.0.1%/Tween-20 and protein bands 
detected with enhanced chemiluminescence (ECL or ECL-plus for phospho-specific 
antibodies) according to the manufacturer’s guidelines. The nitrocellulose membrane 
was then exposed to autoradiography film.
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Where appropriate, gels were stained with Coomassie blue for 10 minutes and then 
destained until only the protein bands were stained blue. The gel was then vacuum 
dried for 1 hour in a Bio-Rad Model 583-Gel dryer, before exposure to 
autoradiography film.
2.3 Cell Proliferation Assay (MTS)
The cells under investigation were plated at 2xl05/ml for cell lines and lx l06/ml or 
greater for primary cells. For factor dependent cell lines, the cells were starved for a 
minimum of 4 hours before pre-incubation with the inhibitor under investigation for 
30 mins and stimulation with appropriate growth factor. They were then incubated at 
37° 5% CO2 for 48 hours. Factor independent cell lines and primary cells were 
incubated with the inhibitor under investigation or DMSO control for 48 hours. 20pl 
of CellTiter aqueous 96® one solution cell proliferation assay, Promega, 
(Wisconsin, USA) was added to 100 pi of cells, in duplicate and analysed according 
to the manufacturer’s guidelines. Results were expressed as a percentage of control 
(cells without inhibitor).
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2.4 Annexin V Binding Assay
2.4.1 Reagents
Annexin-V Binding Buffer
lOmM HEPES pH 7.4 
140mM NaCl2 
5mM CaCl2
2.4.2 Methods
Cells were stained with FITC-Annexin V ((l828681) Roche Biochemicals, Lewes 
UK) according to the manufacturer’s guidelines; briefly, cells were pelleted by 
centrifugation and washed with 1ml of Annexin-V binding buffer. To the cell pellet 
lOOpl of Annexin-V binding buffer with 10pl/ml of FITC-Annexin-V was added 
and incubated for 10 mins at room temperature. A further 250pl of Annexin-V 
binding buffer was added and the samples placed on ice prior to analysis by flow 
cytometry (Epics Elite, Beckman Coulter, High Wycombe, UK).
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2.5 JAK 2 Kinase Assay
Storage Buffer Kinase Assay Buffer
150mM NaCl 50mM NaCl
50mM Tris-HCL pH 8.0 lOmM HEPES pH7.4
10% glycerol 5mM MgCh
O.lmMEDTA 5mM M11CI2
0.1 mM sodium orthovanadate 0.1 mM sodium ortho vanadate
50mM NaF 
0.5% NP40
2.5.7 Method
10-20pi of settled JAK 2 immune complex agarose (CAT 14-134 Upstate, Lake 
Placid, NY 12946) beads were taken per assay point and washed twice with 1 ml of 
kinase buffer then aspirated to dryness. The agarose beads were then suspended in 
lOpl of kinase buffer. Five pi of inhibitor dilution were then added to the appropriate 
tube and 5 pi of kinase buffer to the control tube, y- PATP was added to a final 
concentration of lpCi/pl. The tubes were then incubated at 30° for 30mins with 
agitation. The reaction was stopped by washing the JAK 2 agarose 3 times in storage 
buffer, 1ml per wash. 50pl of SDS-PAGE sample buffer was then added and the 
sample boiled for 5 minutes. 25pl of sample was then run on a 7.5% SDS-PAGE
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gel. The gel was fixed with Coomassie Blue stain, dried and visualised by standard 
methods of autoradiography.
2.6 Formation of stable cell lines
2.6.1 Plasmids
Tel-JAK2, Tel-JAK3 in pBabeNeo vector were kindly donated by Dr Virginie 
Lacronique (Paris, France)
HA-JAK2 and 3 in pEF-BOS vector kindly donated by Dr Jane McGlade, Toronto, 
Canada.
mAKT-ER , mA2-ER myristolated Akt A4-129 and the control A2myrAkt A4-129 
are fused to an oestrogen receptor in a PWZL retrovirus vector containing a 
neomycin resistance gene, kindly donated by Dr R. Roth, Stanford University82
2.6.2 Bacterial transformation
A vial of DH5a competent cells (donated by Dr G Morley, University College 
London) was thawed slowly on ice. 100 pi of cells was placed in a 1.5ml 
centrifugation tube and returned to the ice. 1-1 Ong of plasmid DNA was added to the
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cells and incubated on ice for lhour. The cells were then heat shocked at 42°C for 45 
seconds. The cells were cooled on ice briefly before being added to 500pl of LB 
medium containing no antibiotics; this was placed at 37°C with constant shaking 
(300rpm) for 30mins-lhour to allow the bacterial cells to express the appropriate 
antibiotic resistance. After this time a proportion of cells were spread on to a 
selective agar plate (1.5% agar) and placed at 37°C in a bacterial incubator.
2.6.3 Plasmid Preparation
A single colony was picked from a selective plate and 2mls of LB medium 
containing the selective antibiotic inoculated. The starter culture was incubated for 
approximately 8 hours at 37°C with vigorous shaking (300rpm) and then used to 
inoculate 250mls of LB medium. This was then grown at 37°C overnight with 
vigorous shaking as before. The following morning the bacterial cells were 
harvested by centrifugation at 5000rpm in a Beckman JA-10 rotor at 4°C. DNA was 
extracted using Qiagen Maxi-Prep kit according to the manufacturer’s protocol.
2.6.4 Electroporation
32D cells in culture were split 1:3 with RPMI/10F the night prior to electroporation 
to ensure that they were in log phase growth. The following day 10- 
20xl06cells/point were taken, centrifuged and washed once in PBS. They were then
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resuspended in 500pl phenol red free media, SIGMA (R-7509) containing 10% FCS 
and 10% WEHI 3B conditioned medium and 20pg of plasmid were added. The cells 
were transferred to a gene pulser cuvette (0.4cm) Bio-Rad (1652088) and 
electroporated at 250V and 960pF in a Bio-Rad Gene Pulser™. Following 
transfection the cells were left to recover for 5-10mins and then transferred to 15- 
20mls of RPMI 1640 10% FCS 10% WEHI conditioned medium for 6 hours. The 
cells were then ficolled to remove any dead cells and suspended in RPMI 10% FCS 
and 10% WEHI conditioned medium. The cells were allowed to grow for 24-48 
hours before selecting out the transfected cells with the appropriate antibiotic.
2.6.5 Calcium phosphate transfection o f293T cells
Promega Profection mammalian transduction kit #E 120040, Promega,Southampton 
UK
293T cells were grown in DMEM 10% FCS until near confluence. The night before 
the transfection the cells were trypsinised in 5mls of lx Trypsin/EDTA, 1ml 
transferred to one 10cm plate per vector and lOmls of media added. The cells were 
allowed to adhere overnight at 37°C 5% CO2 . Two sterile tubes were taken per 
vector to be transfected, to the first (A) 416|ul of H2O, 20pg of vector DNA and 64pl 
of 2M CaCl2 were added and mixed well. 500pl of 2xHEPES buffered saline was 
added to the second tube (B). The contents of tube A were added gradually to tube B 
with constant agitation and the mixture added drop-wise to cover the whole area of
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the appropriate 10cm plate. The following morning the plates were washed 3 times 
gently with 5mls of PBS added to the side of the plate so as not to disturb the cells. 
The media was replaced with fresh media and the cells left to express the plasmid 
for 24-48hours.
2.7 Immunoprecipitation
2.7.1 Reagents
Protein G immobilised on Sepharose 4B fast flow (P 3296) Sigma 
Protein A immobilised on Sepharose 4B fast flow (P 3391) Sigma
Species Protein A Protein G
Rabbit ++++ +++
Goat - ++
Rat +/- ++
Sheep +/- ++
Mouse
IgGl + ++++
IgG2a ++++ ++++
IgG2b +++ +++
IgG3 ++ +++
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2.7.2 Method
Cell lysates were prepared according to method 2.2.5. The immunoprecipitating 
antibody was added according to manufacturer’s protocol usually between l-5pg. 
The tubes were mixed thoroughly and placed on a mixer wheel at 4°C overnight. 
25 pi of protein A or Protein G 50% slurry was added and placed on a mixer wheel 
for 90mins at 4°C. The beads were then washed 3 times with cold PBS/0.1% Triton- 
X-100 using micro bio-Spin chromatography columns, according to manufacturer’s 
guidelines. Briefly the seal on the column is broken and the column placed on ice. 
The sample is then added to the column and the aqueous phase drains through. 1ml 
of PBS/0.1% Triton-X-100 was then added and when all the fluid has drained 
through this step is repeated for 2 further washes. The tubes were then placed in a 
1.5ml centrifugation tube and spun at lOOOrpm for 2mins to dry the column. The 
column is then removed and sealed using seals provided and placed in a clean 1.5ml 
centrifugation tube. 30pl of lx boiling sample buffer was then added to the column 
for 3mins, before removing the seal and spinning the tube at 5000rpm for 5mins. 
The eluate is then boiled for an additional 1 minute.
84
2.8 JAK3 Kinase Assay
2.8.1 Reagents
Kinase Buffer
Na Cl 50mM 
HEPES pH 7.6 lOmM 
MgCl2 5mM 
MnCl2 5mM 
Na3 V04 0.1 mM
2.8.2 Method
293T cells were transfected with HA-JAK3 according to method in 2.6.5, one 10cm 
plate per point. The cells were lysed in 1ml of lysis buffer on ice as previously 
described. The lysates were clarified of nuclear debris by spinning at 14000rpm for 
lOmins, at this point the lysates from different plates were pooled and divided into 
lml aliquots. lOjul of anti-HA antibody was added and the sample placed on a mixer 
wheel at 4°C overnight. 25pl of Protein G agarose beads 50:50 slurry were added 
and mixed at 4°C for 90mins. The immobilised JAK 3 was then washed twice in 
PBS 0.1%Triton-X 2mM EDTA and the samples were again pooled. One further
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wash was carried out in Kinase buffer and the agarose beads were aspirated to 
dryness. 45pi of kinase buffer were then added to each tube and 5pi of indicated 
inhibitor concentration for lOmins at room temperature. lOpCi of y 32PATP were 
then added and the tubes incubated for 30mins at room temperature with regular 
agitation. The reaction was stopped by the addition of 1ml of cold PBS/0.1% Triton 
X-100/2mM EDTA and the beads washed twice further using micro bio-spin 
chromatography columns Bio-Rad (732-6204) according to the manufacturer’s 
protocol. 25pl of sample was then loaded on to a 7.5% PAGE gel and run. The gel 
was then fixed with Coomassie and vacuum dried according to manufacturer’s 
guidelines. The JAK 3 was then visualised by standard autoradiography methods.
2.9 Cell Sorting
Leukaemic blasts were either labelled with CD38 FITC clone AT 13/5, (DAKO), 
CD34 Phycoerythrin (PE) BD (Biosciences Pharmingen) or the appropriate FITC 
and PE controls, according to manufacturer’s guidelines. They were then 
electronically sorted on an EPICS, Beckman-Coulter flow cytometer.
2.10 Luciferase Reporter Assay
The NF-kB and P53 luciferase reporter plasmids and the renilla luciferase plasmid 
(pRL-CMV) were obtained from Promega. Between 1 and 5xl06 AML blasts/
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CD34+cells were nucleofected (Amaxa, CD34 kit, using the manufacturer’s 
instructions) with 2 pg of either NF-kB or P53 reporter plus 0.5 pg of pRL-CMV. 
Transfected cells were incubated overnight (with or without LY294002) in 
RPMI/10% FCS. Cells were lysed and NF-kB or p53 reporter activity was corrected 
for the constitutive renilla luciferase expression using a Dual Luciferase Kit 
(Promega). Results were compared to the background reading obtained with the 
backbone pGL2 luciferase vector (Promega) that lacks eukaryotic promoter and 
enhancer sequences. Readings above background were considered positive.
2.11 DNA Extraction
2.11.1 Reagents
Lysis Buffer
DTAB 8% 
NaCl 1.5M 
Tris Cl lOOmM 
dd H20
Chloroform
Ethanol
20g
22g
25mls of 1M Tris 
to 250mls
100% and 70%
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2.11.2 Method
The cells were suspended in PBS at a concentration of lxlO6 cells per 100pi and 
DTAB was added at a ratio of 2:1. The sample was mixed well and placed in a water 
bath at 68°C for 5minutes and then allowed to cool down. A volume of chloroform 
equal to the total sample volume was added and mixed well. This was then 
centrifuged at 3000rpm for 20mins. The upper layer was then carefully removed to a 
clean tube and an equal volume of 100% ethanol was added and the sample gently 
mixed until the DNA could be seen precipitating. When fully precipitated the DNA 
was removed with a yellow tip to a 1.5ml centrifugation tube containing 200pl of 
70% ethanol in order to wash the pellet. The tube was centrifuged at 14000rpm for 
5mins to pellet the DNA, the ethanol was removed and the pellet allowed to air dry. 
The pellet was dissolved in dd H2O and Optical Density at 260nm was measured 
using the Gene Quant pro (Amersham-Pharmacia), to measure the DNA 
concentration.
2.12 Mutational analysis
2.12.1 Reagents
Primers
FLT3/ITD
1 IF (5’-GCAATTTAGGTATGAAAGCCAGC-3’) 
12R (5 ’ -CTTTC AGCATTTTGACGGCAACC-3 ’).
FLT3/D835
F 5 ’-CCGCCAGGAACGTGCTTG-3 ’
R 5 ’-GCAGCCTCACATTGCCCC-3 ’
NRAS/Exon 1
1F 5 ’-GCTCGCCAATTAACCCTGATTAC-3 ’,
1R 5 ’ -T GGGT AA AG AT G ATCCGAC AAGT G A-3 ’
NRAS/Exon 2
2F 5 ’ - AC ACCCCC AGGATT CTT AC AG A-3 ’
2R 5’-TCTTCCCTAGTGTGGTAACCTC-3’
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BIOTAQ DNA polymerase-Bioline, London, UK 
lOx DNA polymerase buffer-Bioline, London, UK 
dNTP-Bioline, London, UK 
EcoRV-New England Biolabs, Ipswich, UK
2.12.2 FLT3/ITD Mutations
Internal tandem duplications (ITDs) in the juxtamembrane region of the FLT3 gene 
were detected using polymerase chain reaction (PCR) amplification of exons 14 and 
15 (previously 11 and 12) and the intervening intron.
Approximately 100 ng DNA was added to a reaction mix containing:- 
1 x buffer (16 mM (NH4)2S04, 67 mMTris HC1 pH 8.8, 0.01% Tween 20), 1.0 mM 
MgCb, 200 pM deoxynucleoside triphosphate (dNTPs) and 10 pmol of each primer 
in a total volume of 19 pL. The mixture was heated to 95°C for 5 minutes and held 
at 85°C while 1 pL containing 0.5 U BIOTAQ DNA polymerase was added; then 30 
cycles each of 95°C for 30 seconds, 62°C for 30 seconds, and 72°C for 30 seconds 
were performed, followed by 5 minutes at 72°C. Amplified products were 
electrophoresed through 2% agarose gels and visualized under UV light with 
ethidium bromide staining. A fragment of 328 base pair (bp) was produced from WT 
alleles.
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2,12.3 FLT3/D835 Mutations
Mutations in the activation loop of FLT3 (D835) were detected by PCR and 
restriction enzyme digestion of exon 20. Approximately 100 ng DNA was added to a 
reaction mix containing lx buffer (16 mM (NH4)2 S0 4 , 67 mM Tris HC1 pH 8.8, 
0.01% Tween 20), 1.0 mM MgC12, 200 pM dNTPs, and 10 pmols of each primer in 
a total volume of 19 pL. The mixture was heated to 95°C for 5 minutes and held at 
85°C while 1 pL containing 0.5U BIOTAQ DNA polymerase was added; then 35 
cycles each of 95°C for 30 seconds, 63°C for 30 seconds, and 72°C for 30 seconds 
were performed, followed by 5 minutes at 72°C. Amplified products were digested 
with EcoKV then electrophoresed through 4% agarose gels and visualized under 
ultraviolet light with ethidium bromide staining. In alleles containing a D835 
mutation, the 114-bp PCR fragment remained uncut, but in WT alleles it was 
digested to fragments of 68 and 46 bps.
2.12.4 N-Ras Mutations
N-Ras mutations were detected using heteroduplex analysis. DNA was amplified 
using Optimase Polymerase ™ (Transgenomic Limited, Crewe, UK) according to 
manufacturer’s specifications with 32 cycles of amplification, each 30 secs at 95°C, 
30 secs at 63°C and 30 secs at 72°C. Primers for N-Ras exon 1 covering codons 12 
and 13 gave a product of 228bps, and for exon 2 covering codon 61 a product of
91
274bps. PCR products were denatured and analysed using denaturing HPLC on a 
Transgenomic WAVE ™ DNA fragment analysis system at 60.5°C for exon 1, 
59.2°C for exon 2. Patterns from patient samples were compared with those from 
DNA of the HL60 myeloid cell line (exon 2 mutation, wild type exon 1). PCR 
products from samples with altered patterns were directly sequenced using the 
CEQ ™ DTCS Quick Start kit and a CEQ ™ 8000 Genetic Analysis System 
(Beckman Coulter, Inc, Fullerton, USA).
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Figure 2.1
N-RAS exonl N-RAS exon2
1A@60.5oC
228bp
Ex2@59.2oC
274bp
-HL60
-5 2
-5 9
-7 7 0
-7058
4 53
— HL60
— Normal control
— 37
— 1249
— 1214
Time (Minutes)
Figure 2.1 Wave sequence showing Ras mutations in exon 1 and 2.
HL60 myeloid cell line is shown as a normal control for exonl and a positive 
control for exon 2.
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CHAPTER 3-GQ6976 IS A POTENT INHIBITOR OF
JAK 2
3.1 Introduction
Members of the Protein Kinase C (PKC) family are phospholipid dependent 
serine/threonine protein kinases and are involved in signal transduction pathways 
that affect a number of processes such as proliferation, differentiation and motility. 
PKC members have been grouped into three categories. The classical PKCs 
(a,p 1,|32 and y) are Ca++ dependent and can be activated by diacylglycerol or 
phorbol ester The novel PKC’s (8,s,0,ri) are Ca++ independent but can be activated 
by phorbol ester and the atypical PKC’s (<^ ,X) are unresponsive to both and can be 
activated by PIP3.83 84
G66976 is a selective PKC inhibitor derived from staurosporine. It is a non 
glycosidic indolocarbazole (Figure 3.1a) which is active against the calcium 
dependent isozymes (a  and pi) in nanomolar concentrations but even micromolar 
concentrations are ineffective against the calcium independent PKC subtypes (5,8 
and Q. Kinetic analysis reveals that G66976 inhibits PKC in a competitive manner 
with respect to ATP, non competitive with respect to substrate and mixed type with 
respect to phosphatidyl-serine. The IC50 for PKC inhibition is 7.9nM. 85 G66976 
also inhibits PKC p /PKD. Go6983, a bisindolylmaleimide, (Figure 3.1b) is a potent
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inhibitor of PKC that inhibits most PKC isozymes (IC50 = 7 nM for PKCa and 
PKCp; 6 nM for PKCr; 10 nM for PKCS; and 60 nM for PKC;)85.
Figure 3.1(a) b)
c h 3o .
CH3 (CH2)2CN .N
h 3c ^  ^ c h 3
Figure 3.1 The chemical structure of G66976 and G66983
(a) illustrates the chemical structure of G66976 an indolocarbazole PKC 
inhibitor, (b) shows the bisindolylmaleimide structure of G56983.
Preliminary experiments in our lab investigating the role of Protein kinase C (PKC) 
in human growth factor signalling found that G66976 had biological effects out of 
keeping with an effect solely on PKC. Incubation of IL-3, GMCSF but not SCF 
dependent cell lines with G66976 led to an increase in apoptosis and reduction in 
proliferation. A panel of PKC inhibitors with a broader spectrum of anti PKC 
activity (G66983, GF109203X, G6787485) had no effect on cell viability. Together 
these results suggested that G66976 may be exerting its effects via another kinase. 
The differential effect between inhibition of IL-3/GMCSF signalling (receptors 
which utilise JAK 2) and the lack of abrogation of stem cell factor signalling (a 
receptor with intrinsic tyrosine kinase activity) suggested that G66976 may be 
inhibiting JAK kinases4. The following chapter identifies the targets of G66976 as
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JAK kinases and further delineates the effects of G66976 on cell survival and
proliferation.
3.2 G66976 inhibits signalling downstream of the cytokine receptor 
super-family but not C-Kit.
3.2.1 G66976 inhibits IL-3 survival signals in 32D cells, a factor dependent 
cell line
To assess the effect of G66976 on IL-3 signalling, 32D cells were starved of growth 
factor for a minimum of 4 hours, incubated with or without G66976 (lOnM-lOpM) 
or G66983 (1 pM), the pan-PKC inhibitor for 30 minutes and then stimulated with 
IL-3 lOng/ml. Total cell lysates were made after 10 minutes (method 2.2.5) 
stimulation and examined by Western blotting utilising phospho-specific antibodies 
against pSTAT 5 (Tyr 694), phospho ERK-p42/44 (Thr 202/Tyr204), pAKT (ser 
473) and the phosphotyrosine antibody 4G10 (method 2.2.7). Figure 3.2a shows 
quiescence of the cells with starvation. Stimulation with IL-3 at 10 minutes led to an 
increase in phosphorylation of STAT5, AKT and ERK. Incubation with increasing 
doses of G66976 completely abrogated these effects; however no effect on 
signalling was seen after incubation with lpM G66983. In Figure 3.2b total tyrosine 
phosphorylation was reduced by growth factor starvation of the cells and markedly 
increased on IL-3 stimulation. Incubation with G66976 led to a reduction in 
phosphorylation of multiple proteins on tyrosine residues whereas G66983 had no
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effect. AG490, a member of the tyrphostin family, which has been reported to 
decrease constitutive JAK 2 activity in B cell Acute lymphoblastic leukaemia and 
has widely been used as a JAK2 inhibitor 54 also reduced tyrosine phosphorylation 
but to a lesser extent than G66976.
Figure 3.2a
pStat 5
113 -
on
pAkt
oU _
63 -
pERK
mm mm Stat 5
-  + + + + + + 
0 0 .01 .1 1 10 1
IL-3
pM
pY (4G10)
Stat 5
 Go76- G o83
+ + + +
o + + +
Go76 AG Go83
Figure 3.2 G66976 reduces signalling downstream of IL-3.
32D cells were quiesced overnight, pre-incubated for 30mins with the indicated 
concentration of G66976 (Go76), and then stimulated with IL-3 (lOng/ml) for 
10 minutes. Immunoblot analysis was carried out with the indicated antibodies 
(phosphorylated STAT 5, Akt and ERK in the left panel and phosphotyrosine 
in the right panel). Comparison was made with a control PKC inhibitor, 
G66983 (Go83) and the JAK2 inhibitor AG490 (AG). Total Stat 5 is shown as a 
protein loading control.
To examine how the above results on signalling translated into biological effects, 
proliferation (MTS) and apoptosis (Annexin V) were examined in two IL-3 
dependent cell lines, 32D and FDCP-1. Cells were starved of growth factors for a 
minimum of 4 hours, pre incubated with increasing concentrations of G66976 or
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G66983 (lpM) and then stimulated with IL-3 (lOng/ml). Annexin V staining was 
carried out at 24 hours (method 2.4.2) and an MTS assay at 48 hours (method 2.3). 
Incubation with G66976 blocked the proliferative effects of IL-3 on 3 2D cells in a 
dose dependent manner with an average IC50 of 93+/-50nM (n=4) with complete 
abrogation at 0.5 pM (Figure 3.3a). Withdrawal of IL-3 from FDCP-1 cells led to a 
34+/-9% increase in apoptosis above control cells (growing with IL-3) after 24 
hours. Incubation of the FDCP1 cells with lpM G66976 plus IL-3 led to a 22+/-6% 
increase in apoptosis showing that G66976 could inhibit the protective effects of IL- 
3 on survival (Figure 3.3b).
These results indicate that G66976 inhibits multiple signalling pathways in response 
to IL-3 stimulation and abrogates IL-3’s effects on survival and proliferation in 
factor dependent cells. These effects appear not to be related to its PKC inhibitory 
activity.
To substantiate these findings, further cytokine signalling pathways were examined.
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+ + + + + + + IL-3
0 0 .01 .1 .25 .5 1 1
G o76-----------------  Go83
, * IL3/G o6976 1pM
alone
Figure 3.3 G66976 reduces proliferation and increases apoptosis in factor 
dependent myeloid cells
32D or FDCP-1 cells were incubated with IL-3 plus G66976 or G66983 and 
apoptosis measured by Annexin V staining at 24hours and proliferation 
assessed by MTS activity at 48 hours. Incubation with G66976 blocked the 
proliferative effects of IL-3 on 32D cells in a dose dependent manner and 
incubation with lpM  G66976 together with IL-3 led to a 22+/-6% increase in 
apoptosis above cells incubated with IL-3 alone.
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3.2.2 G'66976 abrogates the effect of GMCSF signalling in factor dependent 
cell lines
To study the consequence of G66976 on GMCSF signalling, 2 factor dependent 
lines were used - Mo7E, a human megakaryoblastic leukaemia line and TF-1 a 
human erythroleukaemia line. After starvation cells were pre-incubated with G66976 
or G66983 and stimulated with GMCSF (20ng/ml) for lOmins. The resultant total 
cell lysates were probed with a phospho-specific ST AT 5 antibody. G66976 led to 
an inhibition of STAT 5 phosphorylation (Figure 3.4)
Similar effects of G66976 were seen on GMCSF induced survival and proliferation. 
Incubation with lpM  Go6976 in the presence of GMCSF led to a 29%+/-9% 
increase in apoptosis of TF-1 cells (0% for G66983 n=3) and a 60%+/-7% reduction 
in proliferation of Mo7E cells (2%+/-7% for G66983 n=3).
3.2.3 Go6976 inhibits STAT 5 phosphorylation in response to other 
cytokines utilising JAK2.
Other cytokines which utilise JAK2 include Thrombopoietin (TPO), Erythropoietin 
(EPO) and IL-6. Mo7E cells are responsive to TPO as well as GMCSF and stem cell 
factor (SCF). To examine the effect of Go6976 on Thrombopoietin signalling, Mo7e 
cells were first starved of growth factor overnight, incubated with increasing 
concentrations of G66976 and lpM G66983 prior to stimulation with TPO
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(45ng/ml) for 10 minutes. Total cell lysates were made and examined by Western 
Blotting (Fig 3.5a). Growth factor withdrawal led to a reduction in phospho-STAT5, 
the levels of which were increased by TPO stimulation. Incubation with lpM 
G66976 led to complete inhibition of STAT 5 phosphorylation.
The same experiment was repeated with TF-1 cells stimulated with EPO (lOiu/ml). 
There was a marked reduction in pSTAT 5 signalling after incubation with G66976 
with complete inhibition at lOOnM (Figure 3.5b).
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Figure 3.4 G66976 abrogates the effect of GMCSF signalling in Mo7E cells.
Mo7E cells were quiesced overnight, pre-incubated with increasing 
concentrations of G66976 for 30mins and stimulated with the indicated 
cytokine for 10 minutes.
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Figure 3.5 Go6976 inhibits STAT 5 phosphorylation downstream of other 
JAK2 utilising cytokines.
Factor dependent cells lines were quiesced overnight, pre-incubated with 
increasing concentrations of G66976 for 30mins and stimulated with the 
indicated cytokine for 10 minutes. Mo7E cells were stimulated with 
thrombopoietin (TPO) and TF-1 cells with erythropoietin (EPO). Immunoblot 
analysis was carried out with the indicated antibodies.
IL-6 signalling was investigated in a myeloma cell line, U266 which although factor 
independent responds to signals through IL-6 and IFNa and y (Figure 3.6). IL-6
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stimulation led to an increase in STAT 5 activation and incubation with lpM 
G66976 completely abrogated this bringing p STAT 5 levels back to baseline. 
Together these results indicate that Go6976 is able to inhibit signalling downstream 
of several cytokines that activate JAK2.
Figure 3.6
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Figure 3.6 G66976 inhibits STAT 5 phosphorylation in response to IL-6 
stimulation in U266 cells.
U266 myeloma cells were pre incubated with G66976 for lhour and then 
stimulated with IL-6 (20ng/ml) for lOmins. Immunoblot analysis was carried 
out with the indicated antibodies.
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3.2.4 G66976 has no effect on signalling after stimulation with stem cell 
factor
Mo7E cells were used to study the effect of G66976 on stem cell factor signalling. 
Stem cell factor stimulation rapidly brought about phosphorylation of Akt and ERK 
above quiescent levels. Incubation with G66976 or G66983 had no effect on this 
phosphorylation (Figure 3.7).
Figure 3.7
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Figure 3.7 G66976 has no effect on signalling after stimulation with stem cell 
factor.
Quiescent Mo7E cells were pre-incubated with the indicated concentrations of 
G66976 (Go76) or G66983 (Go83), then stimulated with Stem Cell Factor (SCF) 
(20ng/ml, 10 minutes) and immunoblot analysis carried out with the indicated 
antibodies.
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3.3 G66983 reduces ERK phosphorylation in response to phorbol 
ester
These experiments show that G66976 has profound effects on signalling in response 
to several growth factors whilst G66983 does not. This indicates that these effects 
are likely to be independent of PKC. To confirm that G66983 is biologically active, 
its effect on Phorbol Ester induced activation of ERK, a PKC dependent mechanism, 
was examined.
Phorbol Ester (TPA) (lpg/ml) stimulation of growth factor starved cells led to an 
increase in ERK phosphorylation. Incubation with G66983 resulted in a dose 
dependent decrease in phospho-ERK signal (Fig3.8). These results indicate that 
Go6983 is an active PKC inhibitor at the concentrations used in these experiments.
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Figure 3.8
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Figure 3.8 G66983 reduces ERK phosphorylation in response to phorbol ester.
Growth factor starved Mo7E cells were pre-incubated with the indicated 
concentration of G66983 and stimulated with Phorbol Ester (TPA) (lpg/ml) for 
10 minutes. Immunoblot analysis was carried out with the indicated antibodies.
3.4 G66976 has a direct effect on JAK2 in vitro kinase activity.
These results suggest that G66976 exerts its effects through a kinase other than PKC. 
Identical results were obtained using G66976 from 3 separate sources (LC Labs, 
Biomol, Calbiochem, data not shown). The fact that signalling downstream of 
several members of the cytokine receptor superfamily but not that of SCF was 
affected led us to postulate an effect on JAK2. In order to assess the direct effect of 
G66976 on JAK2 activity, in vitro kinase assays were carried out. Recombinant JAK 
2 was utilised according to the method in 2.5.1. In vitro kinase activity using y32P- 
ATP was detected by autoradiography following SDS-PAGE. As can be seen in 
figure 3.9a, incubation of recombinant JAK2 with 1 pM G66976 led to a marked 
reduction in JAK2 kinase activity compared to the control (no inhibitor) whereas
+ + + + + +  +
0 0 .01 .05 .1 .25 .5 1
-----------—Go83------------
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incubation with the control PKC inhibitor G66983 had no effect. Using scanning 
densitometry, incubation with 1 pM G66976 reduced JAK 2 activity to 18+/-5% of 
control (n=5).
The above experiment was repeated with varying concentrations of G66976 (Figure 
3.9b) which resulted in a dose dependent reduction in JAK2 kinase activity with an 
IC50 of 130nM (by densitometry).
We compared the effect of AG490 on JAK 2 kinase activity to that of G66976 using 
the above method. Incubation with AG490 led to a dose dependent reduction of 
JAK2 kinase activity with an in vitro IC50 of 35pM (by densitometry) (Figure 
3.9c). Incubation with lOOpM AG490 led to a 70% reduction in JAK2 kinase 
activity whereas lpM G66976 by comparison led to a 74% reduction in the same 
experiment suggesting that these two doses have similar efficacy (Figure 3.9d).
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Figure 3.9 G66976 has a direct effect on JAK2 in vitro kinase activity
a) Recombinant JAK2 was used in a kinase assay with 32P labelled ATP in the 
absence or presence of G66976 (Go76) or G56983 (Go83) and phosphorylation 
of JAK2 (125kD) detected by autoradiography (upper panel). Equal loading 
was measured by immunoblotting with anti-JAK2 (lower panel)
b) Autokinase activity was measured in the presence of increasing 
concentrations of Go6976. Figure 3.9c Autokinase activity was measured in the 
presence of increasing concentrations of AG490. Figure 3.9d Autokinase 
activity was measured in the presence of G66976, G66983 and the known JAK2 
inhibitor, AG490 (AG).
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3.5 To examine the effect of Go6976 on other JAK kinases
3.5.1 Go6976 has a direct effect on the in vitro kinase activity o f  JAK3
To assess G66976 activity against JAK3, recombinant HA tagged JAK3 was 
expressed in 293T cells, immunoprecipitated using an anti HA antibody and in vitro 
kinase assays carried out. (method 2.8.2). The activity of G66976 was compared 
with AG490 and G66983. Incubation with 1 pM G66976 led to an 81% reduction in 
JAK3 in vitro kinase activity compared to a 64% reduction for lOOpM AG490. 
G66983 had no effect on phosphorylation. (Figure 3.10)
Figure 3.10
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Figure 3.10 G66976 has a direct effect on JAK 3 kinase activity.
HA-tagged JAK 3 was transfected into 293T cells, immunoprecipitated with an 
anti-HA antibody and an in vitro kinase assay with 32P labelled ATP was 
carried out. The upper panel is an autoradiograph showing JAK3 
autophosphorylation and the lower panel is an immunoblot with anti HA 
antibody as a loading control. The activity of G66976 was compared with 
AG490 and G66983.
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3.5.2 G66976 inhibits JAK3 mediated IL-2 signalling in peripheral blood 
derived lymphocytes.
IL-2 signalling is thought to be primarily mediated by JAK3. To further investigate 
G66976 inhibition of JAK3, we examined the effect of G66976 on IL-2 stimulation 
of peripheral blood derived T-lymphocytes. Isolated lymphocytes were incubated 
with lOpg/ml of phytohaemaglutinin (PHA), a plant mitogen with specificity for T 
cells, for 72 hours prior to incubation with the indicated concentration of inhibitor 
and stimulated with IL-2 lOiu/ml. Phosphorylated proteins were examined by 
Western blotting.
STAT 5 phosphorylation in the presence of IL-2 was abrogated by G66976 in a dose 
dependent manner (Figure 3.11a). ERK phosphorylation did not appear to be 
increased by IL-2. The above experiment was repeated and a MTS assay carried out 
at 72 hours after IL-2 addition. Incubation with Go6976 led to a dose dependent 
reduction in proliferation with an IC50 of 370nM (Fig 3.11b). These results show 
that G66976 is able to inhibit JAK3 in vitro kinase activity and abrogate IL-2 
induced STAT 5 phosphorylation in intact cells.
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Figure 3.11 G66976 inhibits JAK3 mediated IL-2 signalling in peripheral blood 
derived lymphocytes.
Peripheral blood derived lymphocytes were cultured in lOpg/ml 
phytohaemaglutinin (PHA) for 72 hours, incubated with G66976 for 30mins 
and stimulated with IL-2 (lOiu/ml). Immunoblot analysis was carried out with 
the indicated antibodies. Figure 3.11b The above experiment was repeated and 
proliferation assessed by an MTS assay carried out at 72 hours after IL-2 
stimulation.
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3.5.3 G66976partially abrogates the effect o f IFN signalling in U266 and 
HELA cells
Interferon signalling is mediated by JAK1 and Tyk2 in the case of IFNa and JAK1 
and JAK2 in the case of IFNy. We examined the effect of G66976 on IFN signalling 
in order to further explore its inhibitory effect on other JAK family members. U266 
cells have low levels of pSTAT 1 (Tyr 701) in the resting state. There is a rapid and 
marked increase in pSTAT 1 level after stimulation with IFNy(500iu). G66976 
reduced stimulated pSTAT 1 levels significantly but not back to pre stimulation 
levels (Figure 3.12a). A similar experiment was done with HELA cells, a human 
cervical carcinoma line which responds to alFN stimulation. Again there are low 
basal levels of p STAT1 in unstimulated HELA cells which increase substantially on 
alFN (20ng/ml) stimulation. G66976 reduces the stimulated pSTAT 1 but not back 
to basal levels (Figure 3.12b).
Therefore in whole cell assays G66976 lpM is sufficient to completely inhibit JAK2 
and JAK3 mediated STAT 5 phosphorylation but has only a partial effect on 
signalling presumed to be via JAK1 and TYK2.
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Figure 3.12 G66976 partially abrogates the effect of IFN signalling, 
a) U266 myeloma cells were incubated with Go6976 for 2 hours prior to 
stimulation with IFNy (500iu/ml) for 10 minutes. Immunoblot analysis was 
carried out with the indicated antibodies, b) HELA cells, a human cervical 
carcinoma line, were incubated with G66976 for 1 hour prior to stimulation 
with IFNa (20ng/ml).
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3.6 G66976 does not inhibit JAK2 Phosphorylation at Y1007 and
Y1008 despite a reduction in down stream signalling
So far we have shown that G66976 inhibits JAK2 tyrosine kinase activity in vitro 
and abrogates the survival and proliferative effects of cytokines utilising JAK2 in 
whole cell systems.
Several studies have shown that JAK2 is phosphorylated on a number of tyrosine 
residues including Y 1007/1008, Y221, Y570 and Y813 in response to cytokine 
stimulation. 8,11,86 JAK2 mutant studies have shown that phosphorylation of Y 1007 
in the activation loop allows access of the catalytic loop to ATP in the ATP binding 
domain and is essential for kinase activity. 8 JAK2 phosphorylation at tyrosines 
1007/1008 was investigated using a polyclonal antibody raised against a chemically 
synthesized phosphopeptide derived from a region of JAK2 containing PY1007and 
1008.
Mo7E cells were quiesced for 6 hours prior to being incubated with increasing 
concentrations of G06976 for 30mins and stimulated with GMCSF 20ng/ml for 
lOmins. Cell lysates were probed with phospho JAK2, p Akt and p ERK. GMCSF 
induced JAK2 phosphorylation at tyrosines 1007/1008 but G66976 did not affect 
this phosphorylation despite clearly abrogating downstream signaling (Figure 3.13).
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Figure 3.13 G66976 does not inhibit JAK2 phosphorylation at Y1007
Quiescent Mo7E cells were preincubated with increasing concentrations of 
G56976 or G66983, stimulated with GMCSF(20ng/ml, 10 minutes) and cell 
lysates analysed by immunoblot with antibodies to phosphorylated JAK2 
(tyrosines 1007/1008), p Akt and pERK.
3.7 Qverexpression of HA-JAK2 in 293T cells leads to activation of 
p STAT 1; Go6976 abrogates this activation
Overexpression of JAK2 is known to result in constitutive activation of JAK2 kinase 
activity. In order to investigate the effect of G66976 on this activation, 293T cells 
were transfected with an HA tagged JAK2 plasmid using the calcium phosphate 
method (method 2.6.5). The cells were trypsinised and split into a 6 well plate,
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allowed to adhere and then incubated overnight with or without G66976. Total cell 
lysates were made and probed with an antibody to pSTAT 1. Non transfected 293T 
cells were treated in an identical manner. Over expression of HA-JAK2 in 293T 
cells led to phosphorylation of the STAT 1 protein which did not occur in mock 
transfected cells (Figure 3.14a). Incubation with increasing concentrations of 
G66976 led to a reduction in this phosphorylation. A marked reduction in STAT 1 
phosphorylation was seen at concentrations as low as lOOnM (Figure 3.14b). The 
samples from the above experiment were re run and probed with JAK2 pYpY1007/8 
(Figure 3.14b). No reduction in JAK2 phosphorylation was evident.
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Figure 3.14 Go6976 abrogates STAT 1 phosphorylation secondary to 
overexpression of JAK2 in 293T cells
a) 293T cells transfected with or without HA-JAK2 were Iysed and immunoblot 
analysis performed with specified antibodies. Transfection of HA-JAK2 alone 
led to increased phosphorylation of STAT 1. b) 293T cells were transfected with 
HA-JAK2. The cells were then incubated over night with increasing 
concentrations of indicated inhibitor. Total cell lysates were made and 
immunoblot analysis was carried out. STAT 1 phosphorylation was reduced by 
incubation with G66976 but not by the control inhibitor G66983. No effect on 
JAK2 phosphorylation at tyrosines 1007/8 was observed with either inhibitor.
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3.8 G66976 does not reduce phosphorylation at Y1007/1008 in JAK2 
expressing 32D cells.
To further investigate these findings, 32D cells were stably transfected with HA 
tagged JAK2 (method 2.6.4). They were starved of growth factor, pre incubated with 
G66976 for 30 minutes and stimulated with IL-3 (lOng/ml). JAK2 was 
immunoprecipitated (method 2.7.2) using an anti HA antibody and samples probed 
with anti-phosphotyrosine. JAK 2 was tyrosine phosphorylated after stimulation 
with IL-3 and incubation with G66976 led to a reduction in total JAK2 
phosphotyrosine content but not back to quiescent levels. Similar results were seen 
with the broad spectrum kinase inhibitor staurosporine. The samples were re run and 
probed with the phospho-specific JAK2 (1007/1008) antibody (Figure 3.15). 
Similar to the Mo7E experiment, JAK2 phosphorylation at Y1007/1008 was not 
reduced by incubation with G66976. Total cell lysates from the same experiment 
were probed with p STAT 5, Akt and ERK and results show that downstream 
signalling was inhibited (data not shown). Staurosporine appeared to behave in the 
same way as G66976 whereas AG490 reduced JAK2 phosphorylation at Y 
1007/1008. These results indicate that unlike downstream signalling, JAK2 
phosphorylation at Y 1007/1008 is not inhibited by G66976 and suggests that 
G66976 binds to and inhibits JAK2 that is already phosphorylated at Y1007/1008. 
The binding of G66976 inhibits JAK2 kinase activity and prevents further auto/trans 
phosphorylation of JAK2 on other tyrosine residues and also inhibits
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phosphorylation of the receptor, adapter proteins and downstream signalling 
molecules.
Figure 3.15
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Figure 3.15 G66976 does not reduce phosphorylation at Y1007/1008 in JAK2 
expressing cells.
Quiescent 32D cells stably expressing HA tagged JAK2 were pre incubated with 
lpM  G66976 (Go76), lOOpiM AG490 (AG) or lpM  Staurosporine (ST) and 
stimulated with IL-3 (lOng/ml, 10 minutes). JAK2 was immunoprecipitated 
using an anti-HA antibody and samples probed by immunoblotting with anti 
phosphotyrosine and phospho-specific JAK2 (1007/1008) antibodies. The last 
lane labelled 32D is an immunoprecipitate from parental 32D cells.
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3.9 Discussion
The aim of this chapter was to identify the mechanism by which G66976 exerted its 
biological effects.
Initial experiments showed that G66976 was able to abrogate signaling downstream 
of IL-3 in factor dependent cells leading to a reduction in phosphorylated STAT 5, 
Akt and ERK. This translated into increased apoptosis and reduced proliferation in 
these cells to levels which were equivalent to growth factor withdrawal. These 
results were reproduced for other cytokines acting via JAK 2: GMCSF, EPO, TPO 
and IL-6. G66976, however, had no effect on Stem cell factor signaling which acts 
on the KIT receptor which has intrinsic tyrosine kinase activity and therefore does 
not utilize the cytosolic JAK tyrosine kinases. Throughout all these experiments the 
control inhibitor G66983 had no effect indicating that these results were not 
mediated through PKC inhibition. Although in vitro kinase assays do not reproduce 
the situation within the whole cell it was necessary to use this method to investigate 
the direct effect of G66976 on JAK 2. We found that G66976 inhibited JAK2 
autophosphorylation with an IC50 of 130nM (compared to its anti-PKCa IC50 
7.9nM). Under the same conditions AG490 was found to have an IC50 of 35pM for 
JAK2 inhibition (quoted AG490 IC50 for JAK2=0.1pM).87
We have also shown that G66976 has an inhibitory effect on JAK3 kinase activity in 
vitro and inhibits the IL-2 stimulatory effect in peripheral blood derived T cells
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which is thought to be mediated predominantly by JAK3. 88 These results together 
indicate that Go6976 is also a potent inhibitor of JAK3. The effects of G66976 on 
JAK1 and Tyk 2 are more difficult to define. Interferon signalling is mediated by 
JAK1 and Tyk2 in the case of IFNa and JAK1 and JAK2 in the case of IFNy.88 For 
both interferons, Go6976 was able to decrease stimulated levels of STAT 1 
significantly but not back to baseline levels. This may suggest that Go6976 is not a 
potent inhibitor of both JAK family members implicated in IFN signaling or other 
pathways are involved in STAT 1 activation. Future work should include individual 
kinase assays for JAK1 and Tyk 2.
Typically, protein kinase inhibitors are directed to the highly conserved ATP binding 
pocket of the catalytic domain. A structure based approach looking at protein 
kinases bound to ATP-analogues or kinase inhibitors has confirmed that although 
the ATP-binding pocket is highly conserved across protein kinases, the proximal 
region does afford some key diversity. 89 Specific inhibitors take advantage of this 
limited sequence variation surrounding the ATP binding pocket as well as 
conformational differences between inactive and active forms of the kinases. The 
activation loop controls catalytic activity in most kinases by switching between 
different states in a phosphorylation dependent manner. In fully active kinases the 
loop is stabilised in an open conformation and the active conformation is similar in 
all known structures of active kinases. There is however great diversity in the loop 
conformation in inactive kinases. 43 Several groups have investigated which of the 
49 tyrosines in JAK2 are autophosphorylated. In many kinases regulation of
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catalytic activity by phosphorylation occurs on residues within the activation loop of 
the kinase domain. Feng et al demonstrated that Y 1007 and Y 1008 are sites of 
trans- or autophosphorylation in vivo and in in vitro kinase reactions.8 They found 
mutation of Y1007 or both Y 1007/1008, to phenylalanine essentially eliminated 
kinase activity, whereas mutation of Y 1008 alone had no detectable effect on kinase 
activity. Other tyrosine residues known to be autophosphorylated include tyrosine 
221, 570 and 813. Argetsinger et al found that when tyrosine 221 was mutated it 
markedly decreased autophosphorylation of JAK2, more than would be expected 
from the loss of just one tyrosine. When tyrosine 570 was mutated the 
phosphorylation associated with 1007/1008 was increased compared to wild type. 
They felt that tyrosine 570 may serve as a binding site for an inhibitor or have some 
steric effect that decreases JAK2 activity. 11 Because receptors that bind with JAK2 
bind to the FERM domain, the FERM domain presumably assumes different 
conformations to transmit signals from the receptor to the JH1 domain. It seems 
likely that conformational changes in the region between Y221 and Y240 (e.g. as a 
result of phosphorylation of Y221 or changes in receptor conformation due to ligand 
binding) would play an important role in the regulation of kinase activity.
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Fig 3. 16 The domain structure of JAK kinases. JAKs comprise FERM, SH2, 
pseudokinase and kinase domains. The FERM domain mediates receptor 
interactions. Both the FERM and pseudokinase domains regulate catalytic 
activity14.
Although we have demonstrated that G66976 is a JAK2 inhibitor, we found that 
JAK2 phosphorylation at Y 1007/1008 as assessed by Western blot with a 
phosphospecific antibody was not reduced by incubation with G66976 despite a 
reduction in total JAK2 phosphorylated tyrosine content and clear inhibition of 
downstream signalling. We obtained similar findings with staurosporine and JAK 
inhibitor 1 60 (data not shown) but not with the tyrphostin AG490. These findings 
also have implications for the screening of JAK2 inhibitory compounds - if 
autophosphorylation at Y 1007/1008 is used as the endpoint, useful inhibitors could 
be scored as inactive.
Our findings indicate that G66976 preferentially binds to and inhibits JAK2 which is 
already phosphorylated at Y 1007/1008. This prevents phosphorylation of other 
tyrosine residues in JAK2 as well as phosphorylation of various substrates, 
preventing activation of downstream signalling. In support of this hypothesis 
Boggon et al have recently reported on the crystal structure of JAK3 in complex
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with AFN941, a staurosporine analogue. They found that the JAK3-AFN941 
complex is crystallized in a catalytically active state and is tyrosine phosphorylated 
on both autophosphorylated sites in the activation loop. 90 AFN 941 binds JAK3 in 
the catalytic cleft between the N- and C-lobes. Sequence identity between JAK2 and 
3 is 62% with almost all residues in the inhibitor-binding cleft conserved and it is 
likely that staurosporine and by implication G66976, binds to JAK2 that is 
phosphorylated at Y 1007/1008 and is in an active conformation. Kinase inhibitors 
have been shown to bind distinct conformations of their target molecules - for 
example imatinib binds to and inhibits an inactive conformation of Abl whereas the 
compound PD173955 binds to and inhibits Abl in multiple, including active, 
conformations.91
3.10 Conclusions
Preliminary experiments suggested that G66976 had biological effects out of 
keeping with its action on PKC. G66976 inhibited signaling downstream of IL-3 and 
reduced levels of pSTAT 5, pAkt and pERK, components of the JAK-STAT, PI3- 
Kinase and MAP-Kinase pathways respectively. Incubation with G66976 abrogated 
the survival signals of IL-3 and led to a fall in proliferation and an increase in 
apoptosis to levels equivalent to growth factor starvation with an IC50 of 93+/- 
50nM. Similar results were obtained when signaling and biological effect were 
examined downstream of other JAK2 utilizing cytokines, GM CSF, IL-6, EPO and 
TPO. These effects were not seen however with signaling downstream of stem cell
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factor which acts via the KIT receptor tyrosine kinase nor was any effect seen on 
signaling or apoptosis/proliferation with the control PKC inhibitor G66983. In vitro 
assays utilizing recombinant JAK2 showed that G66976 directly inhibits JAK2 
kinase activity (IC50 130nM). G66976 was significantly more potent than the 
known JAK2 inhibitor AG490 (IC50 35micromolar). In spite of clear evidence, both 
in whole cell systems and in in vitro kinase assays, that G66976 inhibits JAK2 
kinase activity, it does not inhibit phosphorylation of JAK2 at Y1007/1008 in the 
catalytic loop using a phosphospecific antibody against these sites. This is probably 
due to preferential binding of G66976 to pre phosphorylated JAK2 preventing 
subsequent phosphorylation of the receptor and adapter molecules and thus 
propagation of downstream signaling.
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CHAPTER 4-THE EFFECT OF G56976 ON
HAEMATOPOIETIC CELL LINES AND PRIMARY AML 
CELLS
4.1 Introduction
Until recently the most direct evidence implicating dysregulation of the JAK/STAT 
pathway in haematopoietic malignancies was the identification of the TEL-JAK2 
fusion. This fusion occurs as a result of t(9;12) or t(9;15;12) and has been reported to 
occur in myeloid and lymphoid leukaemias. 92,93 JAK2 is also likely to be activated 
by fusion of JAK2 with PCM1 resulting from a novel t(8;9) which has been 
described in a variety of haematopoietic malignancies93 and JAK2 gene 
amplification has been shown to be a common finding in Hodgkin’s and primary 
mediastinal B-cell lymphomas.24,94 Recently a mutation at position 617, resulting in 
a conversion from valine to phenylalanine, in the JAK homology 2 (JH2) domain of 
JAK2 has been reported to be present in myeloproliferative disorders including the 
majority of cases of polycythaemia vera and also in essential thrombocythaemia and 
idiopathic myelofibrosis. This mutation in the pseudokinase domain of JAK2 is 
thought to lead to loss of autoregulation and increased kinase activity.68,95
In addition to these well characterised JAK2 abnormalities constitutive STAT 
activation has been reported in many malignancies including multiple myeloma, 
acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), non Hodgkins
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lymphoma and anaplastic cell lymphoma (ALCL). 96,97 STAT activation can occur 
as a result of increased tyrosine kinase activity -  for example, by chromosomal 
translocation and formation of a novel fusion product such as BCR-ABL, by 
acquired mutations such as internal tandem duplications in the Flt3 gene (FLT3 ITD) 
or secondary to autocrine/paracrine growth factor secretion. The frequency of 
constitutive STAT activation reported in AML varies between studies. Biethahn et al 
reported constitutive STAT 3 activation in all of 25 patients examined and 
constitutive STAT 5 activation in 21 out of 25 patients examined.98 This is similar 
to the findings of Hayakawa et al who found STAT 5 activation in 80% and STAT 3 
activation in 74% of samples. 99 Benekli et al, however, only found constitutive 
STAT 3 phosphorylation in 28 out of 63 (44%) patients100 and Xia et al found STAT 
3 and STAT 5 activation in 28% and 22% of patients respectively. 101 The reasons 
for the difference in reported frequencies is not clear but may relate to different 
methods of detection i.e. tyrosine phosphorylation versus DNA binding or may be 
due to differences in sample handling.The observation that STATs are activated in 
most cases of AML suggests that selective pharmacologic inhibition of activation of 
these proteins could be a valid therapeutic strategy in this disease.
In this chapter we examine the effect of G66976 on survival and proliferation of 
haematopoietic cell lines expressing activated forms of JAK2 as well as of other 
tumour-derived cell lines We also investigate the frequency of constitutive STAT 
activation in primary AML cells and the effect of JAK2 inhibition by G66976 on 
this activation and on survival and proliferation.
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4.2 G56976 reduces constitutive Tel-JAK2 signalling and signalling 
downstream of the JAK2 V617F mutant.
The data so far detailed in chapter 3 show that G66976 can inhibit cytokine induced 
changes in signalling, survival and proliferation mediated by JAK2 and 3.
The Tel-JAK 2 fusion protein, consisting of the amino terminal 336 amino acids of 
the oligomerisation domain of Tel and the tyrosine kinase domain of JAK2 (amino 
acids 814-1130) was stably expressed in 32D cells, (method 2.6.4) This resulted in 
constitutive activation of tyrosine kinase activity and growth factor independence on 
these cells, which normally require IL-3 for survival.
32D cells stably expressing Tel-JAK2 were incubated with increasing concentrations 
of G66976 and 1 pM G66983 for 6 hours. Phosphorylated proteins were examined 
by Western blotting.
Tyrosine phosphorylation of a number of proteins was markedly increased when 
compared to the parental 32D line. Constitutive phosphorylation of PI3-Kinase/Akt, 
MAPK and of STAT 3 and STAT 5 was detected. Incubation with increasing 
concentrations of G66976 showed a marked reduction in global tyrosine 
phosphorylation as well as phosphorylation of STAT 3, 5, ERK and Akt. (Figure 
4.1a/b)
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Figure 4.1 G56976 reduces constitutive Tel-JAK2 signalling
32D cells stably expressing the leukaemia associated Tel-JAK2 fusion were 
incubated with G06976 for 6hours and immunoblot analysis carried out with 
indicated antibodies. In 4.1b, lane 1 (marked 32D) contains lysate from parental 
32D cells.
Tel-JAK2 cells were incubated with G66976 and apoptosis (Annexin V staining) at 
24 hours and proliferation (MTS assay) at 48 hours were examined. Apoptosis was
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increased by an average of 20+/-3% by incubation with lpM G66976. The IC50 for 
apoptosis was 242+/-15nM (range 210-300nM n=5).
Proliferation fell to an average of 37+/-8% of control cells (no inhibitor) on 
incubation with lpM  G66976. The average IC50 was 291+/-44nM G66976 (range 
130-445nM n=7). (Figure 4.2a/b) In contrast, G66983 had no significant effect on 
apoptosis or proliferation.
To confirm these results cell number and viability (trypan blue) were assessed after 
48 hours incubation with Go6976. The control cell number increased from lx l0 5 to 
4.5x105 viable cells at 48 hours. Incubation with 600nM G66976 reduced viable cell 
number from lxlO5 to 6xl04 at the same time point. There was no significant effect 
of the G66983 on viable cell number (3.4xl05). G66976 is therefore able to inhibit 
signaling downstream of the Tel-JAK2 fusion protein and negate its effects on 
survival and proliferation.
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30
25
20
15
10
5
§ 0 O 0 .01 .1 .5 .75 1 5 10 1|iM
2  140
O 120 O 
-  100
80
60
40
tnn
&
>
8 20 
P  0
-----------------Go76----------------- Go83
a □ a
0 .001 .01 .1 .5 .75 1 1|iM
---------------G o76-----------------   Go83
Figure 4.2 G66976 reduces proliferation and increases apoptosis in Tel-JAK2 
expressing cells.
TeI-JAK2 expressing 32D cells were incubated with the indicated concentration 
of G66976 and apoptosis assessed at 24hours (Annexin V (n=5» and 
proliferation at 48hours (MTS assay (n=7)).
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The JAK2 V617F mutation is present in myeloproliferative disorders including 
polycythemia vera and results in its constitutive activation. 102 103 The following 
experiment was carried out by Dr T Everington in the Department of Haematology 
at UCL. The HEL cell line which has a homozygous JAK2 mutation 104 was utilized 
to evaluate the effects of G66976 on JAK2 V617F induced signalling and 
proliferation. The JAK inhibitor Compound 6 or JAK Inhibitor 1 (JI1) previously 
shown to be active against JAK2V617F 104 was used for comparison. HEL cells 
were incubated with increasing concentrations of G66976 or JI1. Total cell lysates 
were made after 6 hours incubation and analysed by Western blot. Figure 4.3 shows 
that Go6976 and JI1 both inhibit downstream signalling pathways in HEL cells 
(STAT 5, Akt, GSK3, ERK/MAPK, PIM1) and also decrease cell proliferation in a 
dose-dependent manner. These results indicate that G66976 is an effective inhibitor 
of the V617F JAK2 mutant.
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Figure 4.3 G66976 inhibits signalling downstream of the JAK2 V617F 
mutation.
HEL cells which have a homozygous JAK2 V617F mutation were incubated 
with increasing concentrations of G66976 or JAK inhibitor 1 (Compound 6). a) 
Cell lysates were made after 6 hours and analysed by immunoblot with the 
indicated antibodies, b) samples were analysed by MTS assay after 48 hours 
and are expressed as a % of control value (no inhibitor).
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4.3 Tel-JAK3 cells are also sensitive to the effects of G66976
The Tel-JAK2 fusion has been reported in leukaemia with the t(9; 12) resulting in 
oligomerisation and constitutive activation of JAK2. The Tel-JAK3 fusion has not 
been described but the construct is useful to investigate signaling downstream of 
JAK3. 32D cells stably expressing the Tel-JAK3 fusion were rendered factor 
independent. The constitutively activated JAK3 activates downstream pathways 
including PI3-Kinase, MAP-Kinase and STAT 5. We examined the effect of 
incubation with increasing doses of G66976 on phosphorylated protein expression. 
The cells were incubated with the indicated concentration of inhibitor for 6 hours 
before total cell lysates were made. Incubation with G66976 led to a marked 
reduction in pSTAT 5 at concentrations as low as lOOnM (Figure 4.4).
Figure 4.4
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Figure 4.4 G56976 inhibits signalling downstream of cells expressing Tel-JAK3.
Tel-JAK3 expressing 32D cells were incubated with increasing concentrations 
of G66976 for 6 hours prior to immunoblot analysis with indicated antibodies.
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To examine the biological effect of inhibition of the Tel-JAK3 fusion protein by 
Go6976, cells were incubated with increasing doses of G66976; apoptosis at 24 
hours and proliferation at 48 hours were assessed. Incubation with lpM G66976 
increased the level of apoptosis by 19%. The percentage of apoptotic cells remained 
at basal levels for the control inhibitor, G66983 (Figure 4.5a).
Go6976 reduced proliferation in Tel-JAK3 expressing cells. Incubation with lpM 
G66976 led to a 75% reduction compared to control cells. The average IC50 was 
144+/-50nM (n=5 range 75-340nM) (Figure 4.5b).
Cell number and viability were also assessed by trypan blue staining after 48 hour 
incubation with Go6976. Initially 3xl05 cells were seeded per point. At 48hours the 
control viable cell number had increased to lxlO6 -however the cells incubated with 
lpM G66976 remained at 4xl05viable cells. G66983 had no significant effect on 
viable cell number (1.1 x 106 cells).
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Figure 4.5 G66976 reduces proliferation and increases apoptosis in Tel-JAK3 
expressing cells.
a) Tel-JAK3 expressing 32D cells were incubated with increasing 
concentrations of G66976 and apoptosis assessed at 24 hours (Annexin V).
b) Tel-JAK3 expressing 32D cells were incubated with the indicated 
concentration of G66976 and proliferation at 48 hours assessed by MTS assay 
(n=5).
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4.4 The effect of G66976 on Haematopoietic tumour-derived cell
lines
4,4,1 Anaplastic lymphoma lines
Two anaplastic lymphoma lines were examined for their sensitivity to G66976, 
Karpas 299 and SUDHL1. Over 50% of cases of Anaplastic lymphoma, and both 
these cell lines, have the t(2;5) which leads to the formation of the NPM-ALK fusion 
protein. It has been reported that constitutive activation of JAK2 contributes to the 
pro-proliferative and anti-apoptotic effect of this fusion protein in anaplastic 
lymphoma cells. 105
These factor independent cell lines were cultured in the presence of increasing 
concentrations of G66976 overnight. Total cell lysates were then made and 
examined by Western blotting. Both cell lines show constitutive activation of STATs 
3 and 5 which was decreased in a dose dependent manner by incubation with 
G66976 (Figure 4.6a/b).
The effect of G66976 on proliferation at 48 hours was also assessed (Figure 4.7). 
Karpas 299 and SUDHL1 were both sensitive to G66976 with IC50’s 108+/-26nM 
(n=3) and 235+/-87nM (n=3) respectively.
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Figure 4.6 G66976 reduces STAT 5 phosphorylation in anaplastic lymphoma 
cell lines.
Karpas 299 (panel a) and SUDHL1 (panel b) anaplastic cell lines were cultured 
overnight in the indicated concentration of inhibitor. Immunoblot analysis was 
performed with specified antibody.
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Figure 4.7 G66976 reduces proliferation in anaplastic lymphoma cell lines.
Karpas 299 (a) and SUDHL1 (b) anaplastic lymphoma cell lines were incubated 
with the indicated concentration of inhibitor. Proliferation was assessed at 
48hours by MTS assay. Proliferation is expressed as a percentage of the 
proliferation of the control cells (no inhibitor).
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4.4.2 G66976 effect on acute leukaemia cell lines
Four acute leukaemia lines were examined for their sensitivity to G66976. This was 
assessed by MTS assay after 48 hours of incubation with increasing doses of 
inhibitor. It was found that Myeloid lines U937 and KG la were sensitive to G66976 
with IC50’s of 310 and 232nM respectively (Figure 4.8), but the AML HL60 cells 
and JURKAT T lymphoblastic cells were resistant to G66976 effect (data not 
shown).
K562, a cell line derived from an erythroleukaemic blast transformation of chronic 
myeloid leukaemia and positive for the BCR-Abl fusion transcript, has constitutive 
activation of Stats 3 and 5 when assessed by Western blot. Incubation with G66976 
for 6 hours reduced phosphorylation of STAT 3 but not STAT 5. However, the 
tyrosine kinase inhibitor, Imatinib which acts specifically to inhibit BCR-Abl, 
reduced STAT 5 phosphorylation but not that of STAT 3. This suggests that BCR- 
Abl may be acting to phosphorylate STAT 5 directly and not acting via JAK2. In 
spite of this, G66976 reduced proliferation in a dose dependent manner with an IC50 
of 240+/-46nM (Figure 4.9).
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Figure 4.9 G66976 reduces STAT phosphorylation and proliferation in K562 
cells
a) K562 cells were cultured with the indicated concentration of inhibitor for 6 
hours after which total cell lysates were made. Immunoblot analysis was 
carried out with the specified antibody, b) Proliferation was assessed after 48 
hours of culture by MTS assay.
4.4.3 The effect o f  G'66976 on proliferation in Multiple Myeloma cell lines
Autocrine IL-6  production has been reported in multiple myeloma cell lines. Four 
myeloma lines; U266, MM IS, KMS BM and KMS PE, were investigated.
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Proliferation was assessed at 48 hours after incubation with increasing doses of 
Go6976. All four lines were found to be insensitive to Go6976 as well as the control 
inhibitor G66983 (Figure 4.10).
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Figure 4.10 G66976 has no effect on proliferation in multiple myeloma cell 
lines.
Four multiple myeloma cell lines were cultured with indicated concentration of 
inhibitor. Proliferation was assessed at 48 hours by MTS assay and results 
expressed as percentage of control inhibitor (no inhibitor).
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4.5 The effect of G66976 in Primary AML cells
4.5.1 The effect o f Go6976 on signalling in Primary AML cells
Constitutive STAT activation has been reported to occur in a number of 
haematopoietic malignancies including AML. 106 The frequency of constitutive 
STAT activation was investigated in 26 cases of primary AML whose 
clinicopathological characteristics are shown in Table 2.
Patient samples were obtained from patients presenting to the University College 
Hospital, London, at presentation or relapse. Informed consent was obtained from all 
patients prior to obtaining the sample. All patients had circulating blasts in the 
peripheral blood and these were isolated by Ficoll gradient centrifugation (method 
2.1.7). All samples tested had >90% blasts by morphology and or 
immunophenotyping. Mononuclear cells were frozen in RPMI, FCS and 10% 
DMSO and stored in liquid nitrogen. Fifty percent of samples were analyzed from 
frozen and the remainder was analyzed fresh.
Primary cells were cultured with lpM  G66976, lpM G66983 or no inhibitor for a 
minimum of 6 hours. Total cell lysates were made and samples probed with phospho 
specific antibodies for STATs 3 and 5, Akt and ERK. Twenty-four out of 26 patient 
samples were found to have constitutive STAT activation: 9 out of 26 had activation
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of both STAT 3 and STAT 5, 14 out of 26 of STAT 3 only and 1 patient had 
activation of STAT 5 alone.
All patients had activation of the MAPK pathway with constitutive phosphorylation 
of ERK and 24/25 assessable patients had activation of the PI3-Kinase pathway. 
When the primary AML cells were cultured in the presence of G66976, STAT 
phosphorylation was reduced in 23 out of the 24 cases examined, suggesting that this 
activation was due at least in part to dysregulation of JAK kinase activity. Of the 24 
patients with constitutive STAT activation, incubation with G66976 in 12 cases 
showed a reduction in all 3 pathways (STATs, Akt, ERK) and 8 showed a reduction 
in STATs alone. The 2 patients without STAT activation both had activation of the 
MAPK and PI3-Kinase pathways and in both cases this activation was reduced after 
incubation with Go6976.The remainder of patients showed complex patterns of 
pathway inhibition.
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Table 2 shows the biological details of the primary AML samples examined.
N/A-Not available, WT-wild type, ITD-Intemal tandem duplication *-MTS assay performed,+-
AnnexinV assay performed.
Patien t STAT
3
STAT5 FAB
Type/Rel/2°
Pres
W CC
x l0 9/l
Cytogenetics Flt 3 
S tatus
N-
R as
1 *+ N/A N/A M l 14 46xx N/A N/A
2 * + - M2 35 46xy W T EX1
3 * + - M l 401 46xx ITD W T
4 * + + M5b 52 46xx W T W T
5 *+ + + M2 117 Del(9) ql2q34 W T EX2
6 + + M5 257 46xy ITD W T
7*+ + + M4 233 Invl6(pl3q22) W T EX2
8 * + - 2° ET 146 complex W T W T
9 * + N/A N/A M5/ Relapse 3 N/A N/A N/A
10*+ + - MO 131 N/A N/A N/A
11* - - M2 29 t(8;21) -y W T N/A
12 * + - M5 69 failed W T W T
13 *+ + + M l 140 46xy ITD W T
14 *+ + - M5a 89 46xx ITD EX1
15 + - N/A relapsed 36 46xx,r(7)(?p? q)t(9; 22)(q34; q 11) W T W T
16 + - M5a 162 46xy del(10) W T EX1/2
17* + - M2 47 Trisomy 21 ITD/D835 W T
18 + - M l 80 46xx W T EX1
19* + + 2°MDS 38.1 N/A W T W T
20 + + - M l 34 N/A W T W T
21* N/A M2 10 Trisomy 11 ITD W T
22* + - M5b 188 46xx W T W T
23 + + + M l 33 46xy ITD W T
24 N/A + W T W T
25 *+ N/A M2 42 W T W T
26 *+ + - 46xx W T W T
2 7 * + - M2 8 45xyadd(8)(q22)add(15)(pl)add(21)(pl) N/A EX2
28 + + M3 ITD N/A
29 + + - M4 50 Trisomy 21 N/A N/A
3 0 * + - M4 541 T (10;ll)
Progressed with 7q-
N/A N/A
31 +* N/A N/A M4 120 46xy N/A N/A
32 +* N/A N/A M4 100 46xx N/A N/A
3 3 * N/A N/A AML M l 43 Abn haplo 
t(3;13)
N/A N/A
3 4 * N/A N/A N/A N/A N/A N/A N/A
3 5 * N/A N/A M2 10 t(8;21) N/A N/A
3 6 * N/A N/A M3 N/A N/A
3 7 * N/A N/A M3 N/A N/A
3 8 * N/A N/A M2 10 ?q- N /A N /A
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Figure 4.11
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Figure 4.11 The effect of G66976 in primary AML cells.
Primary AML cells were cultured for a minimum of 6 hours with indicated 
inhibitor and total cell lysates were made. Immunoblot analysis was performed 
with the given antibodies. Total STAT 5 is shown as a protein loading control.
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A number of different signalling patterns were seen. The second panel of Figure 
4.11 which shows four patient examples illustrates this. It can be seen that examples 
28, 13 and 19 show activation of STATs 3 and 5 whereas patient 22 shows 
activation of STAT 3 alone. All cases show a reduction in STAT phosphorylation 
after incubation with lpM G66976 but not lpM G66983. In all 4 examples there is 
evidence of constitutive activation of the PI3-Kinase and MAPK pathways with 
phosphorylation of Akt and ERK respectively. In patients 28 and 22 neither Akt nor 
ERK phosphorylation are affected by incubation with G66976. However in patients 
13 and 19 both pAkt and pERK are markedly reduced by G66976 (but not G66983). 
This dissociation of effect between inhibition of STAT and Akt/MAPK 
phosphorylation suggests that in patients 28 and 22 other molecular abnormalities 
may be cooperating with dysregulation of the JAK/STAT pathway.
Patients 13, 23 and 28 have a FLT3 ITD and patient 16 has a Ras mutation. 
Oncogenic signalling by FLT3 ITD is known to activate aberrant signalling 
pathways including activation of STAT 5 79. It may therefore seem unususal that 
some of the FLT3 ITD positive patients in our series lacked constitutive 
phosphorylation of STAT 5. However, Pallis et al, using a flow cytometric 
phosphorylated STAT 5 assay, showed that STAT5 activation in AML is a 
continuum with no logical cutoff between positive and negative fluorescence. They 
found just under 50% of their samples possessed a FLT3 ITD and found no 
association between the level of STAT 5 phosphorylation and the presence of a 
FLT3 ITD.
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4.3.2 The effect o f G36976 on survival and proliferation in primary AML
cells
The biological effects of G66976 on primary AML cells were examined by 
measuring apoptosis at 24 hours and cell number at 48 hours. The results are shown 
in Figure 4.12. Incubation with G66976 led to a reduction in cell number to 63+/- 
3% (n=29) of control. The MTS results could be due to an increase in apoptosis, a 
reduction in proliferation or a combination of both. These results were at least partly 
due to an increase in apoptosis which was increased by 19+/-6% (n=15). G66983 
had no effect on cell number or apoptosis. Although events at the signalling pathway 
level differed between patients it should be noted that 85% of samples showed a 
greater than 20% reduction in MTS activity in response to lpM G66976. Further 
work carried out in our laboratory showed that when primary AML cells were 
cultured in the presence of IL-3, an increase in cell number was seen which was 
abrogated by incubation with lpM G66976 (data not shown). In 2 patients the 
CD34+ CD38- subset was isolated by flow cytometric sorting; this subset is thought 
to include the leukaemic stem cell population. In one patient apoptosis was 
measured after incubation with lpM G66976 or G66983 for 24 hours. Apoptosis in 
the bulk and CD34+38- populations increased by 8% and 26% respectively. In the 
second patient an MTS assay was carried out after 48hours incubation with G66976. 
This led to a 93% reduction in cell number in the CD34+38- group compared to 61% 
in the unselected cells. G66983 had no effect on apoptosis or cell number in either 
experiment.
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Figure 4.8 G66976 reduces proliferation in leukaemia cell lines.
a/b Leukaemic cell lines were cultured with indicated concentration of inhibitor 
and proliferation assessed by MTS assay at 48hours. Results are given as a 
percentage of control cells (no inhibitor).
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Figure 4.12 G66976 reduces cell number and increases apoptosis in AML cells.
Primary AML cells were incubated with lpM  G66976, lpM G66983 or no 
inhibitor. Apoptosis was assessed at 24 hours by annexin V staining and flow 
cytometry (a) and cell number was assessed by MTS assay at 48hours (b).
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4.6 Discussion
The previous chapter has shown that G66976 is a potent inhibitor of JAK 2 kinase 
activity and inhibits signalling downstream of JAK2 utilising cytokines leading to a 
reduction in proliferation and an increase in apoptosis in factor dependent cell lines. 
G66976 is also a direct inhibitor of JAK3 kinase activity.
The aim of this chapter was to explore G66976 effect on cell lines derived from 
haematopoietic malignancies thought to have a dysregulated JAK/STAT pathway 
with either constitutive JAK activation resulting from a fusion protein or activating 
mutation. This was taken further to investigate the consequence of G66976 exposure 
on primary AML cells.
There is increasing evidence for the involvement of JAK2 in haematological 
malignancies with the descriptions of Tel-JAK2 and PCM1-JAK2 fusion genes in 
leukaemia and myeloproliferative disease, 93,108 the amplification and overexpression 
of JAK2 in certain lymphomas 24,94,105,109 and most recently with the identification of 
the V617F mutation at very high frequencies in polycythaemia vera, essential 
thrombocythaemia and idiopathic myelofibrosis 68’95 104 and exon 12 mutations in 
polycythaemia and idiopathic erythrocytosis110.
In order to further evaluate the effect of G66976 on JAK2 kinase, its effect on the 
constitutively active Tel-JAK2 kinase was investigated. The Translocated Ets 
leukaemia (TEL) protein gene is frequently rearranged in human malignancies. It
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has been reported to be fused to the catalytic domain of JAK2 in pre B ALL (t(9; 12)) 
and in an atypical CML (t(9;15;12).92 This fusion protein is able to transform BAF3 
cells and lead to growth factor independence. Mice transplanted with bone marrow 
infected with the fusion gene develop a rapidly fatal mixed myeloproliferative and 
lymphoproliferative disease which is thought to be dependent on ST AT 5. 111 Tel- 
JAK2 fusion proteins have a diffuse cytoplasmic location and are not associated with 
the intracellular moiety of the receptor. Constitutive activation of STATs 3 and 5 in 
32D cells expressing the Tel-JAK2 fusion was found which concurs with the 
findings of Ho112 et al. Lacronique, however reports only constitutive activation of 
STAT 5.108 Both Lacronique and Ho found that Tel-JAK2 does not phosphorylate 
wild type JAK2 or the IL-3pR suggesting that Tel-JAK 2 fusions are directly able to 
activate signalling pathways that lead to cell proliferation and inhibition of apoptosis 
independently of the cytokine receptor. Our results indicate that G66976 is able to 
inhibit the constitutively active Tel-JAK2 fusion protein and decrease 
phosphorylation of STATs 3, 5, Akt and ERK. Further work carried out in the 
laboratory has shown that Go6976 also inhibits signalling downstream of the 
constitutively active JAK2 V617F mutation in HEL cells and reduces proliferation 
in this cell line. Although it would be predicted that tyrosines 1007 and 1008 would 
be phosphorylated in myeloproliferative disorders with activating JAK mutations 
this has not yet been formally demonstrated. JAK2 V617F retrovirally transfected 
into murine bone marrow cells produces a non fatal polycythaemia when 
transplanted into Balb/c mice. Continuous parenteral administration of the JAK2 
inhibitor AG490 to polycythaemic mice over a 2 week period led to a reduction in
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haematocrit and a fall in reticulocyte count113. Together these results show that 
Go6976 can inhibit signalling from JAK2 in its wild type, fusion protein and V617F 
forms.
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Figure 4. 13A schematic representation of JAK 2 illustrating the location of 
some of the mutations and fusion proteins occurring in haematological
disorders. The T875N mutation has been reported in AMKL cell lines.114
Transformation to AML is a known complication of myeloproliferative disorders. 
The frequency of the JAK V617F somatic mutation in AML is low at around 
| 0/o68,ii5-ii8 j^ee gt aj foun(j 3 2 mutations in 113 samples screened giving a
frequency of 2.7%. Only 2 of these were JAK2V617F with the other being K607F. 
The 2 JAKV617F mutations were found in patients with t(8;21) translocation116. 
Schnittger et al found 2 cases expressing JAK2V617F in 24 cases of AML 
expressing t(8;21) AML1/ETO, both of which were therapy related119 and Desta et 
al found 2 cases in 140 cases of therapy related MDS and AML. The latter 2 cases
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had myeloproliferative feaures120. Theocharides et al investigated the role of JAK 
V617F in leukaemic transformation and examined 27 patients with 
myeloproliferative disorders who had transformed to AML. The JAK2 V617F was 
found in 17/27 patients at diagnosis whereas 9/17 transformed to JAK2V617F 
negative AML. They concluded that JAK2-V617F positive MPD frequently yields 
JAK2-V617F negative AML and transformation of a common JAK2-V617F 
negative precursor represented a possible mechanism.
The Tel-JAK3 fusion protein, although not reported in leukaemia, has provided us 
with a useful tool with which to investigate signalling downstream of constitutively 
active JAK3. 32D cells stably expressing this construct were rendered factor 
independent and had constitutive activation of MAPK and PI3-Kinase pathways as 
well as the JAK/STAT axis. G66976 reduced activation of all three pathways which 
translated into a reduction in proliferation of these cells and an increase in apoptosis. 
It appears therefore that Go6976 as well as being able to inhibit JAK3 kinase activity 
and wild type JAK3 is also able to inhibit this JAK3 fusion protein.
Constitutive ST AT activation has been reported in many malignancies including 
multiple myeloma, acute myeloid leukaemia (AML), chronic myeloid leukaemia 
(CML), non Hodgkin’s lymphoma and anaplastic large cell lymphoma (ALCL). 96,97 
The effect of G66976 in 2 anaplastic lymphoma cell lines, Karpas 299 and SUDHL1 
was investigated. The t(2;5), is thought to be present in greater than 50% of ALCL 
and leads to the formation of an 80kda fusion protein, fusing nucleophosmin (NPM) 
with the ALK kinase. Both ST AT 5b and JAK2 contribute to cellular proliferation in
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NPM-ALK expressing cell lines. 105 Activation of STATs 3 and 5 was seen in both 
cell lines which was reduced in a dose dependent manner after incubation with 
G66976. These effects were accompanied by a reduction in cell proliferation. 
Ruchatz et al 105 investigated the role of JAK2 activation in NPM-ALK transformed 
cells. They found that incubation of these cells with AG490, a tyrphostin JAK2 
inhibitor led to a reduction in JAK phosphorylation and also a reduction in 
proliferation and increase in apoptosis, thus concurring with our results.
The effect of G66976 on K562 cells (chronic myeloid leukaemia in blast crisis) 
which possess the BCR-Abl fusion transcript was explored. These cells were found 
to be sensitive to the effect of JAK2 inhibition. Of interest, both ST AT 3 and ST AT 
5 were found to be constitutively activated, however G66976 only reduced 
activation of STAT 3 and not of STAT 5. This was in contrast to the effect of 
Imatinib, a specific inhibitor of the BCR-Abl fusion, which reduced only STAT 5, 
thus suggesting that BCR-Abl is activating STAT 5 directly and not via JAK2. Xie 
et al found JAK2 phosphorylation in the absence of IL-3 in a BCR-Abl expressing 
cell line. They found that the C terminal of Abl was involved in a complex with 
JAK2 and that tumour formation by K562 cells in nude mice was JAK 2 dependent 
and inhibited by a kinase inactive JAK2 mutant. 121 Interestingly De Vos et al found 
that their K562 cells were insensitive to JAK2 inhibition by AG49055.
IL-6, which signals via JAK2, has been widely implicated in the pathogenesis of 
Multiple Myeloma (MM) and is thought to be a major growth and survival factor in
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this disease. Several MM lines, including U266 are thought to be dependent on 
autocrine IL-6 for survival. The effect of G66976 on 4 MM cell lines was 
investigated, including U266, and found none of them to be sensitive to this agent. 
This contrasts with the findings of De Vos et al who found that AG490 inhibited 
proliferation and induced apoptosis in U266 cells, together with reducing STAT 3 
phosphorylation. 55 The findings of Alas et al agreed with this and they also found 
that JAK2 inhibition potentiated certain cytotoxic drugs. 122 The reason why our 
results differ may relate to the cells used and the possibility that further mutations 
have been acquired during passage that confer additional survival benefit. 
Alternatively, some of the effects of AG490 could be attributable to non-JAK2 
inhibitory activity, such as its inhibition of CDK2 activation.
Having identified G66976 as a potent JAK inhibitor and investigated its effect in 
several haematopoietic cell lines the next step was to examine its effects on 
signalling, survival and proliferation in primary AML cells. Constitutive tyrosine 
phosphorylation of STATs 3 and/or 5 was found in 24 of 26 primary AML samples 
examined. This was reduced by incubation with G66976 in 23 of 24 cases. This 
result suggests that the STAT activating event in AML is occurring upstream of 
STATs rather than involving the STATs themselves and is due to the activation of 
JAKs rather than other tyrosine kinases implicated in STAT activation (such as src 
family kinases). 4 The FLT3-ITD abnormality has been reported to activate STAT 5 
106 but it is not clear if this is due to direct phosphorylation or via JAK activation. In 
our study, STAT5 activation in cases that were FLT3 positive was sensitive to 
G66976 suggesting that STAT activation is indirect, but further studies are required
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to investigate this in more detail. STAT activation in AML could potentially result 
from novel fusion proteins such as Tel-JAK2 or PCM1-JAK2, 93,108 
autocrine/paracrine growth factor secretion or activating mutations such as the 
V617F mutation within JAK2. 68 Activation of PI3-Kinase and MAPK pathways 
was also found in the majority of AML cases examined and is consistent with our 
previous findings. 123 In 12 out of 24 patients inhibition of JAKs by Go6976 led to 
reduced activation of all three pathways suggesting that dysregulation of the JAK 
pathway was one of the main aberrant signaling events in these patients. Eight out of 
24 patients had a reduction in STAT alone and the remainder of patients had more 
complex patterns of inhibition. There was no clear correlation between pattern of 
signaling inhibition and degree of reduction in MTS activity in response to G66976, 
but this may be a limitation of the sample number examined. It should be noted that 
despite the differences in pathway inhibition, a greater than 20% reduction in cell 
number was seen in 85% of patients tested.
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Figure 4. 14 Downstream signalling pathways in AML
4.7 Conclusions
In conclusion we have shown that G66976 is a potent inhibitor of JAK2 and that it is 
able to inhibit signalling downstream of wild type JAK2, JAK2 constitutively 
activated by fusion with Tel and mutant JAK2 V617F. We have also shown similar 
effects on JAK3 wild type and the Tel-JAK3 fusion protein. Investigation of several 
haematopoietic cell lines reported to have some dysregulation of the JAK/STAT 
pathway, revealed that Go6976 was able to inhibit proliferation in 2/2 ALCL lines 
(Karpas 299, SUDHL1), 2/4 leukaemia lines (Kgla, U937) and 1 CML line (K562) 
but had no effect on any of the 4 MM lines examined. When we investigated
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primary AML cells we found STAT activation in 24/26 patient samples examined 
which was reduced by G66976 incubation in 23/24 cases, providing evidence of 
JAK STAT dysregulation. In 50% of cases this would appear to have been the main 
aberrant signalling event. We have also shown that G66976 is an active inhibitor of 
survival and proliferation in AML blasts. Together these findings infer that small 
molecule tyrosine kinase inhibitors based on the structure of G66976 would be a 
valid therapeutic modality.
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CHAPTER 5-THE ROLE OF THE PI3-KINASE
PATHWAY IN ACUTE MYELOID LEUKAEMIA
5.1 Introduction
The PI3-Kinases are important regulators of intracellular signal transduction 
pathways mediating cell proliferation, differentiation and survival. There is now 
increasing evidence for PI3-Kinase/Akt dysregulation in human malignancy. 28 The 
role of PI3-Kinase activation in AML is less clear. Recently constitutive 
phosphorylation of Akt has been described in a significant proportion of patients 
with AML. 124 126 The method of Akt activation is not clear but does appear to be 
important for leukaemia cell survival. 124 125 The presence of constitutive Akt 
phosphorylation has also been linked to a shorter overall survival in AML. 124 In this 
chapter the frequency of constitutive activation of PI3-Kinase in AML was 
investigated together with the effect of PI3-Kinase inhibition on survival in bulk 
primary AML blasts and on leukaemic progenitors. The potential for combining PI3- 
Kinase inhibition with conventional cytotoxics was examined and key downstream 
effector molecules that mediate the pro-survival effect of PI3-Kinase in AML, were 
identified.
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5.2 Akt is constitutively active in primary AML Cells
In order to determine if Akt is activated in primary AML cells we utilised AML 
blasts from patients at presentation or relapse. For analysis both fresh and frozen 
samples were used. Primary cells were cultured overnight in RPMI 10% FCS in the 
absence of growth factors either with or without the PI3-Kinase inhibitor LY 
294002. Total cell lysates were made and Akt phosphorylation was detected by 
western blot, using an antibody directed against phosphorylated Akt at serine 473. 
Twenty-four out of 25 assessable patients had activated Akt indicating that the PI3- 
Kinase pathway is activated in AML blasts. Overnight incubation with the selective 
PI3-Kinase inhibitor, LY294002 resulted in reduced or abolished Akt 
phosphorylation (Figure 5.1).
Figure 5.1
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Figure 5.1 Constitutive Akt activation is reduced by LY294002 in AML cells.
Primary AML cells were incubated for 24 hours with or without LY294002 
25pM and total cell lysates made. The blot was probed with phospho Akt 
ser473 and total STAT 5 to check for protein loading. The patient sample n° 
refers to Table 1.
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This was also seen after incubations as short as 4 hours (Figure 5.2a). Using 
scanning densitometry the mean reduction was 53+/-4% (n=20). To illustrate that 
this was constitutive activation, Akt phosphorylation in the AML blasts was 
compared to that found in normal CD34+ cells grown in myeloid culture in the 
presence of SCF, IL-3 and GCSF (day 7) (Figure 5.2b). Akt phosphorylation was 
not detected in the normal myeloid cells.
Figure 5.2
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Figure 5.2 LY294002 reduces Akt phosphorylation even after short 
incubations; Akt is not active in normal CD34+ cells.
a) Primary AML cells were incubated with LY294002 for periods as short as 4 
hours. Immunoblot analysis with indicated antibody was performed.b). 
Western blot to show activation of Akt in 2 patient samples but not in non- 
leukaemic myeloid cells (CD34+cells in myeloid culture, day 7). Tubulin is 
shown as a loading control.
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Akt phosphorylation at serine (ser) 473 is thought to occur after initial 
phosphorylation at threonine (thr) 308 - phosphorylation at both residues is required 
for full activation of Akt. Primary AML blasts were incubated (8 cases) with 
LY294002 as described above and total cell lysates made. Phosphorylation at Thr 
308 was examined by Western blot using a phosphospecific antibody. Constitutive 
activation of Akt at Thr 308 was seen in all samples examined and incubation with 
LY294002 led to a reduction in phosphorylation at this residue (Figure 5.3).
Figure 5.3
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Figure 5.3 Akt is constitutively active at threonine 308 in primary AML cells.
Western blot showing constitutive activation of Akt at Thr 308 in primary 
AML blasts ( 8 samples shown here), b) Primary AML blasts were incubated 
with LY294002 for 24hours and total cell lysates made. Immunoblot analysis 
with phospho Akt Thr 308 was carried out.
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Akt activation could be due to downregulation of one of the negative regulators of 
PI3-Kinase, such as PTEN. PTEN (phosphatase and Tensin homologue) is 
commonly deleted in a diverse array of cancers including haematological 
malignancies ’ . PTEN deletion in MX-l/Cre mice leads to a myeloproliferative 
disease within days and a transplantable leukaemia within weeks127.Interestingly 
PTEN deletion also led to Haematopoietic stem cell (HSC) proliferation which led to 
a loss of self renewal capacity, a contrast to the leukaemia initiating stem cell. 
Treatment with rapamycin, a mTOR inhibitor, restored the self renewal capacity of 
HSC’s and depleted leukaemia initiating cells ,2?. PTEN expression in 12 patients 
with AML was at a similar level to a mononuclear cell fraction from a normal donor 
(Figure 5.4) and there appeared to be no correlation with pAkt expression, (data not 
shown) Mutational analysis revealed that 3 out of the 16 patients tested had a FLT3 
ITD and 5 had N-ras mutations. One patient had both a FLT3 ITD and N-ras 
mutation. Of the 18 patients examined no patients were found with a FLT3 D835 
mutation.
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Figure 5.4
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Figure 5.4 PTEN expression in primary AML cells.
Western blot showing PTEN protein in 12 patients with AML and a normal 
mononuclear cell preparation. The blot was re-probed with an anti-tubulin 
antibody to check protein loading.
5.3 Effect of PI3-Kinase blockade on leukaemic cell survival
In order to investigate the role of PI3-Kinase in AML survival primary AML blasts 
were incubated with 25pM LY294002 and an MTS assay carried out at 48 hours. 
Cell number was reduced by an average of 51+/-3.6% (range 6-85%, n=29 patient 
samples) (Figure 5.5a). This could represent a reduction in proliferation or an 
increase in apoptosis or both. The level of apoptosis was therefore examined after 
incubation with LY294002 using a flow-cytometric annexin V assay to detect the 
percentage of apoptotic cells. After 24hours, 19+/-4% of control cells and 43+/-5% 
of LY294002 treated cells were annexin positive (range 21-63%, n=9) (Figure 
5.5b), suggesting that the reduction in MTS activity was at least partly due to 
increased apoptosis. A dose response for LY294002 was carried out in blasts from 7
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patients. AML blasts were incubated with increasing doses of LY294002 (0-50pM) 
and an MTS assay carried out at 48 hours. The mean IC50 was 7pM LY294002. 
Figure 5.5c shows the mean cell number as a percentage of control +/- SEM for each 
concentration used. The inhibitory effect of LY 294002 on AML blast MTS activity 
is in keeping with the in vitro IC 50 of PI3-Kinase activity by LY294002 reported as 
10 pM by Davies et a l .128
5.4 P13-Kinase blockade reduces MAPK activation in some patients 
with AML
The ERK MAP-Kinase (MAPK) pathway is another key regulator of cellular 
processes including differentiation, proliferation and apoptosis. Primary AML 
samples were incubated with and without LY294002 for a minimum of 4 hours, total 
cell lysates made and examined by Western Blotting using a phospho-specific 
MAPK p42/44 antibody. We found that all of 18 AML samples investigated had 
constitutively active MAPK. When these cells were incubated with 25pM 
LY294002 MAPK phosphorylation was reduced in 10/18 patients (Figure 5.6a). 
Quantification by scanning densitometry showed a decrease to 36+/-6% (mean+/- 
SEM) of control. This suggested that PI3-Kinase activity is upstream of MAPK, and 
raises the possibility that some of the effects of PI3-Kinase inhibition on leukaemic 
cell survival may be due to reduced MAPK activity. To assess this further the effect 
of U0126, a selective MEK inhibitor, on cell proliferation and apoptosis was
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assessed. MTS assay at 48hours showed a reduction in cell number of 23+/-7% 
(range 0-69%, n=19) when compared to control cells (c.f. LY 51%) (Figure 5.6b). 
Annexin V assay, at 24 hours, showed apoptosis levels of 31+/-6% (range 14-61%, 
n=9) compared to control 19+/-4% (Figure 5.6c). This indicated that although 
MAPK has a role in AML cell survival the effect of PI3-Kinase inhibition on AML 
survival could not solely be attributed to MAPK inhibition.
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Figure 5.5 LY294002 reduces cell number and increases apoptosis in primary 
AML cells.
a/b) Primary AML cells were incubated with and without LY294002 25pM and 
apoptosis was assessed at 24hours by annexin V staining and an MTS assay was 
carried out at 48hours to assess cell number, c) Primary leukaemic blasts were 
incubated with increasing doses of LY294002 and an MTS assay carried out at 
48 hours. The mean results for each concentration are shown +/- SEM (n=7).
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Figure 5.6a
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Figure 5.6 PI3-Kinase blockade reduces MAPK activation in some primary 
AML cells.
a/b Western blot showing ERK activation in four primary AML samples and 
reduction in phosphorylation after 24 hours incubation with LY294002 25pM. 
The blot was probed initially for Phospho ERK 1/2 and then re-probed with 
total Stat 5 to check for protein loading, b). Cells were incubated with U0126 
lOpM an MTS assay was carried out at 48 hours and apoptosis measured by 
annexin V staining afer 24 hours incubation. Results were expressed as a 
percentage of control. The mean reduction in MTS activity was 23+/-7% (range 
0-69%, n=19). Apoptosis was 31+/-6% (rangel4-61%) compared to a control 
level of 19+/-4% (n=9).
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5.5 Effect of PI3-Kinase inhibition on viability of CD34+38- AML 
cells
In four cases, AML blasts were sterile sorted to isolate the CD34+38-fraction in 
which the leukaemic stem cell is thought to reside. The cells were incubated with 
25 pM LY294002 and cell viability assessed after 24-48 hours by annexin V binding 
or MTS assay. The results were compared with results for the bulk (unsorted) blast 
population. Figure 5.7 shows that PI3-Kinase inhibition by LY294002 reduces the 
viability of the 34+38- fraction to 51+/-18% (n=4)(c.f. bulk 48+/-12%). The effect of 
MAPK inhibition was compared with that of PI3-Kinase blockade. Using U0126, 
cell viability was again assessed after 24-48 hours: MAPK blockade reduced bulk 
blast viability to 72+/-10% but did not affect the CD34+38- cells (n=3, 100+/-4%). 
These results suggested that inhibiting a given pathway in the bulk leukaemic blast 
population does not necessarily predict what would happen when the same pathway 
is inhibited in individual sub populations.
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Figure 5.7 The effect of PI3-Kinase inhibition on viability of CD34+CD38- 
AML cells.
CD34+CD38- cell were isolated by sterile sorting and incubated with either 
LY294002 25pM or U0126 (MEK1 inhibitor) 10 pM for 24-48 hours. Either an 
MTS assay or annexin V staining was carried out to assess cell viability and 
expressed as a percentage of control.
5.6 P13-Kinase regulates NF-kB and p53 activity in AML cells
NF-kB is a ubiquitously expressed transcription factor and increased activity is 
associated with anti-apoptotic effects. NF-kB has been reported to be constitutively 
active in a number of malignancies including AML, 129 and may be regulated by 
PI3-Kinase. Using a novel technique for high level transfection into primary AML 
cells (“Nucleofection”) we measured the effects of PI3-Kinase blockade on NF-kB 
reporter gene activity. The cells were transfected with the NF-kB reporter gene 
(transfection efficiency by GFP was 39+/-6%). Transfected cells were incubated 
overnight (with or without LY294002) in RPMI/10% FCS. Cells were lysed and
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induced NF-kB reporter activity was corrected for the constitutive renilla luciferase 
expression. Constitutive NF-kB activity (above background levels) was seen in all 
patients examined. Incubation with LY294002 led to a reduction of constitutive NF- 
kB activity in 9/10 patients to 34+/-7% of control (Figures 5.8a and b). These results 
suggest that PI3-Kinase is a positive regulator of the constitutive NF-kB activity 
seen in AML cells.
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Figure 5.8 PI3-Kinase regulates NF-kB in primary AML cells.
a) Primary AML cells or normal CD34+ cells were transfected with an NF-kB 
reporter gene. The transfection efficiency for the CD34+cells was 54+/-9% and 
for AML blasts was 39+/-6%. All patients had constitutive activation of NF-kB, 
above levels seen in un-stimulated CD34+ cells, b) Incubation with LY294002 
25pM led to a reduction in NF-kB activity in 9/10 patients. The activity was 
reduced to a mean of 34+/-7% of control (n=9). NF-kB reporter activity as a 
percentage of untreated control cells is shown for each individual.
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Further work carried out in our laboratory investigated the contribution of the PI3- 
Kinase/pll05 isoform in regulating NF-kB in primary AML cells. Constitutive 
activation of the NF-kB construct was found in 6 of 6 AML samples investigated. 
When the cells were incubated with IC87114, a selective pi 105 isoform inhibitor, 
the basal NF-kB activity was only slightly reduced (5/6 cases) in contrast to 
LY294002. This could be due to the more profound PI3-Kinase inhibition by 
LY294002 or to off-target effects of this compound.
P53 is a central mediator of the cells response to DNA damage and other stresses. 
Mutations in p53 are a common occurrence in many malignant disorders and may 
confer a degree of chemoresistance. p53 is regulated by mdm 2, an E3 ubiquitin 
ligase, which is itself regulated by PI3-Kinase /Akt.130 In order to investigate the 
effect of PI3-Kinase blockade on p53 activity in primary AML cells, a p53 reporter 
assay was used. Primary AML cells were transfected with a p53 reporter gene and 
incubated with or without LY294002 overnight. Blockade of PI3-Kinase activity 
with LY294002 led to a more than 2 fold increase in p53 activity in 4 out of 9 
patients tested (Figure 5.9).
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Figure 5.9 PI3-Kinase regulates p53 activity in AML cells.
Primary AML cells were transfected with a p53 reporter gene and incubated 
overnight with LY294002 25pM. PI3-Kinase inhibition led to a more than 2 fold 
increase in p53 activity in 4/9 patients examined. p53 reporter assay readings 
are shown after incubation with LY294002 25pM as a percentage of untreated 
control cells, for individual patients.
5.7 PI3-Kinase inhibition can enhance the cytotoxic effect of Ara-C
The enhancement of anti-apoptotic mechanisms by constitutively activated PI3- 
Kinase/Akt may reduce the effectiveness of cytotoxic agents. Therefore the effect of 
blocking the PI3-Kinase pathway on sensitivity to Ara-C, a central cytotoxic 
component of many AML treatment regimens was examined. As Ara-C exerts its 
cytotoxic activity at least partly in a cell cycle dependent manner, it was possible 
that PI3-Kinase blockade could reduce cell proliferation and have a deleterious
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effect on the Ara-C response. AML cells were co-incubated with varying 
concentrations of LY294002 (0-50pM) and Ara-C (0-2pg/ml) and an MTS assay 
carried out at 48 hours. PI3-Kinase blockade did not have an adverse impact on the 
cell kill obtained with maximal effective Ara-C concentration for each patient tested. 
Using the Calcusyn® program for calculating the amount of synergy between 
different drug combinations, the combination indices for Ara-C and LY294002 were 
calculated for each patient. A combination index of <1 represents a synergistic 
interaction, of =1 signifies an additive interaction and >1 represents an antagonistic 
interaction. One patient out of the 8 patients examined was not sensitive to Ara-C 
and therefore synergy could not be calculated. Of the remaining patients, 5 out of 7 
exhibited synergy (values at ED50 of 0.2, 0.7, 0.6, 0.5, 0.9), 1 showed an additive 
interaction (ED50 value 1) and 1 a moderately antagonistic interaction (ED50 value 
1.4). Other groups have shown that PI3-Kinase blockade potentiates the response to 
several chemotherapeutic agents including paclitaxel, vincristine, doxorubicin, 
trastuzumab, and etoposide.131-133 In our laboratory C Billotet et al incubated 
primary AML cells with IC87114 (l-5pM) together with low dose VP 16 (0.5pM) 
and carried out an MTS assay at 72hours. They found an additive interaction 
between IC87114 and VP 16 in 6 patients and a synergistic interaction in 8 patients. 
These results suggest that a more selective inhibition of just the pi 106 isoform can 
also potentiate chemotherapeutic effect in primary AML cells.
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5.8 The effect of activating Akt on chemotherapeutic effect
The results with primary AML cells indicate that PI3-Kinase is involved in basal cell 
survival and implicated in resistance to chemotherapy induced apoptosis. PI3-Kinase 
has a number of downstream targets of which Akt is one of the most important in 
survival signalling. To investigate if activation of Akt alone is sufficient to protect 
haematopoietic cells from cytotoxic effects of chemotherapy, an inducible activated 
Akt vector system was used. Myristolation of Akt targets it to the membrane, 
making it constitutively active. By fusing myristolated Akt to a mutant murine 
estrogen receptor hormone binding domain (mAkt-ER), the activation can be turned 
on and off by incubation with tamoxifen. A construct in which the membrane 
targeting ability of the myristolation sequence was abrogated by mutation of glycine 
to alanine at the second amino acid position, was used as a control (A2 mAkt-ER).82 
An IL-3 dependent murine line, 32D, was used to stably express these constructs. 
The cells were incubated overnight with or without tamoxifen (0.5pM), in the 
presence of murine IL-3. To demonstrate the activation of Akt on incubation with 
tamoxifen in the mAkt-ER but not the A2mAkt-ER expressing cells, total cell 
lysates were made and probed with phospho Akt (Figure 5.10).
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Figure 5.10 The effect of tamoxifen on Akt activation in mAkt-ER expressing 
cells.
32D cells stably expressing either the active mAkt-ER or control A2 mAkt-ER 
construct were incubated with or without tamoxifen (0.5pM) overnight. 
Western blot analysis illustrating that incubation with tamoxifen led to 
phosphorylation of mAkt in the mAkt-ER cells but not the A2 mAkt-ER 
expressing cells. The blot was then reprobed with total Akt to check for protein 
loading.
To assess the effect of Akt activation on chemotherapeutic effect the cells were 
incubated overnight with or without tamoxifen (0.5pM), in the presence of murine 
IL-3 (mIL-3) lOng/ml The following day, the cells were washed and resuspended, at 
a concentration of 4xl05/ml, in RPMI/10% FCS with or without lOng/ml mIL-3, in 
the presence or absence of tamoxifen. Ara-C (0-lpg/ml) or etoposide (0-50pM) was 
then added, mixed and incubated for 48 hours, when an MTS assay was carried out.
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Results were normalised to the lOng/ml mIL-3 cells (no cytotoxics) with or without 
tamoxifen.
Activation of Akt by incubation with tamoxifen was sufficient to protect these cells 
from factor withdrawal and led to a significant reduction in cell kill in the presence 
or absence of IL-3, for Ara-C (p =0.009 and p=0.002 respectively by paired t test) 
and for Etoposide (p=0.05 and 0.01) (Figure 5.11). Incubation of 32D cells 
expressing the inactive control plasmid (A2mAkt-ER) with tamoxifen did not alter 
the cytotoxic effects of Ara-C and Etoposide (p>0.05 for all conditions), indicating 
that Akt activation was responsible for the results seen. These results add further 
evidence to suggest that Akt and the pathways that it regulates are involved in 
chemoresistance in haematopoietic cells.
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10ng /m l IL3
55 75  
^  65  
i i 55
£ o 45 
3 °  35  
£  25  
S  15
0 0 .5  5 50 \iM
E to p o s id e
0 0.5 5 50 pM
E top os ide
1 p g /m l 
A ra -C
w _  85  
<  O 7 5
5  c  65 | 
•£  O 55 
O  O  4 5
1 0 n g /m l IL3
0.25  0 .5  1 pg /m l
A ra -C
115
105
9 5
8 5
7 5
65
5 5
4 5
35
2 5
15
f c = j  m A k t E R  + T a m o x ife n  
| | m A kt E R  -T a m o x ife n
fTTTTTl A 2 m  A k t-E R  + T a m o x ife n  
A 2 m A k t-  E R  -T am o xifen
Figure 5.11 The effect of Akt activation on chemotherapeutic effect in a myeloid 
cell line.
Cells were incubated overnight with or without tamoxifen. The following day 
they were washed and resuspended in RPMI 10% FCS with or without murine 
IL-3 lOng/ml, in the presence or absence of tamoxifen. Ara-C (0-lpg/ml) or 
Etoposide (0-50pM) were added and the cells incubated at 37°C. An MTS assay 
was carried out at 48 hours. Results were normalised to cells stimulated with 
lOng/ml IL-3, in the absence of cytotoxics.
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5.9 The effect of PI3-Kinase blockade on other downstream
signalling pathways
So far it has been shown that PI3-Kinase potentially regulates survival by influences 
on MAPK, NF-kB and p53 pathways. Akt is also known to regulate survival and 
proliferation by phosphorylation of a number of other downstream signalling 
proteins. We looked at several of these, to see which, if any, were affected by PI3- 
Kinase blockade in AML cells. Bel xl and BIM levels can be regulated by PI3- 
Kinase, 28,134 but we found no evidence for this in the AML cells tested 4 examples 
of which are shown in Figure 5.12. We found GSK 3 and P70S6 Kinase, which can 
be targets of the PI3-Kinase/Akt pathway, 28 to be constitutively phosphorylated in 
AML cells. However inhibition of PI3-Kinase by LY294002 did not appear to alter 
this phosphorylation. This suggests that alternative signalling pathways are 
responsible for this phosphorylation and we have found this to be the case in several 
leukaemic lines tested (data not shown). In some AML cases constitutive 
phosphorylation of the Forkhead family member FKHRL1 was detected and found 
to be regulated in a PI3-Kinase dependent manner. Addition of LY294002 appeared 
to have no significant effect on the total levels of the cell cycle regulators p21 and 
p27.
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Figure 5.12
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Figure 5.12 The effect of PI3-Kinase blockade on other downstream signalling 
pathways.
Primary AML cells were incubated with and with out LY294002 25pM 
overnight and total cell lysates made. 4xl05 cell equivalents were resolved by 
SDS-PAGE. The blot was probed with primary antibody annotated on the right 
and re-probed with total stat 5 to assess protein loading (4 examples shown).
5.10 Discussion
I have found that the PI3-Kinase pathway is activated in all the AML samples I 
tested. This is demonstrated by the presence of phosphorylated Akt ser473 on 
western blotting which was reduced or abolished when the cells were incubated with 
the selective PI3-Kinase inhibitor, LY294002. Previous studies in AML have shown
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PI3-Kinase/Akt activation. Min et al reported that 72% of their samples showed 
phosphorylation of Akt at ser473 124 and Xu et al showed that most of their patient 
samples had constitutively active Akt.125 It is possible that there may be a selection 
bias with the patients studied in my work as only those with a high level of 
circulating blasts were chosen.
The mechanism underlying constitutive PI3-Kinase/Akt activation in AML is not 
clear. I have demonstrated that there does not appear to be a reduction in PTEN 
protein in these patients. This contrasts with the findings of Xu et al who found low 
or absent PTEN expression in all their AML samples but did not find that PTEN 
expression correlated with Akt phosphorylation. Of the patients I examined, 3/18 
had FLT3 ITDs and 5 had N-ras mutations (exon 1 and 2). One patient had both 
FLT3 ITD and N-ras mutations and no patient had a D835 FLT3 mutation. In this 
series there was no clear difference in the level of Akt activation between patients 
with or without mutations. These experiments were carried out without exogenous 
cytokines, but autocrine cytokine production is another possible mechanism of PI3- 
Kinase activation.135,136
It appears that PI3-Kinase activation is important for leukaemic cell survival, as 
incubation with LY294002 resulted in a reduction in cell number related to an 
increase in apoptosis. The MAPK pathway can also regulate cell survival and was 
found to be activated in these samples. When this pathway was inhibited, there was 
an increase in apoptosis, but to a lesser extent than that seen with PI3-Kinase
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blockade. Milella et al found constitutive activation of MAPK in 74% of their 
patients with AML and showed that MEK inhibition led to a net increase in 
apoptosis of 13% (10-23%), 137 this is similar to the data presented here (12% 
increase). I demonstrated that PI3-Kinase blockade brings about a reduction in 
MAPK activation in 10/18 patients, suggesting that in AML, PI3-Kinase can act 
upstream of MAPK. Although MAPK can be regulated by PI3-Kinase, this is 
unlikely to be the major anti-apoptotic pathway in AML because the reduction in 
cell number after MAPK inhibition was considerably less than after PI3-Kinase 
blockade (23% v 51% respectively) and PI3-Kinase blockade had effects in cells 
where it was not involved in MAPK activation. Several possible mechanisms have 
been described for PI3-Kinase regulation of MAPK. Yart et al have shown that in 
EGF signalling, there is a PI3-Kinase dependent pathway for MAPK activation 
involving SHP2, GAB1, Ras and thus Raf/MEK/ERK. 138 MAPK activation by IL-3 
in BAF/3 cells appears to be under PI3-Kinase regulation due to influences on SHP2 
and GAB2 phosphorylation. 138 Another possible mechanism involves PKC 
activation by PDK1, a PI3-Kinase target, and PKC activation of MAPK. 139 ,40 in 
addition, PI3-Kinase activation of Rac, a member of the Rho family of GTPases, and 
its effector Pak (p21 activating kinase) has been described which can activate R af141 
and facilitate MEK/ERK association and ERK activation.142 It is not evident at 
present which, if any, of these mechanisms is relevant in AML.
AML stem cells are thought to reside in the CD34+/CD38- compartment of 
leukaemic blasts.143 Inhibition of PI3-Kinase in leukaemic stem cells led to a similar
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fall in cell viability as blockade in the bulk population, suggesting that this pathway 
is equally necessary for survival in both populations. This concurs with the findings 
of Xu et al who treated leukaemic cells with LY294002 for 16 hours prior to 
injecting them into NOD/SCID mice. They found reduced engraftment after 
LY294002 treatment compared to control cells. In contrast to the result with PI3- 
Kinase blockade, inhibition of the MAPK pathway appears to have a more 
prominent effect on the bulk population compared to the stem cell subset, implying 
that this pathway may not be as important for survival in the leukaemic stem cell 
population. These results should be interpreted with caution however, as only a 
small number of patient samples have been examined.
Having found that PI3-Kinase/Akt activation was important for AML cell survival I 
went on to investigate downstream effector molecules that could mediate this 
process. Akt has been reported to regulate several proteins involved in the control of 
apoptosis, for example by phosphorylating serine 136 of the Bad protein leading to 
reduced binding to Bel 2/Bcl Xl and increased cell survival.144 Phosphorylated Bad 
was not detected in my AML samples (Data not shown). This contrasts with the 
findings of Zhao et al, who found constitutive BAD phosphorylation in primary 
AML cells. 126 Akt is also able to promote cell survival by inhibition of FKHRL1, a 
member of the Forkhead family of transcription factors. In some AML cases studied 
constitutive phosphorylation of the Forkhead family member FKHRL1 was detected 
and found to be regulated in a PI3-Kinase dependent manner. PI3-Kinase/Akt may 
also regulate apoptosis by upregulation of Bel X mRNA in response to IL-3 and
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IGF-1, leading to increased expression of the anti-apoptotic factor.134 No alteration 
in Bel X levels was found on incubation with LY294002 in the cases studied here.
These findings suggest that alternative targets of PI3-Kinase/Akt may be responsible 
for regulating survival in AML. Therefore further investigation of other mediators of 
PI3-Kinase/Akt survival signals was necessary. Constitutive activation of NF-kB 
was found in AML cells using a novel transfection technique (Nucleofection) and 
reporter assay.129 Inhibition of the PI3-Kinase pathway led to a reduction in 
constitutive NF-kB activity in the majority of the AML samples tested, suggesting 
that PI3-Kinase/Akt can stimulate signalling pathways that upregulate the activity of 
NF-kB. This transcription factor is a heterodimeric protein composed of p50 and p65 
subunits which is regulated by the I kappa B (IkB) family of proteins that restrain 
NF-kB in the cytoplasm. Following cellular stimulation, IkB becomes 
phosphorylated by IkB kinases, leading to its ubiquitination and degradation 
allowing NF-kB to translocate to the nucleus and regulate transcription. Several 
groups have reported that PI3-Kinase and Akt are involved in the activation of NF- 
kB, which may be mediated by phosphorylation and activation of IKKs or by up 
regulation of the transcriptional activity through the transactivation domain of the 
p65 subunit. 145 147 Inhibition of endogenous Akt activity can result in the loss of l i­
ras’ induced NF-kB transcriptional activity and sensitisation of fibroblast cells to 
apoptosis. 145,148 There have been many reports of constitutively active NF-kB in 
malignancy.149' 152 My findings are consistent with those of Guzman et al who found 
NF-kB activation in all the AML specimens they examined (n=ll). NF-kB was
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constitutively active in leukaemic (CD34+, CD38-, CD 123+) but not normal stem 
cells. Leukaemic stem cells underwent apoptosis with the proteasomal inhibitor 
MG 132 (which reduces NF-kB activity via increasing IkB) whereas normal stem 
cells did not.129
I have also shown that inhibition of PI3-Kinase/Akt leads to an increase in 
constitutive p53 activity by reporter assay in primary cells. Genes trans-activated by 
p53 can either induce cell cycle arrest or promote apoptosis. Low p53 activity due to 
mutation can lead to aggressive tumour behaviour and reduced therapeutic 
sensitivity but mutations are uncommon in AML (5-15%).153-155 p53 normally has a 
very short half life because of rapid binding to mdm2, ubiquitination, and 
degradation. 130 Elevated mdm2 levels can cause genomic instability by inactivating 
DNA damage responses and have been found in multiple human malignancies. 156 
Phosphorylation of mdm2 by Akt allows mdm2 to translocate to the nucleus, bind 
p53, and target it for degradation. Downregulation would be expected to enhance the 
p53 response by shifting the balance from degradation to stabilisation. This could be 
a pathway for overactive PI3-Kinase to promote resistance to cytotoxic agents - 
blockade of PI3-Kinase/Akt could lead to increased chemosensitivity by increasing 
p53 levels. Regulation of both NF-kB and p53 by PI3-Kinase/Akt in AML cells 
could reduce the apoptotic response to cytotoxic chemotherapy. My data showing 
that PI3-Kinase blockade appears to be synergistic with Ara-C supports this 
possibility. Madrid et al have shown that Akt induced activation of NF-kB was able 
to protect Akt expressing cells from etoposide induced apoptosis.145 Other groups
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have shown that PI3-Kinase blockade potentiates the response to several 
chemotherapeutic agents including paclitaxel, vincristine, doxorubicin, trastuzumab, 
and etoposide. 131133
PI3-Kinase has several downstream effectors which could be responsible for the 
reduction in chemotherapy induced apoptosis in AML cells. Using an inducible 
myristolated Akt construct stably expressed in 32D cells I have shown that 
activation of Akt alone is sufficient to protect these factor dependent cells from 
cytokine withdrawal induced apoptosis. This is consistent with the finding that PI3- 
Kinase blockade in primary AML cells leads to a reduction in basal survival. 
Activation of Akt also protects 32D cells from the cytotoxic effect of both Ara-C 
and etoposide. This was seen even in the presence of maximal concentrations of IL-3 
(lOng/ml) which activate PI3-Kinase/Akt. However, in contrast to the transient Akt 
activation seen following IL-3 stimulation, with a return to baseline after 2-3 hours, 
(Data not shown), the 32D cells expressing the inducible activated Akt-ER construct 
have sustained Akt activation. This indicates that persistent Akt activity, as is seen in 
the primary AML cells, has an enhanced anti-apoptotic effect and may make a 
significant contribution to chemoresistance.
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Figure 5.13 PI3-Kinase activity is involved in many cell functions 
5.11 C onclusions
In conclusion, we have found that the PI3-Kinase pathway is activated in all the 
AML samples we tested. We have shown that inhibition of this pathway leads to an 
increase in apoptosis in the leukaemic stem cell pool, unlike MAPK blockade, and 
that it potentiates the response to cytotoxic chemotherapy. We have demonstrated 
that PI3-Kinase/Akt positively regulates the anti apoptotic NF-kB pathway and 
negatively regulates the P53 pathway in AML blasts. These results indicate the
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potential for PI3-Kinase inhibition in the treatment of AML. Further work 
investigating the role of the different class I isoforms of PI3-Kinase in AML has 
since been carried out in our laboratory. Fourteen cases of AML were examined. 
The pi 105 isoform was detected in all cases whereas expression of the other class I 
PI3-Kinases varied more widely and was often undetectable. Incubation of AML 
cells with IC87114, a pi 105 selective inhibitor, led to a reduction in constitutive Akt 
phosphorylation and a reduction in cell number partly accounted for by an increase 
in apoptosis. Unlike LY294002, IC87114 did not have direct adverse effects on 
normal haematopoietic progenitors suggesting that isoform selective inhibitors may 
be the preferred therapeutic approach in AML either alone or combined with 
cytotoxic therapy.
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CHAPTER 6 CONCLUSIONS
6.1 JAK/STAT Pathway
I have shown that G66976 is a potent inhibitor of JAK 2 in in vitro kinase assays and 
also in whole cell systems, where it inhibits signaling downstream of multiple JAK2 
coupled cytokines including IL-3, GM-CSF and EPO. Go6976 is also a potent 
inhibitor of JAK 3 but its effects on JAK1 and Tyk 2 are less clear. Further work 
would include delineation of the effect o f Go6976 on these kinases using in vitro 
kinase and cell based systems.
G66976 was also found to inhibit signalling downstream of disease-associated forms 
of JAK2 such as JAK2 constitutively activated by fusion with TEL and mutant 
JAK2 V617F. Investigation of several haematopoietic cell lines reported to have 
some dysregulation of the JAK/STAT pathway, revealed that G66976 was able to 
inhibit proliferation in 2/2 ALCL lines (Karpas 299, SUDHL1), 2/4 acute myeloid 
leukaemia lines (Kgla, U937) and 1 CML line (K562) but had no effect on any of 
the 4 MM lines examined.
I found that the majority of primary AML cells investigated had constitutive STAT 
activation. This was reduced by incubation with G66976 in 23 of 24 cases. In 12 out 
of 24 patients inhibition of JAKs by G66976 led to reduced activation of all three
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pathways (MAPK, PI3K, STAT) suggesting that dysregulation of the JAK pathway 
was one of the main aberrant signalling events in these patients. I have also shown 
that G66976 is an active inhibitor of survival and proliferation in AML blasts.
This work leads to the proposal that JAK2 inhibition would be a possible therapeutic 
strategy in AML. However, given that JAK2 is utilised by the major haematopoietic 
cytokines any JAK2 inhibitor could potentially have severe adverse effects on 
normal haematopoiesis. Some initial work carried out in our laboratory supports this 
in that G66976 appears to reduce colony numbers in a colony assay. However, it is 
possible that the phenomenon of oncogene addiction may lead to a therapeutic 
window narrow enough for AML cells to be susceptible to inhibition without 
toxicity to normal haematopoiesis. In fact Meydan et al reported that AG490, a 
tyrphostin JAK2 inhibitor, selectively blocked leukaemic cell growth in vitro and in 
vivo by inducing programmed cell death, with no deleterious effect on normal 
haematopoiesis.54 CP-690-550 is a potent JAK3 inhibitor. It has an IC50 of InM for 
JAK3 but also inhibits JAK2, although it is 20 times less potent, with an IC50 of 
20nM. It has been used in various murine models to prevent rejection of organ 
allografts. Dose limiting anaemia, presumed to be due to JAK2 inhibition was only 
seen in the higher dosing groups and the animals in the four fold lower dosing 
groups only had minor decreases in haemoglobin which recovered to baseline 
values. 157 This suggests that it may be possible to develop therapeutically useful 
JAK2 inhibitors.
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6.2 PI3-Kinase Pathway
I have found that the PI3-Kinase pathway is activated in AML as demonstrated by 
the presence of phosphorylated Akt ser473 on western blotting. This was reduced or 
abolished when the cells were incubated with the PI3-Kinase inhibitor, LY294002. 
The mechanism underlying constitutive PI3-Kinase/Akt activation in AML is not 
clear but did not appear to be directly related to PTEN expression or the presence of 
FLT3 or Ras mutations. It appears that PI3-Kinase activation is important for 
leukaemic cell survival, as incubation with LY294002 resulted in a reduction in cell 
number related to an increase in apoptosis. This is also true for the leukaemic stem 
cell population. MAPK inhibition appeared to have a more prominent effect on the 
bulk population compared to the stem cell subset thus implying that this pathway 
may not be as important for survival in the leukaemic stem cell population.
The search for downstream effector molecules of the PI3-Kinase pathway in AML 
led me to investigate the role of NF-kB in AML cell survival. Inhibition of the PI3- 
Kinase pathway led to a reduction in constitutive NF-kB activity in the majority of 
the AML samples tested, suggesting that PI3-Kinase/Akt can stimulate signalling 
pathways that upregulate the activity of NF-kB. I have also shown that inhibition of 
PI3-Kinase/Akt leads to an increase in constitutive p53 activity in primary AML 
cells.
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From the work with 3 2D cells stably expressing an activated AKT-ER construct it 
appears that activation of Akt alone is sufficient to protect factor dependent cells 
from cytokine withdrawal induced apoptosis and also from the cytotoxic effects of 
Ara-C and Etoposide. This Akt activation is persistent and mirrors the activity seen 
in AML cells, suggesting that activation of the PI3-Kinase pathway may contribute 
to chemoresistance.
The specific mechanism for PI3-Kinase activation in AML will differ between 
patients. It may result from mutations of receptor tyrosine kinases, such as FLT3, or 
of the Ras proto-oncogene or be the result of chromosomal translocations leading to 
the creation of aberrant kinase activity. Small molecule signalling pathway inhibitors 
are increasingly being investigated for use in acute leukaemia. One approach to 
therapy has been to try and find selective inhibitors to particular aberrant pathways 
such as famesyl transferase inhibitors directed at the Ras/MEK/ERK pathway or 
FLT3 inhibitors. Theoretically this could be advantageous by reducing the likelihood 
of excessive non-specific toxicity. However it seems unlikely, especially in the case 
of acute leukaemia, that the malignancy would be dependent on just one pathway for 
its growth and survival. It also seems likely that there would be a significant level of 
cross talk between molecules within different signaling pathways. Another approach 
would be to use less selective kinase inhibitors and target several pathways 
simultaneously. This has been successfully used in the case of Imatinib for the 
treatment of gastrointestinal stromal tumours where response is thought to be due to 
the inhibition of KIT and PDGFR. The draw back for some agents relates to the
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differential in IC50’s for each target. This can sometimes vary by 10-100 fold and so 
it may not be possible to inhibit both targets safely in vivo. Inhibition of so called 
‘nodal’ pathways, such as the PI3-Kinase pathway is a further option. These 
pathways are common to many activating events and may therefore be applicable to 
more tumours whilst avoiding the problems associated with combining several 
agents or using multitargeted drugs. Billotet at al have shown that the leucocyte 
restricted isoform, pi 108, of PI3-Kinase appears to be expressed at higher levels 
than the other class 1 PI3-Kinases in acute myeloid leukaemia. It is also susceptible 
to inhibition with an isoform selective compound, IC87114, leading to an increase in 
apoptosis and reduction in proliferation of primary AML cells. Thus the 
development of isoform specific inhibitors may have the advantage of inhibiting a 
nodal pathway without the toxicity related to pan PI3-Kinase inhibition.
The development of specific small molecule inhibitors of tyrosine kinases such as 
Imatinib is a landmark in anticancer therapy. However in contrast to CML, 
deregulated receptor tyrosine kinases are only one of several targets involved in the 
pathophysiology of AML. As discussed in chapter 1.8 class I mutations including 
fusion tyrosine kinases and activating mutations of receptor tyrosine kinases provide 
a proliferative advantage whereas class II mutations impair cellular differentiation. 
In addition other chromosomal abnormalities may cooperate in leukaemogenesis. 
The complex nature of these changes may explain the poor efficacy of some tyrosine 
kinase inhibitors in AML so far. As increasing numbers of deregulated enzymes are 
identified in AML, so this therapeutic challenge will intensify. It seems likely that
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future therapeutic regimens in AML will consist of rationally designed combinations 
of specific agents with or without classical chemotherapy which will hopefully lead 
to an improvement in overall outcome.
6.3 Future Directions
I have shown that the majority of cases of primary AML exhibit constitutive STAT 
phosphorylation indicating activation of the JAK/STAT pathway. The mechanisms 
resulting in this activation are not clear. The somatic JAK2 V617F mutation has 
been reported in a small number of de novo AML cases although it has been found 
to be present in a larger number of cases secondary to myeloproliferative 
disorders115. Another novel JAK2 mutation has been described in acute 
megakaryoblastic cell lines resulting from a threonine to aspargine switch at position 
875. this also results in aa contitutively activated JAK2114. Several gain of function 
mutations in JAK3 have also been described in acute megakaryoblastic cells lines 
l58. In the light of these discoveries further mutational analysis of JAKs 1,2,3 and 
Tyk2 to locate other novel activating mutations would be a valid approach to further 
clarifying this situation.Autocrine/paracrine production of growth factors such as IL- 
6 and GMCSF is well described in AML and may result in JAK/STAT activation. 
Therefore the use of neutralizing monoclonal antibodies to block these signals would 
further elucidate what contribution autocrine/paracrine cytokine production played 
in these cases.
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It is important to fully characterize the spectrum of G66976 activity. Although the 
anti-JAK2 and 3 activity has been clearly demonstrated, the effect of G66976 on 
JAK1 and Tyk2 has not. This could be investigated by utilising both in vitro kinase 
assays and whole cell systems.
Further characterization of the effects of G66976 on normal progenitor cell growth 
and engraftment is needed to help to clarify if there is preferential activity against 
AML cells. This could be achieved by using CD34 initiated colony assays, long­
term cultures (LT-CIC) and looking at effects on engraftment in NOD SCID mice.
In clinical practice it is likely that small molecule inhibitors of JAK2 will be used in 
combination with classical chemotherapeutic agents. Therefore the effect of 
blocking the JAK/STAT pathway on sensitivity to central cytotoxic components of 
AML treatment regimens should be examined. This work could then be further 
developed by investigating the effect of G66976 on leukaemic stem cell engraftment 
in NOD SCID mice alone and in combination with chemotherapeutic agents.
Constitutive PI3-Kinase activation is frequently found in AML although the reasons 
for this are less clear. PIK3CA mutations have been described in other malignancies 
but have been rarely described in AML. I have screened 92 AML samples and found 
no PIK3CA mutations - however other PI3-Kinase isoforms, in particular PI3KCD, 
have not been extensively examined and therefore mutational analysis of would be 
crucial in furthering our current knowledge. The results of this analysis would guide
196
us in the trial of isoform specific inhibitors on proliferation and apoptosis in AML 
cases. The logical extension of this work would be to investigate the effect of PI3- 
Kinase isoform inhibitors on the ability of leukaemic progenitors to engraft NOD 
SCID mice.
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APPENDIX 1
Amino Acid abbreviations
A ala alanine M met methionine
C cys cysteine N asn asparagine
D asp aspartate P pro proline
E glu glutamate Q gin glutamine
F phe phenylalanine R arg arginine
G giy glycine S ser serine
H his histidine T thr threonine
I ile isoleucine V val valine
K lys lysine W trp tryptophan
L leu leucine Y tyr tyrosine
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